Gentiva Health Services (GTIV) 10-Q 14 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 10, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'GENTIVA HEALTH SERVICES INC	'
Entity Central Index Key	'0001096142	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	36,966,127

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$114,206	$86,957
Accounts receivable, less allowance for doubtful accounts of $10,303 and $10,680 at September 30, 2014 and December 31, 2013, respectively	285,718	289,905
Deferred tax assets, net	24,270	28,153
Prepaid expenses and other current assets	48,776	64,746
Total current assets	472,970	469,761
Note receivable from CareCentrix	25,000	28,471
Fixed assets, net	42,048	49,375
Intangible assets, net	247,033	253,727
Goodwill	374,024	383,487
Other assets	64,151	68,647
Total assets	1,225,226	1,253,468
Current liabilities:	'	'
Current portion of long-term debt	51,138	45,325
Accounts payable	16,370	15,659
Payroll and related taxes	45,736	64,857
Deferred revenue	47,919	43,864
Medicare liabilities	17,640	23,894
Obligations under insurance programs	78,310	82,634
Accrued nursing home costs	19,014	22,219
Accrued interest expense	7,788	17,239
Other accrued expenses	59,039	59,779
Total current liabilities	342,954	375,470
Long-term debt	1,105,750	1,124,432
Deferred tax liabilities, net	6,264	8,483
Other liabilities	55,456	53,084
Gentiva shareholders' equity:	'	'
Common stock, $0.10 par value; authorized 100,000,000 shares; issued 38,272,830 and 37,713,302 shares at September 30, 2014 and December 31, 2013, respectively	3,827	3,771
Additional paid-in capital	466,777	462,262
Treasury stock, 1,370,544 and 1,337,882 shares at September 30, 2014 and December 31, 2013, respectively	-19,165	-18,773
Accumulated deficit	-740,449	-758,136
Total Gentiva shareholders' deficit	-289,010	-310,876
Noncontrolling interests	3,812	2,875
Total deficit	-285,198	-308,001
Total liabilities and shareholders' deficit	$1,225,226	$1,253,468

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivables, allowance for doubtful accounts	$10,303	$10,680
Common stock, par value	$0.10	$0.10
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	38,272,830	37,713,302
Treasury stock, shares	1,370,544	1,337,882

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Net revenues	$498,006	$410,492	$1,483,551	$1,240,507
Cost of services sold	270,659	220,478	811,077	660,998
Gross profit	227,347	190,014	672,474	579,509
Selling, general and administrative expenses	-188,494	-161,078	-567,722	-483,243
Goodwill and other long-lived asset impairment	0	0	0	-210,672	[1]
Interest income	633	639	1,899	2,066
Interest expense and other	-25,352	-22,981	-75,805	-68,849
Income (loss) before income taxes and equity in net loss of CareCentrix	14,134	6,594	30,846	-181,189
Income tax expense	-5,601	-2,943	-12,499	-2,827
Equity in net loss of CareCentrix, net of tax	-490	0	-490	0
Net income (loss)	8,043	3,651	17,857	-184,016
Less: Net income attributable to noncontrolling interests	2	-88	-170	-425
Net income (loss) attributable to Gentiva shareholders	8,045	3,563	17,687	-184,441
Comprehensive income (loss)	$8,043	$3,651	$17,857	($184,016)
Net income (loss) attributable to Gentiva shareholders:	'	'	'	'
Earnings Per Share, Basic	$0.22	$0.12	$0.49	($5.97)
Earnings Per Share, Diluted	$0.21	$0.11	$0.48	($5.97)
Weighted average shares outstanding:	'	'	'	'
Basic	36,369	31,037	36,285	30,921
Diluted	37,546	31,532	37,052	30,921
[1]	(2)At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. See Note 9.In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million.Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of the impairment.

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
OPERATING ACTIVITIES:	'	'
Net income (loss)	$17,857	($184,016)
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	21,207	14,541
Amortization of debt issuance costs	4,813	9,687
Provision for doubtful accounts	3,927	3,766
Equity-based compensation expense	6,643	5,984
Windfall tax benefits associated with equity-based compensation	-56	-92
Goodwill and other long-lived asset impairment	0	210,672	[1]
Equity in net loss of CareCentrix, net of tax	490	0
Deferred income tax expense (benefit)	7,715	-6,696
Changes in assets and liabilities, net of effects from acquisitions and dispositions:	'	'
Accounts receivable	260	5,126
Prepaid expenses and other current assets	16,281	62
Accounts payable	711	-1,471
Payroll and related taxes	-19,121	-12,171
Deferred revenue	4,055	1,582
Medicare liabilities	-6,254	-12,156
Obligations under insurance programs	-4,324	5,555
Accrued nursing home costs	-3,205	2,430
Other accrued expenses	-9,915	-26,793
Other, net	4,955	2,559
Net cash (used in) provided by operating activities	46,039	18,569
INVESTING ACTIVITIES:	'	'
Purchase of fixed assets	-9,268	-14,214
Proceeds from sale of businesses, net of cash transferred	0	508
Proceeds from sale of assets	2,004	0
Acquisition of businesses, net of cash acquired	0	-4,638
Net cash used in investing activities	-7,264	-18,344
FINANCING ACTIVITIES:	'	'
Proceeds from issuance of common stock	1,937	2,459
Windfall tax benefits associated with equity-based compensation	56	92
Payment of contingent consideration accrued at acquisition date	0	-1,675
Repayment of long-term debt	-13,744	-25,000
Debt issuance costs	-150	-449
Minority interest capital contribution	1,160	1,600
Distribution to minority interests	-393	-563
Other	-392	-447
Net cash used in financing activities	-11,526	-23,983
Net change in cash and cash equivalents	27,249	-23,758
Cash and cash equivalents at beginning of period	86,957	207,052
Cash and cash equivalents at end of period	114,206	183,294
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:	'	'
Interest paid	80,148	68,374
Income taxes paid	$416	$924
[1]	(2)At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. See Note 9.In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million.Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of the impairment.

Background_and_Basis_of_Presen

Background and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Background and Basis of Presentation	'
	Background and Basis of Presentation
	Gentiva Health Services, Inc. (“Gentiva” or the “Company”) provides home health, hospice and community care services throughout most of the United States. The Company’s operations involve servicing its patients and customers through its (i) Home Health segment, (ii) Hospice segment and (iii) Community Care segment.
	The accompanying interim consolidated financial statements are unaudited and have been prepared by the Company using accounting principles consistent with those described in the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2013 and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all adjustments necessary for a fair statement of financial position, results of operations and cash flows for each period presented. Certain information and disclosures normally included in the consolidated statements of financial position, comprehensive income and cash flows prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") have been condensed or omitted as permitted by such rules and regulations. Results for interim periods are not necessarily indicative of results for a full year. The year-end balance sheet data was derived from audited financial statements.
	The Company’s consolidated financial statements include the accounts and operations of the Company and its subsidiaries in which the Company owns more than a 50 percent interest. Noncontrolling interests, which relate to the minority ownership held by third party investors in certain of the Company’s hospice and home health programs, are reported below net income (loss) under the heading “Net loss (income) attributable to noncontrolling interests” in the Company’s consolidated statements of comprehensive income and presented as a component of equity in the Company’s consolidated balance sheets. All balances and transactions between the consolidated entities have been eliminated.

Restatement_and_Revision_of_Pr

Restatement and Revision of Previously Reported Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Restatement and Revision of Previously Reported Consolidated Financial Statements	'
	Restatement and Revision of Previously Reported Consolidated Financial Statements
	The Company determined that historically it had incorrectly applied applicable accounting guidance in accounting for its indefinite-lived intangible assets related to closed or consolidated licenses on a pooled basis and did not write-off license costs when the Company closed or consolidated individual operating locations and to correct certain assumptions used in its valuation models for goodwill and indefinite-lived intangibles. The Company has determined it should amortize the full license cost over the period of closure or consolidation.
	In connection with the restatement of the Company's consolidated financial statements as of and for the year ended December 31, 2013 and as of and for the quarter ended March 31, 2014, in this Form 10-Q the Company has revised its consolidated statement of comprehensive loss and consolidated statement of cash flows as of and for the six month and nine month periods ended June 30, 2013 and September 30, 2013, respectively.
	The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding revised amounts:
		For the Six Months Ended June 30, 2013
	Revised Consolidated Statement of Comprehensive Loss amounts (In thousands)	As Previously Reported				Revision Adjustments				Revised
	Selling, general and administrative expenses	$	(321,814	)		$	(351	)		$	(322,165	)
	Goodwill and other long-lived asset impairment	(224,320		)		13,648				(210,672		)
	Income (loss) before income taxes	(201,080		)		13,297				(187,783		)
	Income tax (expense) benefit	587				(471		)		116
	Net income (loss)	(200,493		)		12,826				(187,667		)
	Net income (loss) attributable to Gentiva shareholders	(200,830		)		12,826				(188,044		)
	Total comprehensive income (loss)	(200,493		)		12,826				(187,667		)
	Basic Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(6.51	)		$	0.42			$	(6.09	)
	Diluted Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(6.51	)		$	0.42			$	(6.09	)
		For the Nine Months Ended September 30, 2013
	Revised Consolidated Statement of Comprehensive Loss amounts (In thousands)	As Previously Reported				Revision Adjustments				Revised
	Selling, general and administrative expenses	$	(482,634	)		$	(609	)		$	(483,243	)
	Goodwill and other long-lived asset impairment	(224,320		)		13,648				(210,672		)
	Income (loss) before income taxes	(194,228		)		13,039				(181,189		)
	Income tax (expense) benefit	(2,457		)		(370		)		(2,827		)
	Net income (loss)	(196,685		)		12,669				(184,016		)
	Net income (loss) attributable to Gentiva shareholders	(197,110		)		12,669				(184,441		)
	Total comprehensive income (loss)	(196,685		)		12,669				(184,016		)
	Basic Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(6.38	)		$	0.41			$	(5.97	)
	Diluted Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(6.38	)		$	0.41			$	(5.97	)
		For the Six Months Ended June 30, 2013
	Revised Consolidated Statement of Cash Flows	As Previously Reported			Revision Adjustments			Revised
	(In thousands)
	Net income (loss)	(200,493	)		12,826			(187,667	)
	Depreciation and Amortization	9,511			351			9,862
	Goodwill and other long-lived asset impairment	224,320			(13,648	)		210,672
	Deferred income tax expense (benefit)	(7,983	)		471			(7,512	)
		For the Nine Months Ended September 30, 2013
	Revised Consolidated Statement of Cash Flows	As Previously Reported			Revision Adjustments			Revised
	(In thousands)
	Net income (loss)	(196,685	)		12,669			(184,016	)
	Depreciation and Amortization	13,932			609			14,541
	Goodwill and other long-lived asset impairment	224,320			(13,648	)		210,672
	Deferred income tax expense (benefit)	(7,066	)		370			(6,696	)

Accounting_Policies

Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Accounting Policies	'
	Accounting Policies
	Cash and Cash Equivalents
	The Company considers all investments with a maturity date three months or less from their date of acquisition to be cash equivalents, including money market funds invested in U.S. Treasury securities, short-term treasury bills and commercial paper. Cash and cash equivalents also included amounts on deposit with several major financial institutions in excess of the maximum amount insured by the Federal Deposit Insurance Corporation. Management believes that these major financial institutions are viable entities.
	The Company had operating funds of approximately $4.2 million and $5.5 million at September 30, 2014 and December 31, 2013, respectively, which relate exclusively to a non-profit hospice operation managed in Florida.
	Investments
	As of December 31, 2013, the Company held an investment, at cost, in CareCentrix Holdings Inc. of $0.9 million for shares that it expected to receive in settlement of certain tax amounts owed to the Company as set forth in the stock purchase agreement. During the third quarter of 2014, the Company finalized the settlement with CareCentrix. See Note 7 for additional information.
	At September 30, 2014 and December 31, 2013, the Company had assets of $36.1 million and $34.7 million, respectively, held in a Rabbi Trust for the benefit of participants in the Company’s non-qualified defined contribution retirement plan. The corresponding amounts payable to the plan participants are equivalent to the underlying value of the assets held in the Rabbi Trust. Assets held in a Rabbi Trust and amounts payable to plan participants are classified in other assets and other liabilities, respectively, in the Company’s consolidated balance sheets.
	Debt Issuance Costs
	The Company amortizes deferred debt issuance costs over the term of its credit agreement and senior notes. As of September 30, 2014 and December 31, 2013, the Company had unamortized debt issuance costs of $24.4 million and $28.3 million, respectively, recorded in other assets in the Company’s consolidated balance sheets.
	Fixed Assets
	Fixed assets, including costs of Company developed software, are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Leasehold improvements are amortized over the shorter of the life of the lease or the life of the improvement. Repairs and maintenance costs are expensed as incurred. As of September 30, 2014 and December 31, 2013, fixed assets, net were $42.0 million and $49.4 million, respectively.
	At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. These charges are recorded in goodwill and other long-lived asset impairment in the Company's consolidated financial statements for the nine months ended September 30, 2013.
	In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge related to developed software, of approximately $1.6 million, which is reflected in goodwill and other long-lived asset impairment in the Company's consolidated financial statements for the nine months ended September 30, 2013.
	Goodwill and Other Indefinite-Lived Intangible Assets
	The Company is required to test goodwill and other indefinite-lived intangible assets for impairment on an annual basis and between annual tests if current events or circumstances require an interim impairment assessment. The Company allocates goodwill to its various reporting units upon the acquisition of the assets or stock of another third party business operation. The Company compares the fair value of each reporting unit to its carrying amount to determine if there is a potential impairment of goodwill and other indefinite-lived intangible assets. If the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the fair value of the goodwill within the operating unit is less than the carrying value of its goodwill. To determine the fair value of the Company's reporting units, the Company uses a present value (discounted cash flow) technique corroborated by market multiples when available, a reconciliation to market capitalization or other valuation methodologies, and reasonableness tests, as appropriate.
	If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of other indefinite-lived intangible assets are determined based on discounted cash flows or appraised values, as appropriate.
	At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million, which is reflected in goodwill and other long-lived asset impairment in the Company's consolidated financial statements for the nine months ended September 30, 2013. See Note 9 for additional information.
	Obligations Under Self Insurance Programs
	As of September 30, 2014 and December 31, 2013, the Company’s obligations under insurance programs were $78.3 million and $82.6 million, respectively. Workers’ compensation and professional and general liability expenses were $5.0 million and $15.0 million for the third quarter and first nine months of 2014, respectively, as compared to $6.6 million and $19.2 million for the corresponding periods of 2013. Employee health and welfare expenses were $21.4 million and $67.8 million for the third quarter and first nine months of 2014, respectively, as compared to $21.0 million and $64.0 million for the corresponding periods of 2013.
	Nursing Home Costs
	For patients receiving nursing home care under a state Medicaid program who elect hospice care under Medicare or Medicaid, the Company contracts with nursing homes for the nursing homes to provide patients’ room and board services. The state must pay the Company, in addition to the applicable Medicare or Medicaid hospice daily or hourly rate, an amount equal to at least 95 percent of the Medicaid daily nursing home rate for room and board furnished to the patient by the nursing home. Under the Company’s standard nursing home contracts, the Company pays the nursing home for these room and board services at the Medicaid daily nursing home rate. Nursing home costs are partially offset by nursing home net revenue, and the net amount is included in cost of services sold in the Company’s consolidated statements of comprehensive income. Net nursing home costs for the third quarter and first nine months of 2014 were $2.9 million and $7.3 million, respectively, as compared to $1.7 million and $7.2 million for the corresponding periods of 2013.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	On May 28. 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. This ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for reporting periods beginning after December 15, 2016.  Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is currently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures.
	On July 18, 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740) (ASU 2013-11), which provides final guidance that requires an entity to net its liability for unrecognized tax positions against a net operating loss carryforward, a similar tax loss or a tax credit carryforward when settlement in this manner is available under the tax law. The provisions of this new guidance were effective as of the beginning of the Company's 2014 year.  The adoption of this new guidance did not have a material impact on the Company’s consolidated financial statements.

Acquisitions_and_Dispositions

Acquisitions and Dispositions	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Acquisitions and Dispositions	'
	Acquisitions and Dispositions
	Wake Forest Baptist Health Care at Home, LLC
	Effective February 2014, the Company sold its Wilkesboro, North Carolina branch to Wake Forest Baptist Health Care at Home, LLC for $2.9 million. Total Care Home Health of North Carolina, LLC, a wholly-owned subsidiary of the Company, owns a 60 percent interest in Wake Forest Baptist Health Care at Home, LLC, which provides home health services in the Winston-Salem and Wilkesboro, North Carolina geographical areas.
	Effective August 23, 2013, the Company acquired 60 percent interest in the membership units of Wake Forest Baptist Health Care at Home, LLC for approximately $2.4 million, consisting of $2.2 million in cash and $0.2 million of other assets, and entered into an operating agreement with Wake Forest University Baptist Medical Center to provide home health services in the Winston-Salem, North Carolina geographical area.
	Harden Healthcare Holdings, Inc.
	Effective October 18, 2013, the Company completed the acquisition of certain net assets relating to the home health, hospice and community care businesses of Harden Healthcare Holdings, Inc. ("Harden") pursuant to an Agreement and Plan of Merger dated as of September 18, 2013. The Company completed the acquisition as an entrance into the community care business, primarily throughout Texas, Oklahoma and Missouri, and to expand its geographic coverage for its home health and hospice businesses. Total consideration for the acquisition was $426.8 million, exclusive of transaction costs, consisting of approximately $365.0 million in cash, $53.8 million in shares of Gentiva's common stock and additional contingent consideration of $9.5 million, recorded at estimated fair value of approximately $8.1 million. The contingent consideration includes (i) a consulting agreement entered into with Capstar Partners, LLC, (ii) a sub-lease termination agreement entered into with Capstar Investment Partners, L.P., both which carry performance criteria tied to certain levels of community care program reimbursement rates in the State of Texas, as defined in the agreements, and (iii) a consulting agreement entered into with a former executive of Harden.
	During the third quarter of 2014, the Company, in connection with finalizing its valuation of Harden, recorded adjustments to the preliminary fair values assigned to the assets and liabilities acquired in the transaction. These adjustments related to (i) an increase in deferred taxes of $9.7 million, (ii) a $0.3 million increase in identifiable intangible assets and (iii) a $0.2 million increase in other accrued liabilities with a corresponding decrease in goodwill. In addition, the Company recorded an increase in the accounts receivable fair value reserve of $1.5 million within the Home Health segment and a corresponding decrease in the accounts receivable fair value reserve for the Community Care segment.
	Appalachian Regional Health Systems
	Effective September 30, 2013, the Company completed its acquisition of the assets and business of Appalachian Regional Health Systems, a provider of home health services with offices in Boone and Newland, North Carolina. Total consideration of $2.7 million, subject to post-closing adjustments, consisted of $2.1 million from the Company's existing cash reserves and $0.6 million held in escrow for certain post closing matters. The purchase price was allocated to goodwill ($2.6 million) and identifiable intangible assets ($0.1 million).
	Hope Hospice, Inc.
	Effective April 30, 2013, the Company completed its acquisition of the assets and business, pursuant to an asset purchase agreement, of Hope Hospice, Inc., a provider of hospice services located in Rochester, Indiana. Total non-cash consideration of $1.0 million consisted of the assumption of Hope Hospice's outstanding debt and existing liabilities as of the closing date. The purchase price was allocated to Medicare licenses ($0.5 million), accounts receivable ($0.3 million) and goodwill ($0.2 million).

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company’s financial instruments are measured and recorded at fair value on a recurring basis, except for the notes receivable from CareCentrix and long-term debt. The fair values for the notes receivable from CareCentrix and non-financial assets, such as fixed assets, intangible assets and goodwill, are measured periodically and adjustments recorded only if an impairment charge is required. The carrying amount of the Company’s accounts receivable, accounts payable and certain other current liabilities approximates fair value due to their short maturities.
	Fair value is defined under authoritative guidance as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:
	•	Level 1—Quoted prices in active markets for identical assets or liabilities.
	•	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Financial Instruments Recorded at Fair Value
	The Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis was as follows (in thousands):
		30-Sep-14										31-Dec-13
		Level 1				Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Money market funds	$	23,091			$	—	$	—	$	23,091	$	23,695	$	—	$	—	$	23,695
	Rabbi Trust:
	Mutual funds	31,175				—		—		31,175		28,945		—		—		28,945
	Money market funds	4,963				—		—		4,963		5,737		—		—		5,737
	Total assets	$	59,229			$	—	$	—	$	59,229	$	58,377	$	—	$	—	$	58,377
	Liabilities:
	Payables to plan participants	$	36,138			$	—	$	—	$	36,138	$	34,682	$	—	$	—	$	34,682
	Acquisition contingent liability	—				—		8,514		8,514		—		—		8,110		8,110
	Total liabilities	$	36,138			$	—	$	8,514	$	44,652	$	34,682	$	—	$	8,110	$	42,792
	Assets held in the Rabbi Trust are held for the benefit of participants in the Company’s non-qualified defined contribution retirement plan. The value of assets held in the Rabbi Trust is based on quoted market prices of securities and investments, including money market accounts and mutual funds, maintained within the Rabbi Trust. The corresponding amounts payable to plan participants are equivalent to the underlying value of assets held in the Rabbi Trust. Assets held in the Rabbi Trust and amounts payable to plan participants are classified in other assets and other liabilities, respectively, in the Company’s consolidated balance sheets. Money market funds held in the Company’s account represent cash equivalents and were classified in cash and cash equivalents in the Company’s consolidated balance sheets at September 30, 2014 and December 31, 2013.
	The estimated fair value of the acquisition contingent liabilities were determined using a discounted cash flow approach utilizing level 2 and level 3 inputs which included observable market discount rates, fixed payment schedules, and assumptions based on achieving certain pre-defined performance criteria. See Note 4 for further information.
	The following table provides a summary of changes in fair value of the Company's Level 3 financial assets (in thousands):
			Estimated Fair Value
	Balance at December 31, 2013		$	8,110
	Payment of contingent liability		(125		)
	Included in earnings		279			(1)
	Harden acquisition contingent liability adjustment		250
	Balance at September 30, 2014		$	8,514
	-1	Accretion of the present value of the contingent liability is recorded in interest expense and other in the Company's consolidated statements of comprehensive income. A 1 percent change in the discount rate would have an impact on the fair value of the contingent liability of approximately $0.2 million.
	Other Financial Instruments
	The carrying amount and estimated fair value of the Company’s other financial instruments were as follows (in thousands):
		30-Sep-14						31-Dec-13
		Carrying				Estimated		Carrying		Estimated
		Amount				Fair Value		Amount		Fair Value
	Assets:
	Note receivable from CareCentrix	$	25,000			$	26,055	$	25,000	$	26,403
	Seller financing note receivable from CareCentrix	—				—		3,471		3,471
	Liabilities:
	Long-term obligations	$	1,163,256			$	1,182,837	$	1,177,000	$	1,183,863
	The estimated fair value of the note receivable from CareCentrix was determined from Level 3 inputs based on an income approach using the discounted cash flow method. The fair value represents the net present value of (i) the after tax cash flows relating to the note's annual income stream plus (ii) the return of the invested principal using a maturity date of March 19, 2017, after considering assumptions relating to risk factors and economic conditions. See Note 7 for additional information.
	In determining the estimated fair value of long-term debt, Level 2 inputs based on the use of bid and ask prices were considered. Due to the infrequent number of transactions that occur related to the long-term debt, the Company does not believe an active market exists for purposes of this disclosure.

Net_Revenues_and_Accounts_Rece

Net Revenues and Accounts Receivable	9 Months Ended
	Sep. 30, 2014
Net Revenues and Accounts Receivable [Abstract]	'
Net Revenues And Accounts Receivable	'
	Net Revenues and Accounts Receivable
	Net revenues in the Home Health and Hospice segments were derived from all major payer classes, while Community Care segment net revenues were derived primarily from Medicaid and Insurance payer classes. Net revenue by major payer classes were as follows (in millions):
		Third Quarter								First Nine Months
		2014			2013			Percentage		2014		2013		Percentage
								Variance						Variance
	Medicare:
	Home Health	$	214.9		$	191.8		12	%	$	642	$	577.7	11.1	%
	Hospice	161.6			163.8			(1.3	)%	486.3		498.8		(2.5	)%
	Total Medicare	376.5			355.6			5.9	%	1,128.30		1,076.50		4.8	%
	Medicaid and Local Government	70.9			17.4			307	%	212.8		54.4		291.4	%
	Commercial Insurance and Other:
	Paid at episodic rates	21.5			15.1			42.8	%	55		43.3		27	%
	Other	29.1			22.4			29.7	%	87.5		66.3		31.8	%
	Total Commercial Insurance and Other	50.6			37.5			35	%	142.5		109.7		29.9	%
	Total net revenues	$	498		$	410.5		21.3	%	$	1,483.60	$	1,240.50	19.6	%
	For the third quarter and first nine months of 2014, the Company recorded hospice Medicare cap expense of $0.4 million and $1.5 million, respectively, as compared to hospice Medicare cap credits of $2.9 million and $4.5 million for the third quarter and first nine months of 2013, respectively, which are reflected in net revenues in the Company’s consolidated statements of comprehensive income. For the Medicare cap year 2014, which began November 1, 2013, the Company has recorded $1.8 million in Medicare cap expense and has seven hospice providers currently estimated to be in excess of Medicare cap limits.
	The Medicare payment cap, which is calculated for each provider by the Medicare fiscal intermediary at the end of the hospice cap period, is determined under the proportional method. The proportional method allocates each beneficiary's Medicare payment cap based on the ratio of the number of days the beneficiary received hospice services from the Company over the total number of days the beneficiary received hospice services from all providers. The Medicare payment cap amount is then further allocated between the hospice cap periods based on the ratio of the number of days the Company provided hospices services during each cap period. The sum of each beneficiary's Medicare cap payment, as determined above, represents the aggregate Medicare payment cap. Medicare revenue paid to a provider during the hospice cap period cannot exceed the aggregate Medicare payment cap. As of September 30, 2014 and December 31, 2013, the Company had Medicare cap liabilities of $3.7 million and $6.5 million, respectively, which are reflected in Medicare liabilities in the Company’s consolidated balance sheets.
	Odyssey HealthCare, Inc. ("Odyssey"), prior to its acquisition by Gentiva, filed appeals with Centers for Medicare & Medicaid Services ("CMS") to change the methodology previously used to calculate the Medicare payment cap in order to utilize the proportional method of determining the payment cap, as described above. This method allocates the Medicare payment cap over the cap years that the beneficiary is on service. In connection with those appeals, the Company has received final settlement letters for many of its providers and recorded approximately $3.4 million and $5.9 million as net revenue for the third quarter and first nine months of 2013, respectively, in the Company's consolidated statements of comprehensive income.
	Corporate Integrity Agreement
	Under Odyssey's five-year Corporate Integrity Agreement ("CIA") with the Office of Inspector General of the United States Department of Health and Human Services ("OIG"), which became effective on February 15, 2012, Odyssey must engage a third party to perform verification and unallowable cost reviews. In addition, Odyssey's eligibility review team must review the eligibility of Odyssey's Medicare beneficiaries for the hospice services those beneficiaries received and prepare an eligibility review report. Odyssey must submit to the OIG annually a report with respect to the status of, and findings regarding, Odyssey's compliance activities. Any overpayments identified by Odyssey are paid back to the various Medicare administrative contractors by April 1st of the following year. If Odyssey fails to comply with the terms of the CIA, it will be subject to penalties. In connection with these eligibility reviews, the Company reduced reserves by approximately $0.4 million for the third quarter of 2014 and recorded reserves of approximately $1.9 million for the first nine months of 2014. The Company recorded reserves of $3.5 million and $5.0 million for the third quarter and first nine months of 2013, respectively, which are reflected as a reduction of net revenues in the Company's consolidated statements of comprehensive income.
	PRRB Appeal
	During the third quarter of 2013, the Company finalized its year 2000 cost reports, which are now being settled by CMS. In connection with the settlements, the Company recorded a positive adjustment of approximately $4.0 million to net revenues for the third quarter and first nine months of 2013, in the Company's consolidated statements of comprehensive income. See Note 14 for additional information.
	Accounts Receivable
	Accounts receivable attributable to major payer sources of reimbursement were as follows (in thousands):
		September 30, 2014			December 31, 2013
	Medicare	$	200,902		$	214,366
	Medicaid and Local Government	51,113			48,183
	Commercial Insurance and Other	44,006			38,036
	Gross accounts receivable	296,021			300,585
	Less: Allowance for doubtful accounts	(10,303		)	(10,680		)
	Net accounts receivable	$	285,718		$	289,905
	As of September 30, 2014 and December 31, 2013, the Commercial Insurance and Other payer group included self-pay accounts receivable relating to patient co-payments of $2.1 million and $2.4 million, respectively.

Investment_in_and_Notes_Receiv

Investment in and Notes Receivable from CareCentrix	9 Months Ended
	Sep. 30, 2014
Note Receivable from and Investment in Entity [Abstract]	'
Note Receivable from and Investment from CareCentrix	'
	Investment in and Notes Receivable from CareCentrix
	The Company holds a $25.0 million subordinated promissory note from CareCentrix, Inc. In connection with the sale of the Company’s ownership interest in CareCentrix Holdings on September 19, 2011, the maturity date of the note was extended to the earlier of March 19, 2017 or a sale of CareCentrix Holdings. The note bears interest at a fixed rate of 10 percent, which is payable quarterly, provided that CareCentrix remains in compliance with its senior debt covenants. Interest on the CareCentrix promissory note, which is included in interest income in the Company’s consolidated statements of comprehensive income, amounted to $0.6 million and $1.9 million for the third quarter and first nine months, respectively, of both 2014 and 2013.
	Pursuant to the terms of the stock purchase agreement, approximately $10.6 million of the sale price due to the Company was placed into an escrow fund for future indemnification claims. As of September 30, 2014, approximately $0.7 million of the escrow fund was paid out to cover expenses related to an indemnified claim.
	On August 24, 2012, the Company received notification from CareCentrix of its election to draw seller financing from the escrow fund pursuant to the terms of the stock purchase agreement. As such, the Company reclassified its escrow receivable of approximately $9.9 million from prepaid expenses and other current assets to a seller financing note from CareCentrix on the Company's consolidated balance sheet as of September 30, 2012. The seller financing note receivable, which bears interest at 18 percent, matures on the earlier of March 19, 2017 or upon the sale of CareCentrix Holdings. Interest on this note is payable quarterly, in kind, and will accrete as additional principal on the note. The Company expects to record interest income at the time of receipt as the note is part of the proposed settlement discussed below.
	On September 17, 2012, the Company received a formal notice of claims for indemnification from CareCentrix. In the notice, CareCentrix asserted that the total claimed amounts exceed the total amount in escrow and demanded that the entire principal amount of the seller financing note receivable be reduced to zero. In anticipation of a settlement of claims alleged by the owner of CareCentrix and working capital adjustments as set forth in the stock purchase agreement, during the fourth quarter of 2012, the Company recorded a $6.5 million adjustment to the seller financing note receivable to reflect its revised estimated fair value of $3.4 million. The Company also established an investment in CareCentrix of $0.9 million for shares that it may receive as part of any settlement. During the third quarter of 2014, the Company received cash of approximately $3.6 million in settlement of the seller financing note receivable and the Company's investment in CareCentrix. In connection with the settlement, the Company recorded a loss of approximately $0.5 million in equity in net loss of CareCentrix, net of tax in the Company's consolidated statement of comprehensive income.
	The Company’s financing receivables consist of the previously described $25.0 million subordinated promissory note from CareCentrix, Inc. dated September 19, 2011. The Company measures impairment based on the present value of expected cash flows after considering assumptions relating to risk factors and economic conditions. On an ongoing basis, the Company assesses the credit quality based on the Company’s review of CareCentrix, Inc.’s financial position and receipt of interest payments when due. Based on the Company’s analysis, as of September 30, 2014 and December 31, 2013, the Company had no allowances for credit losses.

Cost_Savings_Initiatives_and_A

Cost Savings Initiatives and Acquisition and Integration Activities	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Cost Savings Initiatives and Acquisition and Integration Activities	'
	Cost Savings Initiatives and Acquisition and Integration Activities
	The Company recorded net charges relating to cost savings initiatives and acquisition and integration activities of $0.5 million and $10.5 million for the third quarter and first nine months of 2014, respectively, and $1.7 million and $2.6 million for the third quarter and first nine months of 2013, respectively, which were recorded in selling, general and administrative expenses in the Company’s consolidated statements of comprehensive income.
	Cost Savings Initiatives
	During the fourth quarter of 2013, the Company undertook a corporate restructuring initiative, referred to as "One Gentiva", to better align its home health, hospice and community care businesses under a common regional management structure. In addition, the Company undertook a branch rationalization initiative to review under performing branches. As a result of this review, the Company closed or consolidated 94 branches through the third quarter of 2014. As such, the Company recorded charges of $0.2 million and $4.3 million for the third quarter and first nine months of 2014, respectively, primarily related to severance and facility lease costs. The Company substantially completed these costs savings initiatives during the second quarter of 2014.
	For the third quarter and first nine months of 2013, the Company recorded charges related to cost savings initiatives of $0.1 million and $0.3 million, respectively. These costs primarily related to a 2012 initiative to reduce ongoing operating costs related to branch structure and support infrastructure. The Company substantially completed these cost savings initiatives during the second quarter of 2013.
	Acquisition and Integration Activities
	The Company recorded charges of $0.3 million and $6.2 million for the third quarter and first nine months of 2014, respectively, and $1.6 million and $2.3 million for the third quarter and first nine months of 2013, respectively, primarily related to the Company's acquisition of Harden. These costs consisted of (i) severance and lease costs associated with consolidation of branches in overlapping markets and consolidation of back office functions and (ii) legal, accounting and other professional fees and expenses associated with the transaction. The Company expects to complete its integration activities in early 2015.
	The costs incurred and cash expenditures associated with these activities by component were as follows (in thousands):
		Cost Savings Initiatives			Acquisition &			Total
					Integration
	Balance at December 31, 2012	$	1,685		$	1,011		$	2,696
	Charge in first quarter 2013	47			94			141
	Cash expenditures	(1,104		)	(322		)	(1,426		)
	Ending balance at March 31, 2013	628			783			1,411
	Charge in second quarter 2013	138			606			744
	Cash expenditures	(685		)	(234		)	(919		)
	Ending balance at June 30, 2013	81			1,155			1,236
	Charge in third quarter 2013	77			1,622			1,699
	Cash expenditures	(240		)	(283		)	(523		)
	Non-cash reclassification	476			(476		)	—
	Ending balance at September 30, 2013	$	394		$	2,018		$	2,412
	Balance at December 31, 2013	$	6,722		$	9,703		$	16,425
	Charge in first quarter 2014	2,713			2,628			5,341
	Cash expenditures	(3,443		)	(3,472		)	(6,915		)
	Non-cash expenditures	(60		)	(86		)	(146		)
	Ending balance at March 31, 2014	5,932			8,773			14,705
	Charge in second quarter 2014	1,409			3,250			4,659
	Cash expenditures	(2,994		)	(3,717		)	(6,711		)
	Non-cash expenditures	(276		)	5			(271		)
	Ending balance at June 30, 2014	4,071			8,311			12,382
	Charge in third quarter 2014	195			284			479
	Cash expenditures	(1,302		)	(1,908		)	(3,210		)
	Non-cash expenditures	35			3			38
	Ending balance at September 30, 2014	$	2,999		$	6,690		$	9,689
	The balance of unpaid charges relating to cost savings initiatives and other restructuring costs and acquisition and integration activities approximated $9.7 million at September 30, 2014 and $16.4 million at December 31, 2013, which were included in other accrued expenses in the Company’s consolidated balance sheets.

Goodwill_and_Identifiable_Inta

Goodwill and Identifiable Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Identifiable Intangible Assets and Goodwill	'
	Identifiable Intangible Assets
	The Company is required to test goodwill and other indefinite-lived intangible assets for impairment on an annual basis and between annual tests if current events or circumstances require an interim impairment assessment. The Company allocates goodwill to its various reporting units upon the acquisition of the assets or stock of another third party business operation. The Company compares the fair value of each reporting unit to the carrying amount of their allocated net assets to determine if there is a potential impairment of goodwill. If the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the fair value of the goodwill within the reporting unit is less than the carrying value of its goodwill.
	To determine the fair value of the Company's reporting units, the Company uses a present value (discounted cash flow) technique corroborated by market multiples when available, a reconciliation to market capitalization or other valuation methodologies and reasonableness tests, as appropriate. Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. The future occurrence of a potential indicator of impairment, such as, but not limited to, a significant adverse change in legal factors or business climate, reductions of projected patient census, an adverse action or assessment by a regulator, as well as other unforeseen factors, would require an interim assessment for some or all of the reporting units.
	If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of other indefinite-lived intangible assets are determined based on discounted cash flows or appraised values, as appropriate.
	The Company's operations include three reporting units: Home Health, Hospice and Community Care. At March 31, 2013, the Company determined that a triggering event had occurred due to lower than expected average daily census and higher than expected discharge rates during the quarter and performed an interim impairment test of its Hospice reporting unit. For purposes of the interim impairment test, the Company applied certain assumptions that included, but were not limited to, patient census projections, gross margin assumptions, operating efficiencies and economies of scale. To determine fair value, the Company considered the income approach, which determines fair value based on estimated future cash flows of the reporting unit, discounted by an estimated weighted-average cost of capital (“discount rate”), which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn. The Company used a discount rate of 9.5 percent to calculate the fair value of its Hospice reporting unit. Based on the results of the interim impairment test, the Company's Hospice reporting unit had an estimated fair value of approximately $555 million. As such, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million, which is reflected in goodwill and other long-lived asset impairment in the Company's consolidated comprehensive statement of income for the nine months ended September 30, 2013.
	The gross carrying amount and accumulated amortization of each category of identifiable intangible assets as of September 30, 2014 and December 31, 2013 were as follows (in thousands):
		30-Sep-14												December 31, 2013 (Restated)												Useful
																										Life
		Home			Hospice			Community Care			Total			Home			Hospice			Community Care			Total
		Health												Health
	Amortized intangible assets:
	Covenants not to compete	$	2,157		$	16,183		$	1,029		$	19,369		$	2,157		$	16,183		$	1,029		$	19,369		2-5 Yrs
	Less: accumulated amortization	(1,709		)	(15,837		)	(327		)	(17,873		)	(1,553		)	(15,720		)	(91		)	(17,364		)
	Net covenants not to compete	448			346			702			1,496			604			463			938			2,005
	Customer relationships	27,196			910			—			28,106			27,196			910			—			28,106			5-10 Yrs
	Less: accumulated amortization	(21,703		)	(549		)	—			(22,252		)	(19,997		)	(481		)	—			(20,478		)
	accumulated impairment losses	(27		)	—			—			(27		)	(27		)	—			—			(27		)
	Net customer relationships	5,466			361			—			5,827			7,172			429			—			7,601
	Tradenames	19,267			17,528			11,922			48,717			19,267			17,528			11,922			48,717			5-10 Yrs
	Less: accumulated amortization	(12,795		)	(4,368		)	(1,134		)	(18,297		)	(11,992		)	(3,763		)	(227		)	(15,982		)
	accumulated impairment losses	(6,421		)	(13,122		)	—			(19,543		)	(6,421		)	(13,122		)	—			(19,543		)
	Net tradenames	51			38			10,788			10,877			854			643			11,695			13,192
	Licenses	714			9,289			—			10,003			714			8,021			—			8,735
	Less: accumulated amortization	(714		)	(8,782		)	—			(9,496		)	(588		)	(6,812		)	—			(7,400		)
	Net licenses	—			507			—			507			126			1,209			—			1,335
	Amortized intangible assets	5,965			1,252			11,490			18,707			8,756			2,744			12,633			24,133
	Indefinite-lived intangible assets:
	Licenses and certificates of need	245,086			104,364			26,011			375,461			245,086			105,632			26,011			376,729
	Less: accumulated impairment	(144,672		)	(2,463		)	—			(147,135		)	(144,672		)	(2,463		)	—			(147,135		)
	losses
	Net licenses and certificates of need	100,414			101,901			26,011			228,326			100,414			103,169			26,011			229,594
	Total identifiable intangible assets	$	106,379		$	103,153		$	37,501		$	247,033		$	109,170		$	105,913		$	38,644		$	253,727
	The Company recorded amortization expense of approximately $2.5 million and $6.7 million for the third quarter and first nine months of 2014, respectively, and $1.2 million and $4.0 million for the third quarter and first nine months of 2013, respectively. The estimated amortization expense for the remainder of 2014 is $1.6 million and for each of the next five succeeding years approximates $4.1 million for 2015, $3.1 million for 2016, $2.4 million for 2017, $1.6 million for 2018, and $1.3 million for 2019.
	The gross carrying amount of goodwill as of September 30, 2014 and December 31, 2013 and activity during the first nine months of 2014 were as follows (in thousands):
		Goodwill, Gross												Accumulated Impairment Losses
		Home Health			Hospice			Community Care			Total			Home Health			Hospice			Total			Net
	Balance at December 31, 2013 (Restated)	$	386,719		$	944,187		$	116,534		$	1,447,440		$	(263,370	)	$	(800,583	)	$	(1,063,953	)	$	383,487
	Harden purchase accounting adjustment	(3,023		)	(3,021		)	(3,419		)	(9,463		)	—			—			—			(9,463		)
	Balance at September 30, 2014:	$	383,696		$	941,166		$	113,115		$	1,437,977		$	(263,370	)	$	(800,583	)	$	(1,063,953	)	$	374,024

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share
	Basic and diluted earnings per share for each period presented have been computed by dividing net income (loss) attributable to Gentiva shareholders by the weighted average number of shares outstanding for each respective period. The computations of the basic and diluted per share amounts were as follows (in thousands, except per share amounts):
		For the Three Months Ended				For the Nine Months Ended
		30-Sep-14		September 30, 2013 (Revised)		30-Sep-14		September 30, 2013 (Revised)
	Net income (loss) attributable to Gentiva shareholders	$	8,045	$	3,563	$	17,687	$	(184,441	)
	Basic weighted average common shares outstanding	36,369		31,037		36,285		30,921
	Shares issuable upon the assumed exercise of stock options and under stock plans for employees and directors using the treasury stock method	1,177		495		767		—
	Diluted weighted average common shares outstanding	37,546		31,532		37,052		30,921
	Earnings per share:
	Basic	$	0.22	$	0.12	$	0.49	$	(5.97	)
	Diluted	$	0.21	$	0.11	$	0.48	$	(5.97	)
	Anti-dilutive shares by type:
	Stock options	1,492		3,054		2,674		2,947
	Performance share units	—		—		—		80
	Restricted stock	—		—		—		232
	Total anti-dilutive shares	1,492		3,054		2,674		3,259
	For the third quarter and first nine months of 2014, approximately 1.5 million and 2.7 million, respectively, of stock options were excluded from the computations of diluted earnings per share, as their inclusion would be anti-dilutive. For the third quarter and first nine months of 2013, approximately 3.1 million and 3.3 million, respectively, of stock options, performance share units and restricted stock awards were excluded from the computations of diluted earnings per share as their inclusion would be anti-dilutive.

LongTerm_Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	Long-Term Debt
	Credit Arrangements
	At September 30, 2014, the the Company’s credit arrangements included a senior secured credit agreement providing (i) a six-year $670 million Term Loan B facility, (ii) a five-year $155 million Term Loan C facility and (iii) a five-year $100 million revolving credit facility (collectively, the “Credit Agreement”), and $325 million aggregate principal amount of 11.5 percent Senior Notes due 2018 (the “Senior Notes”). The Credit Agreement’s revolving credit facility also includes borrowing capacity of $80 million available for letters of credit and $15 million for borrowings on same-day notice, referred to as swing line loans.
	As of September 30, 2014 and December 31, 2013, the Company’s long-term debt consisted of the following (in thousands):
		September 30, 2014			December 31, 2013
	Credit Agreement:
	Term Loan B, maturing October 18, 2019, net of unamortized discount of $5,780 and $6,508 as of September 30, 2014 and December 31, 2013, respectively	$	659,196		$	663,492
	Term Loan C, maturing October 18, 2018, net of unamortized discount of $589 and $735 as of September 30, 2014 and December 31, 2013, respectively	145,692			154,265
	11.5% Senior Notes due 2018	325,000			325,000
	Revolving Credit Facility	27,000			27,000
	Total debt	1,156,888			1,169,757
	Less: current portion of long-term debt	(51,138		)	(45,325		)
	Total long-term debt	$	1,105,750		$	1,124,432
	As of September 30, 2014, advances under the revolving credit facility could be made, and letters of credit could be issued, up to the $100 million borrowing capacity of the facility at any time prior to the facility expiration date of October 18, 2018. Outstanding letters of credit were $56.2 million and $52.0 million at September 30, 2014 and December 31, 2013, respectively. The letters of credit were issued to guarantee payments under the Company’s workers’ compensation program and for certain other commitments. As of September 30, 2014, the Company’s unused and available borrowing capacity under the Credit Agreement was $16.8 million. As governed by the indenture covering the unsecured Senior Notes, the Company has a maximum permitted borrowing capacity, as defined, which may limit the Company's ability to borrow up to the full capacity of the revolving credit facility.
	The Term Loan B facility is subject to mandatory principal payments of $6.7 million per year, payable in equal quarterly installments, with the remaining balance of the original $670 million loan payable on October 18, 2019. The Term Loan C facility is subject to mandatory principal payments, payable in quarterly installments. The mandatory principal payments for 2014 are $11.6 million and increase each year through the maturity date of the loan, October 18, 2018.
	As of September 30, 2014, the mandatory aggregate principal payments of long-term debt were $51.1 million due during the twelve months ending September 30, 2015, $29.0 million due during the twelve months ending September 30, 2016, $35.8 million due during the twelve months ending September 30, 2017, $60.9 million due during the twelve months ending September 30, 2018, $30.0 million due during the twelve months ending September 30, 2019 and $631.5 million thereafter under the Credit Agreement, and $325.0 million due in September 2018 under the Senior Notes. The weighted average cash interest rate on outstanding borrowings was 7.8 percent per annum at September 30, 2014 and 8.2 percent per annum at December 31, 2013.
	The Company may voluntarily repay outstanding loans under the revolving credit facility or the term loans at any time without premium or penalty, other than customary “breakage” costs with respect to LIBOR loans. Prepayment and commitment reductions will be required in connection with (i) certain asset sales, (ii) certain extraordinary receipts such as certain insurance proceeds, (iii) cash proceeds from the issuance of debt and (iv) 75 percent of “Excess Cash Flow” (as defined in the Credit Agreement) with two step-downs based on the Company’s leverage ratio.
	The interest rate per annum on borrowings under the Credit Agreement is based on, at the option of the Company, (i) the Eurodollar Rate, adjusted for certain costs plus an Applicable Margin or (ii) the Base Rate, plus an Applicable Rate. The Base Rate represents the highest of (x) the Barclays Bank prime rate, (y) the federal funds rate plus 0.50 percent or (z) the Eurodollar Rate adjusted for certain costs plus 1.00 percent. In connection with determining the interest rates on the Term Loan B and Term Loan C facilities, in no event shall the Eurodollar Rate be less than 1.25 percent and the Base Rate be less than 2.25 percent. The Company may select interest periods of one, two, three or six months for Eurodollar Rate loans. Interest is payable at the end of the selected interest period. The Company must also pay a fee of 0.50 percent per annum on unused commitments under the revolving credit facility. As of September 30, 2014, the interest rate on Term Loan B borrowings was 6.50 percent, on Term Loan C borrowings was 5.75 percent and on revolving credit borrowings was 4.77 percent.
	The Applicable Rate component of the interest rate under the Company's Credit Agreement is based on the Company's consolidated leverage ratio as follows:
		Applicable Rates
		Eurodollar Rate for Revolving Credit Facility and Letter of Credit Fees		Base Rate for Revolving Credit Facility	Term Loan B			Term Loan C
	Consolidated				Eurodollar Rate		Base Rate	Eurodollar Rate	Base Rate
	Leverage Ratio
	> 4.0:1	4.50%		3.50%	5.25%		4.25%	4.50%	3.50%
	< 4.0:1	4.25%		3.25%	5.25%		4.25%	4.50%	3.50%
	Debt Covenants
	The Credit Agreement contains a number of covenants that, among other things, restrict, subject to certain exceptions, the Company’s and its subsidiaries’ ability to incur additional indebtedness or issue certain preferred stock, create liens on assets, enter into sale and leaseback transactions, engage in mergers or consolidations with other companies, sell assets, pay dividends, repurchase capital stock, make investments, loans and advances, make certain acquisitions, engage in certain transactions with affiliates, amend material agreements, repay certain indebtedness, change the nature of the Company’s business, change accounting policies and practices, grant negative pledges and incur capital expenditures. The Credit Agreement also requires the Company to maintain a maximum consolidated leverage ratio, as calculated based on provisions in the Credit Agreement that provide for certain defined adjustments to consolidated EBITDA, and contains certain customary affirmative covenants and events of default.
	Gentiva’s permitted maximum consolidated leverage ratio is set forth in the following table:
	Four Quarters Ending	Maximum Consolidated
		Leverage Ratio
	March 31, 2014 to March 31, 2015	≤ 6.75:1
	June 30, 2015 to March 31, 2016	≤ 6.50:1
	June 30, 2016 to March 31, 2017	≤ 6.25:1
	June 30, 2017 to December 31, 2017	≤ 6.00:1
	March 31, 2018 and each fiscal quarter thereafter	≤ 5.75:1
	As of September 30, 2014, the Company’s consolidated leverage ratio was 5.8x. As of September 30, 2014, the Company was in compliance with all covenants in the Credit Agreement.
	Guaranty Agreement and Security Agreement
	Gentiva and substantially all of its subsidiaries (the “Guarantor Subsidiaries”) entered into a guaranty agreement pursuant to which the Guarantor Subsidiaries have agreed, jointly and severally, fully and unconditionally to guarantee all of the Company’s obligations under the Credit Agreement. Additionally, Gentiva and its Guarantor Subsidiaries entered into a security agreement pursuant to which a first-priority security interest was granted in substantially all of the Company’s and its Guarantor Subsidiaries’ present and future real, personal and intangible assets, including the pledge of 100 percent of all outstanding capital stock of substantially all of the Company’s domestic subsidiaries to secure full payment of all of the Company’s obligations for the ratable benefit of the lenders.
	Senior Notes
	The Senior Notes are unsecured, senior subordinated obligations of the Company. The Senior Notes are guaranteed by all of Gentiva’s subsidiaries that are guarantors under the Credit Agreement. Interest on the Senior Notes accrues at a rate of 11.5 percent per annum and is payable semi-annually in arrears on March 1 and September 1. Gentiva will make each interest payment to the holders of record on the immediately preceding February 15 and August 15.
	The Senior Notes mature on September 1, 2018 and are generally free to be transferred. Gentiva may redeem the Senior Notes, in whole or in part, at any time prior to the first interest payment of 2014, at a price equal to 100 percent of the principal amount of the Senior Notes redeemed plus an applicable make-whole premium based on the present value of the remaining payments discounted at the treasury rate plus 50 basis points plus accrued and unpaid interest, if any, to the date of redemption.
	On or after September 1, 2014, Gentiva may redeem all or part of the Senior Notes at redemption prices set forth below plus accrued and unpaid interest and Additional Interest, if any, as defined in the indenture relating to the Senior Notes during the twelve month period beginning on September 1 of the years indicated below:
	Year	Redemption Percentage
	2014	105.75%
	2015	102.88%
	2016 and thereafter	100.00%

Equity

Equity	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Equity	'
	Equity
	Changes in equity for the nine months ended September 30, 2014 and 2013 were as follows (in thousands, except share amounts):
		Gentiva Shareholders
		Common Stock			Additional			Retained			Treasury Stock			Noncontrolling Interests
					Paid-in Capital			Earnings
		Shares	Amount					Accumulated (Deficit)									Total
	Balance at December 31, 2012 (Revised)	32,009,286	$	3,201	$	399,148		$	(153,075	)	$	(17,852	)	$	1,538		$	232,960
	Comprehensive (loss) income:
	Net (loss) income	—	—		—			(184,441		)	—			425			(184,016		)
	Total comprehensive (loss) income	—	—		—			(184,441		)	—			425			(184,016		)
	Income tax expense associated with the exercise of non-qualified stock options	—	—		(330		)	—			—			—			(330		)
	Equity-based compensation expense	—	—		5,984			—			—			—			5,984
	Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	640,805	64		2,392			—			—			—			2,456
	Minority interest capital contribution	—	—		—			—			—			1,600			1,600
	Distribution to partnership interests	—	—		—			—			—			(563		)	(563		)
	Treasury shares:
	Stock withheld (25,801 shares) for payroll tax withholdings related to equity-based compensation	25,801	3		—			—			(286		)	—			(283		)
	Balance at September 30, 2013 (Revised)	32,675,892	$	3,268	$	407,194		$	(337,516	)	$	(18,138	)	$	3,000		$	57,808
	Balance at December 31, 2013 (Restated)	37,713,302	$	3,771	$	462,262		$	(758,136	)	$	(18,773	)	$	2,875		$	(308,001	)
	Comprehensive income:
	Net income	—	—		—			17,687			—			170			17,857
	Total comprehensive income	—	—		—			17,687			—			170			17,857
	Income tax expense associated with the exercise of non-qualified stock options	—	—		(2,261		)	—			—			—			(2,261		)
	Equity-based compensation expense	—	—		6,643			—			—			—			6,643
	Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	559,528	56		1,881			—			—			—			1,937
	Minority interest capital contribution	—	—		—			—			—			1,160			1,160
	Acquisition of non-controlling interest	—	—		(1,748		)	—			—			—			(1,748		)
	Distribution to partnership interests	—	—		—			—			—			(393		)	(393		)
	Treasury shares:
	Stock withheld (32,662 shares) for payroll tax withholdings related to equity-based compensation	—	—		—			—			(392		)	—			(392		)
	Balance at September 30, 2014	38,272,830	$	3,827	$	466,777		$	(740,449	)	$	(19,165	)	$	3,812		$	(285,198	)
	Comprehensive income amounted to $8.0 million and $17.9 million for the third quarter and first nine months of 2014, respectively, as compared to comprehensive income of $3.7 million and comprehensive loss of $184.0 million for the third quarter and first nine months of 2013, respectively.
	The Company has an outstanding stock repurchase plan authorized by its Board of Directors to repurchase of up to $5,000,000 of shares of the Company’s outstanding common stock (the “2012 Repurchase Program”). During the nine months ended September 30, 2014 and September 30, 2013, the Company did not repurchase shares of its outstanding common stock. As of September 30, 2014, the Company had remaining authorization under the 2012 Repurchase Program to repurchase common stock with an aggregate purchase price of up to $1.5 million, subject to the additional limitations set forth below.
	The Company’s Credit Agreement provides for repurchases of the Company’s common stock not to exceed $7.5 million per year, and not to exceed $25.0 million per year if the consolidated leverage ratio is less than or equal to 3.5:1 immediately after giving effect on a pro forma basis to the repurchase. The indenture governing the Company’s Senior Notes also contains limitations on the Company’s repurchases of its common stock.

EquityBased_Compensation_Plans

Equity-Based Compensation Plans	9 Months Ended
	Sep. 30, 2014
Share-based Compensation [Abstract]	'
Equity-Based Compensation Plans	'
	Equity-Based Compensation Plans
	The Company provides several equity-based compensation plans under which the Company’s officers, employees and non-employee directors may participate, including (i) the 2004 Equity Incentive Plan (amended and restated as of March 16, 2011, as further amended by Amendment Nos. 1 and 2 thereto) (“2004 Plan”), (ii) the Stock & Deferred Compensation Plan for Non-Employee Directors (“DSU Plan”) and (iii) the Employee Stock Purchase Plan (“ESPP”). Collectively, these equity-based compensation plans permit the grants of (i) incentive stock options, (ii) non-qualified stock options, (iii) stock appreciation rights, (iv) restricted stock, (v) performance units, (vi) stock units and (vii) cash, as well as allow employees to purchase shares of the Company’s common stock under the ESPP at a pre-determined discount.
	For the third quarter and first nine months of 2014, the Company recorded equity-based compensation expense, as calculated on a straight-line basis over the vesting periods of the related equity instruments, of $2.3 million and $6.6 million, respectively, as compared to $2.0 million and $6.0 million for the corresponding periods of 2013, which were reflected as selling, general and administrative expense in the consolidated statements of comprehensive income.
	Stock Options
	The weighted average fair values of the Company’s stock options granted during the first nine months of 2014 and 2013 calculated using the Black-Scholes option pricing model and other assumptions were as follows:
		Nine Months Ended
		September 30, 2014				September 30, 2013
	Weighted average fair value of options granted	$	5.08			$	10.74
	Risk-free interest rate	0.46% - 0.51%				0.29% - 0.54%
	Expected volatility	60% - 63%				76% - 79%
	Contractual life	7 years				7 years
	Expected life	3.4 - 5.4 years				3.4 - 5.4 years
	Expected dividend yield	—		%		—		%
	During the first nine months of 2014, the Company issued 375,000 stock options that are both time-vesting (one-third each year) and carry a market vesting feature based on the average 30-day closing stock price of the Company's common stock based on stock price thresholds of $14, $16, and $18 (each covering one-third of the options granted). The fair value of the stock options granted ranged from $5.15 to $5.88 and was determined using the Monte Carlo stock option valuation model. Assumptions used in the model included volatility of 63 percent, risk-free interest rate of 1.32 percent, zero percent dividend yield, a forfeiture rate based on the Company's historical experience and a contractual life of seven years.
	Stock option grants in 2011 through 2014 vest over a three-year period based on a vesting schedule that provides for one-third vesting after each year. In addition, the Company also issued stock options in 2013 and 2014 that are both time-vesting (one-third each year) and carry a market vesting feature based on the average 30-day closing stock price of the Company's common stock. Stock option grants in 2010 fully vest over a four-year period based on a vesting schedule that provides for one-half vesting after year two and an additional one-fourth vesting after each of years three and four. The Company’s expected volatility assumptions are based on the historical volatility of the Company’s stock price over a period corresponding to the expected term of the stock option. Forfeitures are estimated utilizing the Company’s historical forfeiture experience. The expected life of the Company’s stock options is based on the Company’s historical experience of the exercise patterns associated with its stock options.
	A summary of Gentiva stock option activity as of September 30, 2014 and changes during the nine months then ended is presented below:
		Number of			Weighted-				Weighted-		Aggregate
		Options			Average				Average		Intrinsic
					Exercise				Remaining		Value
					Price				Contractual
									Life (Years)
	Balance as of December 31, 2013	4,005,589			$	15.4
	Granted	737,500			10.9
	Exercised	(27,268	)		7.16
	Cancelled	(722,674	)		19.65
	Balance as of September 30, 2014	3,993,147			$	13.86			4.4		$	20,692,356
	Exercisable options	2,404,269			$	16.71			3.6		$	9,208,192
	Shares expected to vest as of September 30, 2014	1,534,806			$	9.51			5.5		$	11,163,322
	The total intrinsic value of options exercised during the nine months ended September 30, 2014 and September 30, 2013 was $0.2 million and $0.4 million, respectively. As of September 30, 2014 and 2013, the Company had $4.2 million and $4.3 million, respectively, of total unrecognized compensation cost related to nonvested stock options. This compensation expense is expected to be recognized over a weighted-average period of 1.4 years and 1.5 years, respectively. The total fair value of options that vested during the first nine months of 2014 was $2.4 million.
	Performance Based Awards
	The Company may grant performance based awards under its 2004 Plan that are either settled in shares of the Company's common stock or settled in cash depending on the individual award type. Performance based awards may result in the issuance of a range of shares of common stock or cash based on the achievement of defined levels of performance criteria. Performance based awards also carry a three-year service period requirement from the date of grant to vest. Forfeitures are estimated utilizing the Company’s historical forfeiture experience.
	A summary of Gentiva's performance based cash award activity by grant year as of September 30, 2014 is presented below:
		2012				2013				2014
	Service period to vest:	3 years				3 years				3 years
	Performance range of target:	0% - 200%				0% - 240%				0% - 240%
	Performance measured on:	EPS				EPS				EPS
	Performance measurement period:	1/2 based on 2012 results				30% based on 2013 results				100% based on 2016 results
		1/2 based on 2014 results				70% based on 2015 results
	Performance target achieved:	2012 - 85%				2013 - 0%
	Performance cash:
	Balance at December 31, 2013 - Earned	$	1,804,656			$	—			$	—
	Cancellations	(28,688		)		—				—
	Balance at September 30, 2014 - Earned	$	1,775,968			$	—			$	—
	Balance at December 31, 2013 - Unearned	$	2,123,125			$	4,638,750			$	—
	Granted	—				—				5,795,250
	Performance target not achieved	—				(1,076,250		)		—
	Cancellations	(33,750		)		—				(80,000		)
	Balance at September 30, 2014 - Unearned	$	2,089,375			$	3,562,500			$	5,715,250
	For the third quarter and first nine months of 2014, the Company recorded $1.0 million and $2.9 million, respectively, of compensation expense associated with its performance based cash awards as compared to $0.8 million and $1.7 million for the corresponding periods of 2013. As of September 30, 2014, the Company had unrecognized compensation cost at target of $5.3 million to be recognized over a weighted-average period of 1.9 years.
	Restricted Stock
	A summary of Gentiva restricted stock activity as of September 30, 2014 is presented below:
		Number of			Weighted-				Aggregate
		Restricted			Average				Intrinsic
		Shares			Exercise				Value
					Price
	Balance as of December 31, 2013	635,400			$	18.27
	Granted	366,000			10.79
	Exercised	(88,900	)		26.58
	Cancelled	(12,200	)		11.27
	Balance as of September 30, 2014	900,300			$	14.54			$	15,107,034
	Nonvested shares expected to vest as of September 30, 2014	846,994			$	14.74			$	14,212,557
	The restricted stock fully vests at the end of a three-year or five-year period, depending on the individual grants. Forfeitures are estimated utilizing the Company’s historical forfeiture experience.
	As of September 30, 2014, the aggregate intrinsic value of the restricted stock awards was $15.1 million. The Company had $6.2 million and $5.8 million of total unrecognized compensation cost related to restricted stock as of September 30, 2014 and 2013, respectively. This compensation expense is expected to be recognized over a weighted-average period of 1.8 years and 2.2, respectively.
Directors Deferred Share Units
Under the Company’s DSU Plan, each non-employee director receives an annual deferred stock unit award credited quarterly and paid in shares of the Company’s common stock following termination of the director’s service on the Board of Directors. The total number of shares of common stock reserved for issuance under this plan is 650,000, of which 160,294 shares were available for future grants as of September 30, 2014. During the first nine months of 2014 and 2013, the Company granted 46,543 and 48,894 stock units, respectively, under the DSU Plan at a grant date weighted-average fair value of $13.54 and $11.04 per stock unit, respectively. Under the DSU Plan, 379,319 stock units were outstanding as of September 30, 2014.
Employee Stock Purchase Plan
The Company provides an ESPP under which the offering period is three months and the purchase price of shares is equal to 85 percent of the fair market value of the Company’s common stock on the last day of the three-month offering period. All employees of the Company are eligible to purchase stock under the ESPP regardless of their actual or scheduled hours of service. Under the Company’s ESPP, compensation expense is equal to the 15 percent discount from the fair market value of the Company’s common stock on the date of purchase. During the first nine months of 2014 and 2013, the Company issued 170,076 and 217,230 shares of common stock, respectively, under its ESPP.

Legal_Matters

Legal Matters	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Legal Matters	'
	Legal Matters
	Litigation
	In addition to the matters referenced in this Note 14, the Company is party to certain legal actions arising in the ordinary course of business, including legal actions arising out of services rendered by its various operations, personal injury and employment disputes. Management does not expect that these other legal actions will have a material adverse effect on the business, financial condition, results of operations, liquidity or capital resources of the Company.
	On May 10, 2010, a collective and class action complaint entitled Lisa Rindfleisch et al. v. Gentiva Health Services, Inc. was filed in the United States District Court for the Eastern District of New York against the Company in which five former employees ("Plaintiffs") alleged wage and hour law violations. The former employees claimed they were paid pursuant to “an unlawful hybrid” compensation plan that paid them on both a per visit and an hourly basis, thereby voiding their exempt status and entitling them to overtime pay. Plaintiffs alleged continuing violations of federal and state law and sought damages under the Fair Labor Standards Act (“FLSA”), as well as under the New York Labor Law and North Carolina Wage and Hour Act (“NCWHA”). On October 8, 2010, the Court granted the Company’s motion to transfer the venue of the lawsuit to the United States District Court for the Northern District of Georgia. On April 13, 2011, the Court granted Plaintiffs’ motion for conditional certification of the FLSA claims as a collective action. On May 26, 2011, the Court bifurcated the FLSA portion of the suit into a liability phase, in which discovery closed on January 15, 2013, and a potential damages phase, to be scheduled pending outcome of the liability phase. Following a motion for partial summary judgment by the Company regarding the New York state law claims, Plaintiffs agreed voluntarily to dismiss those claims in a filing on December 12, 2011. Plaintiffs filed a motion for certification of a North Carolina state law class for NCWHA claims on January 20, 2012. On August 29, 2012, the Court denied Plaintiffs' motion for certification of a North Carolina state law class. The Company filed a motion for partial summary judgment on Plaintiffs’ claims under the NCWHA on March 22, 2012, which the Court granted on January 16, 2013. On February 14, 2013, the Company filed two motions for partial summary judgment with regard to the Company's liability for Plaintiffs' FLSA claims. On the same day, Plaintiffs filed a motion for partial summary judgment in their favor with regard to the Company's liability. On July 26, 2013, the Court denied the Company's motion for summary judgment with regard to the Company's liability for Plaintiffs' FLSA claims and granted Plaintiffs' motion for summary judgment. On November 4, 2013, the Court denied the Company's motion to amend the District Court's July 26 Order to certify two legal issues for immediate interlocutory appeal to the Eleventh Circuit Court of Appeals. In its Order, the Court established a 30-day deadline for the Company to file its motion for decertification of the FLSA collective action class, which the Company then filed on December 4, 2013. On April 18, 2014, the Court issued an Order granting the Company's motion for decertification and dismissing the opt-in plaintiffs from the lawsuit without prejudice. On the same day, Plaintiffs filed a motion to amend the Court's Order to delay the effective date of the dismissal of the opt-in plaintiffs' claims for 60 days, until June 17, 2014. On May 8, 2014, the Court entered an Order granting Plaintiffs’ motion to amend, thereby extending the effective date of dismissal through June 17, 2014.  On June 17, 2014, approximately 194 of the former 999 opt-in plaintiffs who had been dismissed from this case filed a new Complaint against the Company in the United States District Court for the Northern District of Georgia as a separate, follow-on lawsuit with identical claims captioned Cynthia Bailey et al. v. Gentiva Health Services, Inc. Plaintiffs amended their Complaint on July 30, 2014 to add an additional 217 plaintiffs to the lawsuit. These were individuals who had been dismissed from the Rindfleisch lawsuit and who wished to continue to pursue their claims.  Given the filing of the follow-on lawsuit, at the June 19, 2014 settlement conference in the Rindfleisch lawsuit, it was determined that this case would be stayed and administratively closed pending the outcome of global mediation of both lawsuits, which took place on September 12, 2014. The parties were unable to resolve the Rindfleisch and Bailey matters at the September 12 global mediation; however, they continue to engage in settlement negotiations notwithstanding. If there is no settlement which resolves all issues in the Rindfleisch lawsuit, this lawsuit will be re-opened upon the request of either party, so long as the request is made within 90 days following the September 12, 2014 mediation. The Company filed its answer and a motion to drop the Bailey plaintiffs for misjoinder on October 10, 2014. Plaintiffs in this lawsuit are seeking attorneys' fees, back wages and liquidated damages going back three years from the filing of the complaint under the FLSA.
	Based on the information the Company has at this time in the Rindfleisch and Bailey lawsuits, the Company is unable to assess the probable outcome or potential liability, if any, arising from these proceedings on the business, financial condition, results of operations, liquidity or capital resources of the Company. The Company does not believe that an estimate of a reasonably possible loss or range of loss can be made for these lawsuits at this time. The Company intends to defend itself vigorously in these lawsuits.
	On June 11, 2010, a collective and class action complaint entitled Catherine Wilkie, individually and on behalf of all others similarly situated v. Gentiva Health Services, Inc. was filed in the United States District Court for the Eastern District of California against the Company in which a former employee alleged wage and hour violations under the FLSA and California law. The complaint alleged that the Company paid some of its employees on both a per visit and hourly basis, thereby voiding their exempt status and entitling them to overtime pay. The complaint further alleged that California employees were subject to violations of state laws requiring meal and rest breaks, overtime pay, accurate wage statements and timely payment of wages. The plaintiff sought class certification, attorneys’ fees, back wages, penalties and damages going back three years on the FLSA claim and four years on the state wage and hour claims. The Company denies the plaintiff's allegations but, following a March 2012 mediation, agreed to pay a total settlement amount of $5 million to settle the collective and class action claims. The federal district court granted final approval of the settlement on March 26, 2013, and funds were disbursed to the participating class members, 99 percent of whom timely negotiated their settlement checks. The unclaimed wages will escheat to the State of California, and any balance remaining will be distributed to a cy pres beneficiary at the conclusion of the escheat process. A status conference is scheduled for June 22, 2015, at which time the parties will present a final accounting of the settlement fund, and the court is expected to approve distribution of the residual to the cy pres beneficiary and dismiss the case.
	On July 10, 2013, the Company was served with a complaint captioned United States ex rel. Vicky White v. Gentiva Health Services, Inc., which had been filed on September 8, 2010 as a qui tam action in United States District Court for the Eastern District of Tennessee by a former employee, Vicky White, as relator. The United States had declined to intervene in this action on April 5, 2013. Relator seeks treble damages and civil penalties under the federal False Claims Act for alleged violations by the Company in presenting false claims for payment and receiving Medicare reimbursement for certain home health services it had provided and also seeks damages relating to her alleged retaliatory discharge by the Company. On September 6, 2013, the Company filed a motion to dismiss the action in its entirety. On June 25, 2014, the court granted in part the Company's motion to dismiss and dismissed four of the five fraudulent schemes alleged by relator. The court denied the Company's motion to dismiss as to the remaining alleged fraudulent scheme of recertifying psychiatric patients and as to relator's claim of alleged retaliatory discharge. The Company filed its answer to the complaint on July 23, 2014. Given the preliminary stage of this action and the limited information that the Company has regarding this matter, the Company is unable to assess the probable outcome or potential liability, if any, arising from this action. The Company intends to defend itself vigorously in this lawsuit.
	Federal Securities Class Action Litigation
	Between November 2, 2010 and October 25, 2011, five shareholder class actions were filed against Gentiva and certain of its current and former officers and directors in the United States District Court for the Eastern District of New York. Each of these actions asserted claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "1934 Act") in connection with the Company’s participation in the Medicare Home Health Prospective Payment System (“HH PPS”). Following consolidation of the actions and the appointment of Los Angeles City Employees’ Retirement System as lead plaintiff, on April 16, 2012, a consolidated shareholder class action complaint, captioned In re Gentiva Securities Litigation, Civil Action No. 10-CV-5064, was filed in the United States District Court for the Eastern District of New York. The complaint, which named Gentiva and certain current and former officers and directors as defendants, asserted claims under Sections 10(b) and 20(a) of the 1934 Act, as well as Sections 11 and 15 of the Securities Act of 1933 (the "1933 Act"), in connection with the Company’s participation in the HH PPS. The complaint alleged, among other things, that the Company’s public disclosures misrepresented and failed to disclose that the Company improperly increased the number of in-home therapy visits to patients for the purposes of triggering higher reimbursement rates under the HH PPS, which caused an artificial inflation in the price of Gentiva’s common stock during the period between July 31, 2008 and October 4, 2011. On June 15, 2012, defendants filed a motion to dismiss the complaint. On March 25, 2013, the court granted defendants' motion to dismiss with leave to amend the complaint in accordance with the court's rulings as set forth in its March 25 order. On May 10, 2013, lead plaintiff filed a consolidated amended class action complaint, and, on June 24, 2013, defendants filed a motion to dismiss. On September 19, 2013, the court granted in part and denied in part defendants’ motion to dismiss. As a result of the court’s decision, the named current officers and directors were dismissed from the action, and certain claims against Gentiva and a former officer and a former officer/director remained. On October 3, 2013, the remaining defendants moved for partial reconsideration of the court’s September 19 order. On December 10, 2013, the court granted in part and denied in part the remaining defendants' motion for partial reconsideration. As a result of the court's decision, Gentiva and the former officer were dismissed from the action, and only a Section 10(b) claim against the former officer/director remains. On January 9, 2014, the former officer/director filed an answer to the consolidated amended class action complaint. On January 28, 2014, lead plaintiff filed a motion for the entry of final judgment under Rule 54(b) of the Federal Rules of Civil Procedure. On March 3, 2014, the court granted in part and denied in part lead plaintiff's motion under Rule 54(b), granting the motion to the extent lead plaintiff sought final judgment for the claims brought pursuant to the 1933 Act as to all defendants, and denying the motion to the extent lead plaintiff sought final judgment for the claims brought pursuant to the 1934 Act as to all defendants other than the former officer/director. As a result of the court's decision, on March 6, 2014, the court entered final judgment in favor of all defendants on lead plaintiff's claims under Sections 11 and 15 of the 1933 Act. On October 17, 2014, lead plaintiff filed a motion for class certification.
	Given the preliminary stage of the action, the Company is unable to assess the probable outcome or potential liability, if any, arising from the action on the business, financial condition, results of operations, liquidity or capital resources of the Company. The Company does not believe that an estimate of a reasonably possible loss or range of loss can be made for the action at this time. The defendants intend to defend themselves vigorously in the action.
	Shareholder Derivative Litigation
	On January 4, 2011 and October 31, 2011, two actions were filed against certain of Gentiva’s current and former directors in Superior Court of DeKalb County in the State of Georgia, alleging, among other things, that Gentiva’s board of directors breached its fiduciary duties to the Company. The actions were consolidated and, on February 9, 2012, plaintiffs filed a consolidated complaint (the “Georgia State Court Action”). The Georgia State Court Action, which named certain of Gentiva’s current and former directors as defendants, alleged, among other things, that Gentiva’s board of directors had actual or constructive knowledge that the Company’s public disclosures misrepresented and failed to disclose that the Company improperly increased the number of in-home therapy visits to patients for the purpose of triggering higher reimbursement rates under HH PPS, which caused an artificial inflation in the price of Gentiva’s common stock. On March 26, 2012, defendants filed a motion to dismiss the Georgia State Court Action and further requested a transfer to the Superior Court of Cobb County. On October 12, 2012, the Cobb County court granted defendants' motion to dismiss the consolidated complaint with prejudice. On November 30, 2012, one of the plaintiffs in the Georgia State Court Action made a demand on Gentiva's board of directors to take action to remedy the breaches of fiduciary duty alleged in the Georgia State Court Action. The board of directors formed a committee (the “Committee”) to consider the demand.
	On October 7 and October 13, 2011, two actions were filed against certain of Gentiva’s current and former directors and officers in the United States District Court for the Northern District of Georgia, alleging, among other things, that Gentiva’s board of directors breached its fiduciary duties to the Company. The actions also asserted a claim under Section 14(a) of the Securities Exchange Act of 1934. The actions were consolidated and, on March 5, 2012, plaintiffs filed a consolidated complaint (the “Georgia Federal Court Action”). The Georgia Federal Court Action, which named certain of Gentiva’s current and former directors and officers as defendants, alleged, among other things, that Gentiva’s board of directors had actual or constructive knowledge that the Company’s public disclosures misrepresented and failed to disclose that the Company improperly increased the number of in-home therapy visits to patients for the purpose of triggering higher reimbursement rates under the HH PPS, which caused an artificial inflation in the price of Gentiva’s common stock. The complaint further alleged that the Company’s Proxy Statement for its 2010 Annual Meeting of Shareholders was materially false and misleading. On April 16, 2012, defendants filed a motion to dismiss the Georgia Federal Court Action and, on February 11, 2013, the court granted defendants' motion to dismiss with prejudice.  On March 11, 2013, one of the plaintiffs in the Georgia Federal Court Action filed a notice of appeal to the United States Court of Appeals for the Eleventh Circuit. On April 10, 2013, that plaintiff and defendants filed a joint motion to dismiss the appeal with prejudice in the Eleventh Circuit. On April 30, 2013, that motion was granted.  On August 2, 2013 and September 24, 2013, respectively, each of the plaintiffs in the Georgia Federal Court Action made a demand on Gentiva’s board of directors to take action to remedy the breaches of fiduciary duty alleged in the Georgia Federal Court Action.  The demands were considered by the Committee along with the November 30, 2012 demand, and, after conducting an investigation of the allegations contained in each of the three demands, the Committee and the Board determined that taking any or all of the demanded actions would not serve the best interests of Gentiva and its shareholders. Accordingly, the Board voted unanimously to reject the demands.
	Government Matters
	PRRB Appeal
	In connection with the audit of the Company’s 1997 cost reports, the Medicare fiscal intermediary made certain audit adjustments related to the methodology used by the Company to allocate a portion of its residual overhead costs. The Company filed cost reports for years subsequent to 1997 using the fiscal intermediary’s methodology. The Company believed the methodology it used to allocate such overhead costs was accurate and consistent with past practice accepted by the fiscal intermediary; as such, the Company filed appeals with the Provider Reimbursement Review Board (“PRRB”) concerning this issue with respect to cost reports for the years 1997, 1998 and 1999. The Company’s consolidated financial statements for the years 1997, 1998 and 1999 had reflected use of the methodology mandated by the fiscal intermediary. In June 2003, the Company and its Medicare fiscal intermediary signed an Administrative Resolution relating to the issues covered by the appeals pending before the PRRB. Under the terms of the Administrative Resolution, the fiscal intermediary agreed to reopen and adjust the Company’s cost reports for the years 1997, 1998 and 1999 using a modified version of the methodology used by the Company prior to 1997. This modified methodology will also be applied to cost reports for the year 2000, which are finalized and being settled. The Administrative Resolution required that the process to (i) reopen all 1997 cost reports, (ii) determine the adjustments to allowable costs through the issuance of Notices of Program Reimbursement and (iii) make appropriate payments to the Company, be completed in early 2004. Cost reports relating to years subsequent to 1997 were to be reopened after the process for the 1997 cost reports was completed.
	The fiscal intermediary completed the reopening of all 1997, 1998 and 1999 cost reports and determined that the adjustment to allowable costs aggregated $15.9 million which the Company has received and recorded as adjustments to net revenues in the fiscal years 2004 through 2006. The 2000 cost reports are now finalized and being settled by the Centers for Medicare & Medicaid Services. In connection with the settlements, the Company recorded approximately $4.0 million as a positive adjustment to net revenues in the third quarter of 2013.
	Investigations
	Odyssey
	On May 5, 2008, Odyssey HealthCare, Inc. (“Odyssey”) received a letter from the U.S. Department of Justice (“DOJ”) notifying Odyssey that the DOJ was conducting an investigation of VistaCare, Inc. (“VistaCare”) and requesting that Odyssey provide certain information and documents related to the DOJ’s investigation of claims submitted by VistaCare to Medicare, Medicaid and the U.S. government health insurance plan for active military members, their families and retirees, formerly the Civilian Health and Medical Program of the Uniformed Services (“TRICARE”), from January 1, 2003 through March 6, 2008, the date Odyssey completed the acquisition of VistaCare. Odyssey has been informed by the DOJ and the Medicaid Fraud Control Unit of the Texas Attorney General’s Office that they are reviewing allegations that VistaCare may have billed the federal Medicare, Medicaid and TRICARE programs for hospice services that were not reasonably or medically necessary or performed as claimed. The basis of the investigation is a qui tam lawsuit filed in the United States District Court for the Northern District of Texas by a former employee of VistaCare. The lawsuit alleges, among other things, that VistaCare submitted false claims to Medicare and Medicaid for hospice services that were not medically necessary and for hospice services that were referred in violation of the anti-kickback statute. The court unsealed the lawsuit on October 5, 2009 and Odyssey was served on January 28, 2010. In connection with the unsealing of the complaint, the DOJ filed a notice with the court declining to intervene in the qui tam action at such time. The Texas Attorney General also filed a notice of non-intervention with the court. These actions should not be viewed as a final assessment by the DOJ or the Texas Attorney General of the merits of this qui tam action. Odyssey continues to cooperate with the DOJ and the Texas Attorney General in their investigation. The relator has continued to pursue the qui tam lawsuit. Odyssey and VistaCare filed motions to dismiss the relator’s complaint on March 30, 2010 and April 2, 2012. The court issued orders on the motions to dismiss on March 9, 2011 and July 23, 2012. Consistent with the court’s orders, relator’s false claims act claims based on alleged medically unnecessary hospice services and for hospice services referred in violation of the anti-kickback statute are permitted to proceed to discovery. On or about September 6, 2013, relator filed her fourth amended complaint. This pleading only alleged wrongdoing against VistaCare from January 1, 2003 through December 31, 2012 and did not allege any substantive wrongdoing against Odyssey or the Company and only asserted claims against them as purported successors in interest. On or about September 27, 2013, VistaCare answered the fourth amended complaint, and the Company and Odyssey moved to dismiss the allegations made against them. That motion to dismiss as to the Company and Odyssey was granted with prejudice by the court on July 23, 2014. The case has been set for trial on September 21, 2015. VistaCare, Odyssey, and the Company deny the allegations made in this qui tam action and will vigorously defend against them. Based on the information available at this time, the Company cannot predict the outcome of the qui tam lawsuit, the governments’ continuing investigation, the DOJ’s or Texas Attorney General’s views of the issues being investigated, other than the DOJ’s and Texas Attorney General’s notice declining to intervene in the qui tam action, or any actions that the DOJ or Texas Attorney General may take.
	On February 23, 2010, Odyssey received a subpoena from the Department of Health and Human Services, Office of Inspector General (“OIG”), requesting various documents and certain patient records of one of Odyssey’s hospice programs relating to services performed from January 1, 2006 through December 31, 2009. Odyssey is cooperating with the OIG and has completed its subpoena production. Based on the limited information that Odyssey has at this time, the Company cannot predict the outcome of the investigation, the OIG’s views of the issues being investigated or any actions that the OIG may take.
	The Company does not believe that an estimate of a reasonably possible loss or range of loss can be made at this time with regard to the above investigations involving Odyssey. Based on the limited information that Odyssey has at this time regarding such investigations, the Company is unable to predict the impact, if any, that such investigations may have on Odyssey’s and the Company’s business, financial condition, results of operations, liquidity or capital resources.
	Harden
	On or about June 19, 2014, the Company received a Civil Investigative Demand from the U.S. Department of Justice, Western District of Missouri, under the federal False Claims Act requesting complete medical records for 14 hospice patients and other documents of Hospice Care of the Midwest, L.L.C., a subsidiary of Harden Healthcare Holdings, LLC (“Harden Holdings”), for the period from January 1, 2009 through June 19, 2014. The Company is in the process of complying with the demand for documents and is cooperating with the investigation. The Company acquired Harden Holdings on October 18, 2013 and in general matters occurring prior to such date are subject to indemnification provisions in the related Merger Agreement.
	On or about June 9, 2014, Iowa Hospice, L.L.C., a subsidiary of Harden Holdings, received a Subpoena Duces Tecum (“Subpoena”) from the Office of Investigations, Kansas City Regional Office of the Office of Inspector General of the Department of Health and Human Services. The Subpoena requests complete medical records for 17 hospice patients and other documents of Iowa Hospice, L.L.C. for the period from January 1, 2007 through June 9, 2014. Harden Holdings is in the process of complying with the Subpoena and is cooperating with the investigation. The Company acquired Harden Holdings on October 18, 2013 and in general matters occurring prior to such date are subject to indemnification provisions in the related Merger Agreement.
	Based on the limited information that the Company has at this time, the Company is unable to predict the financial impact, if any, arising from the above investigations.
	Other
	On May 16, 2014, the Company received a letter from the U.S. Department of Justice, Civil Division, Commercial Litigation Branch and the United States Attorney’s Office of the Eastern District of Pennsylvania notifying it of an investigation under the federal False Claims Act regarding Gentiva Health Services, Inc. and related entities. The letter requested various documents related to the Company’s home health business for the time period January 1, 2008 through May 16, 2014 including documents related to chart audits of Medicare claims. The Company is cooperating with the investigation and is continuing to produce documents in response to the letter request. Based on the limited information that the Company has at this time, the Company is unable to predict the financial impact, if any, arising from this investigation.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The Company recorded an income tax provision of $5.6 million and $12.5 million for the third quarter and first nine months of 2014, respectively. The Company’s effective income tax rate for the first nine months of 2014 was a 40.5 percent. The difference between the federal statutory income tax rate of 35 percent and the Company’s effective rate of 40.5 percent for the first nine months of 2014 is primarily due to state income taxes, net of federal benefit (approximately 3.5 percent) and other items (approximately 2.0 percent).
	The Company recorded an income tax provision of $2.9 million and $2.8 million for the third quarter and first nine months of 2013, respectively. The Company recorded tax expense on a book loss because the majority of goodwill impairment booked in the first quarter of 2013 was nondeductible for tax resulting in a small tax benefit being booked on the goodwill impairment.
	The Company's effective income tax rate for the first nine months of 2013 was a negative 1.6 percent. The difference between the federal statutory income tax rate of 35 percent and the Company’s effective rate of negative 1.6 percent for the first nine months of 2013 is primarily due to the impact of goodwill (approximately 36.0 percent) and other items (approximately 0.6 percent).
	As of September 30, 2014 and December 31, 2013, the Company had tax refund receivables of $11.4 million and $21.2 million, respectively. Tax refund receivables are classified in prepaid expenses and other current assets in the Company’s consolidated balance sheets.

Business_Segment_Information

Business Segment Information	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Business Segment Information	'
	Business Segment Information
	The Company’s operations involve servicing its patients and customers through its Home Health, Hospice and Community Care segments.
	Home Health
	The Home Health segment is comprised of direct home nursing and therapy services operations, including specialty programs. The Company conducts direct home nursing and therapy services operations through licensed and Medicare-certified agencies, located in 38 states, from which the Company provides various combinations of skilled nursing and therapy services and paraprofessional nursing services to adult and elder patients. The Company’s direct home nursing and therapy services operations also deliver services to its customers through focused specialty programs that include:
	•	Gentiva Orthopedics, which provides individualized home orthopedic rehabilitation services to patients recovering from joint replacement or other major orthopedic surgery;
	•	Gentiva Safe Strides®, which provides therapies for patients with balance issues who are prone to injury or immobility as a result of falling;
	•	Gentiva Cardiopulmonary, which helps patients and their physicians manage heart and lung health in a home-based environment;
	•	Gentiva Neurorehabilitation, which helps patients who have experienced a neurological injury or condition by removing the obstacles to healing in the patient’s home; and
	•	Gentiva Senior Health, which addresses the needs of patients with age-related diseases and issues to effectively and safely stay in their homes.
	Hospice
	The Hospice segment serves terminally ill patients and their families through Medicare-certified providers operating in 30 states. Comprehensive management of the healthcare services and products needed by hospice patients and their families are provided through the use of an interdisciplinary team. Depending on a patient’s needs, each hospice patient is assigned an interdisciplinary team comprised of a physician, nurse(s), home health aide(s), medical social worker(s), chaplain, dietary counselor and bereavement coordinator, as well as other care professionals.
	The Hospice segment also delivers services through focused specialty programs that include:
	•	Memory Care Specialty Program, which provides an individualized disease management program addressing the physical needs specific to Alzheimer's and dementia patients and support mechanisms for their caregivers; and
	•	Cardiac Specialty Program, which helps patients and their physicians aggressively manage symptoms associated with heart disease, focusing on quality of life and pain control.
	Community Care
	The Community Care segment serves patients who have chronic or long-term disabilities and need help with routine personal care operating in 4 states: Texas, Missouri, Oklahoma and North Carolina. These services include help with personal needs, such as bathing and dressing, and household activities, such as laundry and shopping, all of which help enable the patient to remain at home. Community Care services are funded primarily through state Medicaid programs which vary state to state.
	Corporate Expenses
	Corporate expenses consist of costs relating to executive management and corporate and administrative support functions that are not directly attributable to a specific segment, including equity-based compensation expense. Corporate and administrative support functions represent primarily information services, accounting and finance, tax compliance, risk management, procurement, marketing, clinical administration, training, legal and human resource benefits and administration.
	Other Information
	The Company’s senior management evaluates performance and allocates resources based on operating contributions of the reportable segments, which exclude corporate expenses, depreciation, amortization and net interest costs, but include revenues and all other costs (including special items) directly attributable to the specific segment. Segment assets represent net accounts receivable, identifiable intangible assets, goodwill, and certain other assets associated with segment activities. All other assets are assigned to corporate assets for the benefit of all segments for the purposes of segment disclosure.
	Segment net revenues by major payer source were as follows (in millions):
		Third Quarter
		2014													2013
		Home			Hospice			Community Care				Total			Home			Hospice		Total
		Health													Health
	Medicare	$	214.9		$	161.6		$	—			$	376.5		$	191.8		$	163.8	$	355.6
	Medicaid and Local Government	8.6			6.1			56.2				70.9			10.8			6.6		17.4
	Commercial Insurance and Other:
	Paid at episodic rates	21.5			—			—				21.5			15.1			—		15.1
	Other	23.4			4.7			1				29.1			17.2			5.2		22.4
	Total net revenues	$	268.4		$	172.4		$	57.2			$	498		$	234.9		$	175.6	$	410.5
		First Nine Months
		2014													2013
		Home			Hospice			Community Care				Total			Home			Hospice		Total
		Health													Health
	Medicare	$	642		$	486.3		$	—			$	1,128.30		$	577.7		$	498.8	$	1,076.50
	Medicaid and Local Government	25.7			18.6			168.5				212.8			33.1			21.3		54.4
	Commercial Insurance and Other:
	Paid at episodic rates	55			—			—				55			43.3			—		43.3
	Other	70.8			14.2			2.5				87.5			52			14.3		66.3
	Total net revenues	$	793.5		$	519.1		$	171			$	1,483.60		$	706.1		$	534.4	$	1,240.50
	Segment information about the Company’s operations is as follows (in thousands):
		Home Health				Hospice				Community Care				Total
	For the three months ended September 30, 2014
	Net revenue	$	268,423			$	172,349			$	57,234			$	498,006
	Operating contribution	$	36,725	-1		$	27,043	-1		$	8,081			$	71,849
	Corporate expenses													(25,709		)	-1
	Depreciation and amortization													(7,287		)
	Interest expense and other, net													(24,719		)
	Income before income taxes and equity in net loss of CareCentrix													$	14,134
	For the three months ended September 30, 2013 (Revised)
	Net revenue	$	234,864			$	175,628			$	—			$	410,492
	Operating contribution	$	31,922	-1		$	22,365			$	—			$	54,287
	Corporate expenses													(20,672		)	-1
	Depreciation and amortization													(4,679		)
	Interest expense and other, net													(22,342		)
	Income before income taxes													$	6,594
	For the nine months ended September 30, 2014
	Net revenue	$	793,467			$	519,073			$	171,011			$	1,483,551
	Operating contribution	$	107,355	-1		$	66,674	-1		$	25,867		-1	$	199,896
	Corporate expenses													(73,937		)	-1
	Depreciation and amortization													(21,207		)
	Interest expense and other, net													(73,906		)
Income before income taxes and equity in net loss of CareCentrix													$	30,846
Segment assets	$	397,678			$	340,412			$	168,686			$	906,776
Corporate assets													318,450
Total assets													$	1,225,226
For the nine months ended September 30, 2013 (Revised)
Net revenue	$	706,141			$	534,366			$	—			$	1,240,507
Operating contribution	$	92,027	-1		$	76,223	-1		$	—			$	168,250
Corporate expenses													(57,443		)	-1
Goodwill and other long-lived asset impairment													(210,672		)	-2
Depreciation and amortization													(14,541		)
Interest expense and other, net													(66,783		)
Loss before income taxes													$	(181,189	)
Segment assets	$	249,313			$	636,705	-2		$	—			$	886,018
Corporate assets													377,935			-2
Total assets													$	1,263,953
-1	For the third quarter and first nine months of 2014, the Company recorded charges relating to cost savings initiatives and acquisition and integration activities of $0.5 million and $10.5 million, respectively. For the third quarter and first nine months of 2013, the Company recorded charges relating to cost savings initiatives and acquisition and integration activities of $1.7 million and $2.6 million, respectively.
The charges were reflected as follows for segment reporting purposes (in millions):
	Third Quarter						First Nine Months
	2014			2013			2014				2013
Home Health	$	0.1		$	0.1		$	0.7			$	0.1
Hospice	0.1			—			5.5				0.7
Community Care	—			—			0.1				—
Corporate expenses	0.3			1.6			4.2				1.8
Total	$	0.5		$	1.7		$	10.5			$	2.6
-2	At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. See Note 9.
In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million.
Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of the impairment.

Supplemental_Guarantor_and_Non

Supplemental Guarantor and Non-Guarantor Financial Information	9 Months Ended
	Sep. 30, 2014
Supplemental Guarantor and Non-Guarantor Financial Information [Abstract]	'
Supplemental Guarantor and Non-Guarantor Financial Information	'
	Supplemental Guarantor and Non-Guarantor Financial Information
	Gentiva’s guarantor subsidiaries are guarantors to the Company’s debt securities which are registered under the Securities Act of 1933, as amended. The condensed consolidating financial statements presented below are provided pursuant to Rule 3-10 of Regulation S-X. Separate financial statements of each subsidiary guaranteeing Gentiva’s debt securities are not presented because the guarantor subsidiaries are jointly and severally, fully and unconditionally liable under the guarantees, and 100 percent owned by the Company. There are no restrictions on the ability to obtain funds from these subsidiaries by dividends or other means.
	The following condensed consolidating financial statements include the balance sheets as of September 30, 2014 and December 31, 2013, statements of comprehensive income for the three months and nine months ended September 30, 2014 and 2013 and statements of cash flows for the nine months ended September 30, 2014 and 2013 of (i) Gentiva Health Services, Inc. and (ii) its guarantor subsidiaries (in each case, reflecting investments in its consolidated subsidiaries under the equity method of accounting) and its non-guarantor subsidiaries along with eliminations necessary to arrive at the information for the Company on a consolidated basis.
	Condensed Consolidating Balance Sheet
	30-Sep-14
	(In thousands)
		Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.			Subsidiaries			Subsidiaries						Total
	ASSETS
	Current assets:
	Cash and cash equivalents	$	84,708		$	—		$	29,498		$	—		$	114,206
	Receivables, net	—			277,263			41,275			(32,820		)	285,718
	Deferred tax assets, net	—			21,840			2,430			—			24,270
	Prepaid expenses and other current assets	—			39,291			9,485			—			48,776
	Total current assets	84,708			338,394			82,688			(32,820		)	472,970
	Note receivable from CareCentrix	—			25,000			—			—			25,000
	Fixed assets, net	—			41,511			537			—			42,048
	Intangible assets, net	—			244,433			2,600			—			247,033
	Goodwill	—			367,550			6,474			—			374,024
	Investment in subsidiaries	766,995			23,709			—			(790,704		)	—
	Other assets	24,440			39,704			7			—			64,151
	Total assets	$	876,143		$	1,080,301		$	92,306		$	(823,524	)	$	1,225,226
	LIABILITIES AND EQUITY
	Current liabilities:
	Current portion of long-term debt	$	51,138		$	—		$	—		$	—		$	51,138
	Accounts payable	—			16,370			—			—			16,370
	Other current liabilities	1,959			241,522			64,785			(32,820		)	275,446
	Total current liabilities	53,097			257,892			64,785			(32,820		)	342,954
	Long-term debt	1,105,750			—			—			—			1,105,750
	Deferred tax liabilities, net	—			6,264			—			—			6,264
	Other liabilities	6,306			49,150			—			—			55,456
	Total Gentiva shareholders’ (deficit) equity	(289,010		)	766,995			23,709			(790,704		)	(289,010		)
	Noncontrolling interests	—			—			3,812			—			3,812
	Total (deficit) equity	(289,010		)	766,995			27,521			(790,704		)	(285,198		)
	Total liabilities and equity (deficit)	$	876,143		$	1,080,301		$	92,306		$	(823,524	)	$	1,225,226
	Condensed Consolidating Balance Sheet
	31-Dec-13
	(In thousands)
	As Restated	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.			Subsidiaries			Subsidiaries						Total
	ASSETS
	Current assets:
	Cash and cash equivalents	$	55,388		$	—		$	31,569		$	—		$	86,957
	Receivables, net	—			284,637			33,878			(28,610		)	289,905
	Deferred tax assets, net	—			25,845			2,308			—			28,153
	Prepaid expenses and other current assets	—			52,971			11,775			—			64,746
	Total current assets	55,388			363,453			79,530			(28,610		)	469,761
	Notes receivable from CareCentrix	—			28,471			—			—			28,471
	Fixed assets, net	—			48,855			520			—			49,375
	Intangible assets, net	—			251,127			2,600			—			253,727
	Goodwill	—			379,880			3,607			—			383,487
	Investment in subsidiaries	782,470			23,493			—			(805,963		)	—
	Other assets	28,266			40,375			6			—			68,647
	Total assets	$	866,124		$	1,135,654		$	86,263		$	(834,573	)	$	1,253,468
	LIABILITIES AND EQUITY
	Current liabilities:
	Current portion of long-term debt	$	45,325		$	—		$	—		$	—		$	45,325
	Accounts payable	—			15,377			282			—			15,659
	Other current liabilities	—			283,483			59,613			(28,610		)	314,486
	Total current liabilities	45,325			298,860			59,895			(28,610		)	375,470
	Long-term debt	1,124,432			—			—			—			1,124,432
	Deferred tax liabilities, net	—			8,483			—			—			8,483
	Other liabilities	7,243			45,841			—			—			53,084
Total Gentiva shareholders’ (deficit) equity	(310,876		)	782,470			23,493			(805,963		)	(310,876		)
Noncontrolling interests	—			—			2,875			—			2,875
Total (deficit) equity	(310,876		)	782,470			26,368			(805,963		)	(308,001		)
Total liabilities and equity (deficit)	$	866,124		$	1,135,654		$	86,263		$	(834,573	)	$	1,253,468
Condensed Consolidating Statement of Comprehensive Income
For the Three Months Ended September 30, 2014
(In thousands)
	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries						Total
Net revenues	$	—		$	485,106		$	16,645		$	(3,745	)	$	498,006
Cost of services sold	—			262,795			11,609			(3,745		)	270,659
Gross profit	—			222,311			5,036			—			227,347
Selling, general and administrative expenses	—			(182,876		)	(5,618		)	—			(188,494		)
Interest (expense) and other, net	(24,772		)	—			53			—			(24,719		)
Equity in earnings of subsidiaries	23,000			(261		)	—			(22,739		)	—
(Loss) income before income taxes and equity in net loss of CareCentrix	(1,772		)	39,174			(529		)	(22,739		)	14,134
Income tax benefit (expense)	9,817			(15,684		)	266			—			(5,601		)
Equity in net loss of CareCentrix	—			(490		)	—			—			(490		)
Net income (loss)	8,045			23,000			(263		)	(22,739		)	8,043
Noncontrolling interests	—			—			2			—			2
Net income (loss) attributable to Gentiva shareholders	$	8,045		$	23,000		$	(261	)	$	(22,739	)	$	8,045
Total comprehensive income (loss)	$	8,045		$	23,000		$	(263	)	$	(22,739	)	$	8,043
Condensed Consolidating Statement of Comprehensive Income
For the Three Months Ended September 30, 2013
(In thousands)
As Revised	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries						Total
Net revenues	$	—		$	398,047		$	16,429		$	(3,984	)	$	410,492
Cost of services sold	—			212,543			11,919			(3,984		)	220,478
Gross profit	—			185,504			4,510			—			190,014
Selling, general and administrative expenses	—			(156,119		)	(4,959		)	—			(161,078		)
Interest (expense) and other, net	(22,355		)	—			13			—			(22,342		)
Equity in earnings of subsidiaries	15,987			(459		)	—			(15,528		)	—
(Loss) income before income taxes	(6,368		)	28,926			(436		)	(15,528		)	6,594
Income tax benefit (expense)	9,931			(12,939		)	65			—			(2,943		)
Net income (loss)	3,563			15,987			(371		)	(15,528		)	3,651
Noncontrolling interests	—			—			(88		)	—			(88		)
Net income (loss) attributable to Gentiva shareholders	$	3,563		$	15,987		$	(459	)	$	(15,528	)	$	3,563
Total comprehensive income (loss)	$	3,563		$	15,987		$	(371	)	$	(15,528	)	$	3,651
Condensed Consolidating Statement of Comprehensive Income
For the Nine Months Ended September 30, 2014
(In thousands)
	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries						Total
Net revenues	$	—		$	1,446,339		$	48,648		$	(11,436	)	$	1,483,551
Cost of services sold	—			790,399			32,114			(11,436		)	811,077
Gross profit	—			655,940			16,534			—			672,474
Selling, general and administrative expenses	—			(551,875		)	(15,847		)	—			(567,722		)
Interest (expense) and other, net	(74,063		)	—			157			—			(73,906		)
Equity in earnings of subsidiaries	62,347			427			—			(62,774		)	—
(Loss) income before income taxes and equity in net loss of CareCentrix	(11,716		)	104,492			844			(62,774		)	30,846
Income tax benefit (expense)	29,403			(41,655		)	(247		)	—			(12,499		)
Equity in net loss of CareCentrix	—			(490		)	—			—			(490		)
Net income	17,687			62,347			597			(62,774		)	17,857
Noncontrolling interests	—			—			(170		)	—			(170		)
Net income attributable to Gentiva shareholders	$	17,687		$	62,347		$	427		$	(62,774	)	$	17,687
Total comprehensive income	$	17,687		$	62,347		$	597		$	(62,774	)	$	17,857
Condensed Consolidating Statement of Comprehensive Income
For the Nine Months Ended September 30, 2013
(In thousands)
As Reported	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries						Total
Net revenues	$	—		$	1,203,258		$	48,498		$	(11,249	)	$	1,240,507
Cost of services sold	—			638,418			33,829			(11,249		)	660,998
Gross profit	—			564,840			14,669			—			579,509
Selling, general and administrative expenses	—			(468,270		)	(14,364		)	—			(482,634		)
Goodwill and other long-lived asset impairment	—			(224,320		)	—			—			(224,320		)
Interest (expense) and other, net	(66,829		)	—			46			—			(66,783		)
Equity in earnings of subsidiaries	(156,813		)	(7		)	—			156,820			—
(Loss) income before income taxes	(223,642		)	(127,757		)	351			156,820			(194,228		)
Income tax benefit (expense)	26,532			(29,056		)	67			—			(2,457		)
Net (loss) income	(197,110		)	(156,813		)	418			156,820			(196,685		)
Noncontrolling interests	—			—			(425		)	—			(425		)
Net (loss) income attributable to Gentiva shareholders	$	(197,110	)	$	(156,813	)	$	(7	)	$	156,820		$	(197,110	)
Total comprehensive (loss) income	$	(182,706	)	$	(156,813	)	$	418		$	142,416		$	(196,685	)
Revision Adjustments	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries						Total
Selling, general and administrative expenses	$	—		$	(609	)	$	—		$	—		(609	)
Goodwill and other long-lived asset impairment	—			13,648			—			—			13,648
Equity in earnings of subsidiaries	12,669			—			—			(12,669		)	—
(Loss) income before income taxes	12,669			13,039			—			(12,669		)	13,039
Income tax benefit (expense)	—			(370		)	—			—			(370	)
Net (loss) income	12,669			12,669			—			(12,669		)	12,669
Net (loss) income attributable to Gentiva shareholders	12,669			12,669			—			(12,669		)	12,669
Total comprehensive (loss) income	12,669			12,669			—			(12,669		)	12,669
As Revised	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries						Total
Net revenues	$	—		$	1,203,258		$	48,498		$	(11,249	)	$	1,240,507
Cost of services sold	—			638,418			33,829			(11,249		)	660,998
Gross profit	—			564,840			14,669			—			579,509
Selling, general and administrative expenses	—			(468,879		)	(14,364		)	—			(483,243		)
Goodwill and other long-lived asset impairment	—			(210,672		)	—			—			(210,672		)
Interest (expense) and other, net	(66,829		)	—			46			—			(66,783		)
Equity in earnings of subsidiaries	(144,144		)	(7		)	—			144,151			—
(Loss) income before income taxes	(210,973		)	(114,718		)	351			144,151			(181,189		)
Income tax benefit (expense)	26,532			(29,426		)	67			—			(2,827		)
Net (loss) income	(184,441		)	(144,144		)	418			144,151			(184,016		)
Noncontrolling interests	—			—			(425		)	—			(425		)
Net (loss) income attributable to Gentiva shareholders	$	(184,441	)	$	(144,144	)	$	(7	)	$	144,151		$	(184,441	)
Total comprehensive (loss) income	$	(184,441	)	$	(144,144	)	$	418		$	144,151		$	(184,016	)
Condensed Consolidating Statement of Cash Flows
For the Nine Months Ended September 30, 2014
(In thousands)
	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries						Total
OPERATING ACTIVITIES:
Net cash (used in) provided by operating activities	$	(32,770	)	$	80,338		$	(503	)	$	(1,026	)	$	46,039
INVESTING ACTIVITIES:
Purchase of fixed assets	—			(9,119		)	(149		)	—			(9,268		)
Proceeds from sale of assets	—			2,004			—			—			2,004
Capital contribution	—			(1,740		)	—			1,740			—
Proceeds from sale of businesses	—			2,900			—			(2,900		)	—
Acquisition of businesses, net of cash acquired	—			—			(2,900		)	2,900			—
Net cash used in investing activities	—			(5,955		)	(3,049		)	1,740			(7,264		)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock	1,937			—			—			—			1,937
Windfall tax benefits associated with equity-based compensation	56			—			—			—			56
Repayment of long-term debt	(13,744		)	—			—			—			(13,744		)
Debt issuance costs	(150		)	—			—			—			(150		)
Minority interest capital contributions	—			—			1,160			—			1,160
Majority interest capital contributions	—			—			1,740			(1,740		)	—
Distribution to minority interests	—			—			(393		)	—			(393		)
Distribution to majority interests	—			—			(1,026		)	1,026			—
Other	(361		)	(31		)	—			—			(392		)
Net payments related to intercompany financing	74,352			(74,352		)	—			—			—
Net cash provided by (used in) financing activities	62,090			(74,383		)	1,481			(714		)	(11,526		)
Net change in cash and cash equivalents	29,320			—			(2,071		)	—			27,249
Cash and cash equivalents at beginning of period	55,388			—			31,569			—			86,957
Cash and cash equivalents at end of period	$	84,708		$	—		$	29,498		$	—		$	114,206
Condensed Consolidating Statement of Cash Flows
For the Nine Months Ended September 30, 2013
(In thousands)
As Revised	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries						Total
OPERATING ACTIVITIES:
Net cash (used in) provided by operating activities	$	(39,122	)	$	41,545		$	3,038		$	13,108		$	18,569
INVESTING ACTIVITIES:
Purchase of fixed assets	—			(13,872		)	(342		)	—			(14,214		)
Proceeds from sale of businesses	—			508			—			—			508
Acquisition of businesses, net of cash acquired	—			(4,538		)	(2,500		)	2,400			(4,638		)
Net cash (used in) provided by investing activities	—			(17,902		)	(2,842		)	2,400			(18,344		)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock	2,459			—			—			—			2,459
Windfall tax benefits associated with equity-based compensation	92			—			—			—			92
Payment of contingent consideration accrued at acquisition date	—			(1,675		)	—			—			(1,675		)
Intercompany dividend	2,300			—			(2,300		)	—			—
Repayment of long-term debt	(25,000		)	—			—			—			(25,000		)
Debt issuance costs	(449		)	—			—			—			(449		)
Minority interest capital contribution	—			—			1,600			—			1,600
Majority interest capital contribution	—			—			2,400			(2,400		)	—
Distribution to minority interests	—			—			(563		)	—			(563		)
Distribution to majority interests	—			—			(1,296		)	1,296			—
Other	(416		)	(31		)	—			—			(447		)
Net payments related to intercompany financing	21,937			(21,937		)	—			—			—
Net cash provided by (used in) financing activities	923			(23,643		)	(159		)	(1,104		)	(23,983		)
Net change in cash and cash equivalents	(38,199		)	—			37			14,404			(23,758		)
Cash and cash equivalents at beginning of period	166,140			—			40,912			—			207,052
Cash and cash equivalents at end of period	$	127,941		$	—		$	40,949		$	14,404		$	183,294

Subsequent_Event

Subsequent Event	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Event	'
	Subsequent Event
	On October 9, 2014, Kindred Healthcare, Inc. (“Kindred”) and Gentiva Health Services, Inc. (“Gentiva”) announced that the companies have entered into a definitive merger agreement under which Kindred will acquire all of the outstanding shares of Gentiva common stock for $19.50 per share in a combination of cash and stock. The agreement was unanimously approved by the boards of directors of both companies.
	Under the terms of the agreement, Gentiva shareholders will receive $14.50 per share in cash and $5.00 of Kindred common stock (which equates to 0.257 shares of Kindred common stock based upon an agreed upon fixed exchange ratio). The transaction is valued at $1.8 billion, including the assumption of net debt. The companies expect the closing of the transaction to occur in the first quarter of 2015.

Accounting_Policies_Policies

Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all investments with a maturity date three months or less from their date of acquisition to be cash equivalents, including money market funds invested in U.S. Treasury securities, short-term treasury bills and commercial paper. Cash and cash equivalents also included amounts on deposit with several major financial institutions in excess of the maximum amount insured by the Federal Deposit Insurance Corporation. Management believes that these major financial institutions are viable entities.
	The Company had operating funds of approximately $4.2 million and $5.5 million at September 30, 2014 and December 31, 2013, respectively, which relate exclusively to a non-profit hospice operation managed in Florida.
Investments	'
	Investments
	As of December 31, 2013, the Company held an investment, at cost, in CareCentrix Holdings Inc. of $0.9 million for shares that it expected to receive in settlement of certain tax amounts owed to the Company as set forth in the stock purchase agreement. During the third quarter of 2014, the Company finalized the settlement with CareCentrix. See Note 7 for additional information.
	At September 30, 2014 and December 31, 2013, the Company had assets of $36.1 million and $34.7 million, respectively, held in a Rabbi Trust for the benefit of participants in the Company’s non-qualified defined contribution retirement plan. The corresponding amounts payable to the plan participants are equivalent to the underlying value of the assets held in the Rabbi Trust. Assets held in a Rabbi Trust and amounts payable to plan participants are classified in other assets and other liabilities, respectively, in the Company’s consolidated balance sheets.
Debt Issuance Costs	'
	Debt Issuance Costs
	The Company amortizes deferred debt issuance costs over the term of its credit agreement and senior notes. As of September 30, 2014 and December 31, 2013, the Company had unamortized debt issuance costs of $24.4 million and $28.3 million, respectively, recorded in other assets in the Company’s consolidated balance sheets.
Fixed Assets	'
	Fixed Assets
	Fixed assets, including costs of Company developed software, are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Leasehold improvements are amortized over the shorter of the life of the lease or the life of the improvement. Repairs and maintenance costs are expensed as incurred. As of September 30, 2014 and December 31, 2013, fixed assets, net were $42.0 million and $49.4 million, respectively.
	At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. These charges are recorded in goodwill and other long-lived asset impairment in the Company's consolidated financial statements for the nine months ended September 30, 2013.
	In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge related to developed software, of approximately $1.6 million, which is reflected in goodwill and other long-lived asset impairment in the Company's consolidated financial statements for the nine months ended September 30, 2013.
Goodwill and Other Indefinite-Lived Intangible Assets	'
	Goodwill and Other Indefinite-Lived Intangible Assets
	The Company is required to test goodwill and other indefinite-lived intangible assets for impairment on an annual basis and between annual tests if current events or circumstances require an interim impairment assessment. The Company allocates goodwill to its various reporting units upon the acquisition of the assets or stock of another third party business operation. The Company compares the fair value of each reporting unit to its carrying amount to determine if there is a potential impairment of goodwill and other indefinite-lived intangible assets. If the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the fair value of the goodwill within the operating unit is less than the carrying value of its goodwill. To determine the fair value of the Company's reporting units, the Company uses a present value (discounted cash flow) technique corroborated by market multiples when available, a reconciliation to market capitalization or other valuation methodologies, and reasonableness tests, as appropriate.
	If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of other indefinite-lived intangible assets are determined based on discounted cash flows or appraised values, as appropriate.
	At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million, which is reflected in goodwill and other long-lived asset impairment in the Company's consolidated financial statements for the nine months ended September 30, 2013. See Note 9 for additional information.
Obligations Under Self Insurance Programs	'
	Obligations Under Self Insurance Programs
	As of September 30, 2014 and December 31, 2013, the Company’s obligations under insurance programs were $78.3 million and $82.6 million, respectively. Workers’ compensation and professional and general liability expenses were $5.0 million and $15.0 million for the third quarter and first nine months of 2014, respectively, as compared to $6.6 million and $19.2 million for the corresponding periods of 2013. Employee health and welfare expenses were $21.4 million and $67.8 million for the third quarter and first nine months of 2014, respectively, as compared to $21.0 million and $64.0 million for the corresponding periods of 2013.
Nursing Home Costs	'
	Nursing Home Costs
	For patients receiving nursing home care under a state Medicaid program who elect hospice care under Medicare or Medicaid, the Company contracts with nursing homes for the nursing homes to provide patients’ room and board services. The state must pay the Company, in addition to the applicable Medicare or Medicaid hospice daily or hourly rate, an amount equal to at least 95 percent of the Medicaid daily nursing home rate for room and board furnished to the patient by the nursing home. Under the Company’s standard nursing home contracts, the Company pays the nursing home for these room and board services at the Medicaid daily nursing home rate. Nursing home costs are partially offset by nursing home net revenue, and the net amount is included in cost of services sold in the Company’s consolidated statements of comprehensive income. Net nursing home costs for the third quarter and first nine months of 2014 were $2.9 million and $7.3 million, respectively, as compared to $1.7 million and $7.2 million for the corresponding periods of 2013.

Restatement_and_Revision_of_Pr1

Restatement and Revision of Previously Reported Consolidated Financial Statements (Table)	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Schedule of Error Corrections and Prior Period Adjustments	'
	The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding revised amounts:
		For the Six Months Ended June 30, 2013
	Revised Consolidated Statement of Comprehensive Loss amounts (In thousands)	As Previously Reported				Revision Adjustments				Revised
	Selling, general and administrative expenses	$	(321,814	)		$	(351	)		$	(322,165	)
	Goodwill and other long-lived asset impairment	(224,320		)		13,648				(210,672		)
	Income (loss) before income taxes	(201,080		)		13,297				(187,783		)
	Income tax (expense) benefit	587				(471		)		116
	Net income (loss)	(200,493		)		12,826				(187,667		)
	Net income (loss) attributable to Gentiva shareholders	(200,830		)		12,826				(188,044		)
	Total comprehensive income (loss)	(200,493		)		12,826				(187,667		)
	Basic Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(6.51	)		$	0.42			$	(6.09	)
	Diluted Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(6.51	)		$	0.42			$	(6.09	)
		For the Nine Months Ended September 30, 2013
	Revised Consolidated Statement of Comprehensive Loss amounts (In thousands)	As Previously Reported				Revision Adjustments				Revised
	Selling, general and administrative expenses	$	(482,634	)		$	(609	)		$	(483,243	)
	Goodwill and other long-lived asset impairment	(224,320		)		13,648				(210,672		)
	Income (loss) before income taxes	(194,228		)		13,039				(181,189		)
	Income tax (expense) benefit	(2,457		)		(370		)		(2,827		)
	Net income (loss)	(196,685		)		12,669				(184,016		)
	Net income (loss) attributable to Gentiva shareholders	(197,110		)		12,669				(184,441		)
	Total comprehensive income (loss)	(196,685		)		12,669				(184,016		)
	Basic Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(6.38	)		$	0.41			$	(5.97	)
	Diluted Earnings Per Share: Net loss attributable to Gentiva shareholders	$	(6.38	)		$	0.41			$	(5.97	)
		For the Six Months Ended June 30, 2013
	Revised Consolidated Statement of Cash Flows	As Previously Reported			Revision Adjustments			Revised
	(In thousands)
	Net income (loss)	(200,493	)		12,826			(187,667	)
	Depreciation and Amortization	9,511			351			9,862
	Goodwill and other long-lived asset impairment	224,320			(13,648	)		210,672
	Deferred income tax expense (benefit)	(7,983	)		471			(7,512	)
		For the Nine Months Ended September 30, 2013
	Revised Consolidated Statement of Cash Flows	As Previously Reported			Revision Adjustments			Revised
	(In thousands)
	Net income (loss)	(196,685	)		12,669			(184,016	)
	Depreciation and Amortization	13,932			609			14,541
	Goodwill and other long-lived asset impairment	224,320			(13,648	)		210,672
	Deferred income tax expense (benefit)	(7,066	)		370			(6,696	)

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Financial assets measured at fair value on a recurring basis	'
	The Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis was as follows (in thousands):
		30-Sep-14										31-Dec-13
		Level 1				Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Money market funds	$	23,091			$	—	$	—	$	23,091	$	23,695	$	—	$	—	$	23,695
	Rabbi Trust:
	Mutual funds	31,175				—		—		31,175		28,945		—		—		28,945
	Money market funds	4,963				—		—		4,963		5,737		—		—		5,737
	Total assets	$	59,229			$	—	$	—	$	59,229	$	58,377	$	—	$	—	$	58,377
	Liabilities:
	Payables to plan participants	$	36,138			$	—	$	—	$	36,138	$	34,682	$	—	$	—	$	34,682
	Acquisition contingent liability	—				—		8,514		8,514		—		—		8,110		8,110
	Total liabilities	$	36,138			$	—	$	8,514	$	44,652	$	34,682	$	—	$	8,110	$	42,792
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following table provides a summary of changes in fair value of the Company's Level 3 financial assets (in thousands):
			Estimated Fair Value
	Balance at December 31, 2013		$	8,110
	Payment of contingent liability		(125		)
	Included in earnings		279			(1)
	Harden acquisition contingent liability adjustment		250
	Balance at September 30, 2014		$	8,514
	-1	Accretion of the present value of the contingent liability is recorded in interest expense and other in the Company's consolidated statements of comprehensive income. A 1 percent change in the discount rate would have an impact on the fair value of the contingent liability of approximately $0.2 million.
Carrying amount and estimated fair value of financial instruments	'
	The carrying amount and estimated fair value of the Company’s other financial instruments were as follows (in thousands):
		30-Sep-14						31-Dec-13
		Carrying				Estimated		Carrying		Estimated
		Amount				Fair Value		Amount		Fair Value
	Assets:
	Note receivable from CareCentrix	$	25,000			$	26,055	$	25,000	$	26,403
	Seller financing note receivable from CareCentrix	—				—		3,471		3,471
	Liabilities:
	Long-term obligations	$	1,163,256			$	1,182,837	$	1,177,000	$	1,183,863

Net_Revenues_and_Accounts_Rece1

Net Revenues and Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2014
Net Revenues and Accounts Receivable [Abstract]	'
Net revenues by major payer classification	'
	Net revenue by major payer classes were as follows (in millions):
		Third Quarter								First Nine Months
		2014			2013			Percentage		2014		2013		Percentage
								Variance						Variance
	Medicare:
	Home Health	$	214.9		$	191.8		12	%	$	642	$	577.7	11.1	%
	Hospice	161.6			163.8			(1.3	)%	486.3		498.8		(2.5	)%
	Total Medicare	376.5			355.6			5.9	%	1,128.30		1,076.50		4.8	%
	Medicaid and Local Government	70.9			17.4			307	%	212.8		54.4		291.4	%
	Commercial Insurance and Other:
	Paid at episodic rates	21.5			15.1			42.8	%	55		43.3		27	%
	Other	29.1			22.4			29.7	%	87.5		66.3		31.8	%
	Total Commercial Insurance and Other	50.6			37.5			35	%	142.5		109.7		29.9	%
	Total net revenues	$	498		$	410.5		21.3	%	$	1,483.60	$	1,240.50	19.6	%
Accounts receivable attributable to major payer sources of reimbursement	'
	Accounts receivable attributable to major payer sources of reimbursement were as follows (in thousands):
		September 30, 2014			December 31, 2013
	Medicare	$	200,902		$	214,366
	Medicaid and Local Government	51,113			48,183
	Commercial Insurance and Other	44,006			38,036
	Gross accounts receivable	296,021			300,585
	Less: Allowance for doubtful accounts	(10,303		)	(10,680		)
	Net accounts receivable	$	285,718		$	289,905

Cost_Savings_Initiatives_and_A1

Cost Savings Initiatives and Acquisition and Integration Activities (Tables)	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Costs incurred and cash expenditures	'
	The costs incurred and cash expenditures associated with these activities by component were as follows (in thousands):
		Cost Savings Initiatives			Acquisition &			Total
					Integration
	Balance at December 31, 2012	$	1,685		$	1,011		$	2,696
	Charge in first quarter 2013	47			94			141
	Cash expenditures	(1,104		)	(322		)	(1,426		)
	Ending balance at March 31, 2013	628			783			1,411
	Charge in second quarter 2013	138			606			744
	Cash expenditures	(685		)	(234		)	(919		)
	Ending balance at June 30, 2013	81			1,155			1,236
	Charge in third quarter 2013	77			1,622			1,699
	Cash expenditures	(240		)	(283		)	(523		)
	Non-cash reclassification	476			(476		)	—
	Ending balance at September 30, 2013	$	394		$	2,018		$	2,412
	Balance at December 31, 2013	$	6,722		$	9,703		$	16,425
	Charge in first quarter 2014	2,713			2,628			5,341
	Cash expenditures	(3,443		)	(3,472		)	(6,915		)
	Non-cash expenditures	(60		)	(86		)	(146		)
	Ending balance at March 31, 2014	5,932			8,773			14,705
	Charge in second quarter 2014	1,409			3,250			4,659
	Cash expenditures	(2,994		)	(3,717		)	(6,711		)
	Non-cash expenditures	(276		)	5			(271		)
	Ending balance at June 30, 2014	4,071			8,311			12,382
	Charge in third quarter 2014	195			284			479
	Cash expenditures	(1,302		)	(1,908		)	(3,210		)
	Non-cash expenditures	35			3			38
	Ending balance at September 30, 2014	$	2,999		$	6,690		$	9,689

Goodwill_and_Identifiable_Inta1

Goodwill and Identifiable Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Gross carrying amount and accumulated amortization of identifiable intangible assets	'
	The gross carrying amount and accumulated amortization of each category of identifiable intangible assets as of September 30, 2014 and December 31, 2013 were as follows (in thousands):
		30-Sep-14												December 31, 2013 (Restated)												Useful
																										Life
		Home			Hospice			Community Care			Total			Home			Hospice			Community Care			Total
		Health												Health
	Amortized intangible assets:
	Covenants not to compete	$	2,157		$	16,183		$	1,029		$	19,369		$	2,157		$	16,183		$	1,029		$	19,369		2-5 Yrs
	Less: accumulated amortization	(1,709		)	(15,837		)	(327		)	(17,873		)	(1,553		)	(15,720		)	(91		)	(17,364		)
	Net covenants not to compete	448			346			702			1,496			604			463			938			2,005
	Customer relationships	27,196			910			—			28,106			27,196			910			—			28,106			5-10 Yrs
	Less: accumulated amortization	(21,703		)	(549		)	—			(22,252		)	(19,997		)	(481		)	—			(20,478		)
	accumulated impairment losses	(27		)	—			—			(27		)	(27		)	—			—			(27		)
	Net customer relationships	5,466			361			—			5,827			7,172			429			—			7,601
	Tradenames	19,267			17,528			11,922			48,717			19,267			17,528			11,922			48,717			5-10 Yrs
	Less: accumulated amortization	(12,795		)	(4,368		)	(1,134		)	(18,297		)	(11,992		)	(3,763		)	(227		)	(15,982		)
	accumulated impairment losses	(6,421		)	(13,122		)	—			(19,543		)	(6,421		)	(13,122		)	—			(19,543		)
	Net tradenames	51			38			10,788			10,877			854			643			11,695			13,192
	Licenses	714			9,289			—			10,003			714			8,021			—			8,735
	Less: accumulated amortization	(714		)	(8,782		)	—			(9,496		)	(588		)	(6,812		)	—			(7,400		)
	Net licenses	—			507			—			507			126			1,209			—			1,335
	Amortized intangible assets	5,965			1,252			11,490			18,707			8,756			2,744			12,633			24,133
	Indefinite-lived intangible assets:
	Licenses and certificates of need	245,086			104,364			26,011			375,461			245,086			105,632			26,011			376,729
	Less: accumulated impairment	(144,672		)	(2,463		)	—			(147,135		)	(144,672		)	(2,463		)	—			(147,135		)
	losses
	Net licenses and certificates of need	100,414			101,901			26,011			228,326			100,414			103,169			26,011			229,594
	Total identifiable intangible assets	$	106,379		$	103,153		$	37,501		$	247,033		$	109,170		$	105,913		$	38,644		$	253,727
Gross carrying amount of goodwill	'
	The gross carrying amount of goodwill as of September 30, 2014 and December 31, 2013 and activity during the first nine months of 2014 were as follows (in thousands):
		Goodwill, Gross												Accumulated Impairment Losses
		Home Health			Hospice			Community Care			Total			Home Health			Hospice			Total			Net
	Balance at December 31, 2013 (Restated)	$	386,719		$	944,187		$	116,534		$	1,447,440		$	(263,370	)	$	(800,583	)	$	(1,063,953	)	$	383,487
	Harden purchase accounting adjustment	(3,023		)	(3,021		)	(3,419		)	(9,463		)	—			—			—			(9,463		)
	Balance at September 30, 2014:	$	383,696		$	941,166		$	113,115		$	1,437,977		$	(263,370	)	$	(800,583	)	$	(1,063,953	)	$	374,024

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Computations of the basic and diluted per share amounts	'
	The computations of the basic and diluted per share amounts were as follows (in thousands, except per share amounts):
		For the Three Months Ended				For the Nine Months Ended
		30-Sep-14		September 30, 2013 (Revised)		30-Sep-14		September 30, 2013 (Revised)
	Net income (loss) attributable to Gentiva shareholders	$	8,045	$	3,563	$	17,687	$	(184,441	)
	Basic weighted average common shares outstanding	36,369		31,037		36,285		30,921
	Shares issuable upon the assumed exercise of stock options and under stock plans for employees and directors using the treasury stock method	1,177		495		767		—
	Diluted weighted average common shares outstanding	37,546		31,532		37,052		30,921
	Earnings per share:
	Basic	$	0.22	$	0.12	$	0.49	$	(5.97	)
	Diluted	$	0.21	$	0.11	$	0.48	$	(5.97	)
	Anti-dilutive shares by type:
	Stock options	1,492		3,054		2,674		2,947
	Performance share units	—		—		—		80
	Restricted stock	—		—		—		232
	Total anti-dilutive shares	1,492		3,054		2,674		3,259

LongTerm_Debt_Tables

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Long-term debt	'
	As of September 30, 2014 and December 31, 2013, the Company’s long-term debt consisted of the following (in thousands):
		September 30, 2014			December 31, 2013
	Credit Agreement:
	Term Loan B, maturing October 18, 2019, net of unamortized discount of $5,780 and $6,508 as of September 30, 2014 and December 31, 2013, respectively	$	659,196		$	663,492
	Term Loan C, maturing October 18, 2018, net of unamortized discount of $589 and $735 as of September 30, 2014 and December 31, 2013, respectively	145,692			154,265
	11.5% Senior Notes due 2018	325,000			325,000
	Revolving Credit Facility	27,000			27,000
	Total debt	1,156,888			1,169,757
	Less: current portion of long-term debt	(51,138		)	(45,325		)
	Total long-term debt	$	1,105,750		$	1,124,432
Applicable Rate for Term Loans	'
	The Applicable Rate component of the interest rate under the Company's Credit Agreement is based on the Company's consolidated leverage ratio as follows:
		Applicable Rates
		Eurodollar Rate for Revolving Credit Facility and Letter of Credit Fees		Base Rate for Revolving Credit Facility	Term Loan B			Term Loan C
	Consolidated				Eurodollar Rate		Base Rate	Eurodollar Rate	Base Rate
	Leverage Ratio
	> 4.0:1	4.50%		3.50%	5.25%		4.25%	4.50%	3.50%
	< 4.0:1	4.25%		3.25%	5.25%		4.25%	4.50%	3.50%
Gentiva's permitted maximum consolidated leverage ratio	'
	Gentiva’s permitted maximum consolidated leverage ratio is set forth in the following table:
	Four Quarters Ending	Maximum Consolidated
		Leverage Ratio
	March 31, 2014 to March 31, 2015	≤ 6.75:1
	June 30, 2015 to March 31, 2016	≤ 6.50:1
	June 30, 2016 to March 31, 2017	≤ 6.25:1
	June 30, 2017 to December 31, 2017	≤ 6.00:1
	March 31, 2018 and each fiscal quarter thereafter	≤ 5.75:1
Senior Notes at redemption prices set forth below plus accrued and unpaid interest and Additional Interest	'
	On or after September 1, 2014, Gentiva may redeem all or part of the Senior Notes at redemption prices set forth below plus accrued and unpaid interest and Additional Interest, if any, as defined in the indenture relating to the Senior Notes during the twelve month period beginning on September 1 of the years indicated below:
	Year	Redemption Percentage
	2014	105.75%
	2015	102.88%
	2016 and thereafter	100.00%

Equity_Tables

Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Changes in Equity	'
	Changes in equity for the nine months ended September 30, 2014 and 2013 were as follows (in thousands, except share amounts):
		Gentiva Shareholders
		Common Stock			Additional			Retained			Treasury Stock			Noncontrolling Interests
					Paid-in Capital			Earnings
		Shares	Amount					Accumulated (Deficit)									Total
	Balance at December 31, 2012 (Revised)	32,009,286	$	3,201	$	399,148		$	(153,075	)	$	(17,852	)	$	1,538		$	232,960
	Comprehensive (loss) income:
	Net (loss) income	—	—		—			(184,441		)	—			425			(184,016		)
	Total comprehensive (loss) income	—	—		—			(184,441		)	—			425			(184,016		)
	Income tax expense associated with the exercise of non-qualified stock options	—	—		(330		)	—			—			—			(330		)
	Equity-based compensation expense	—	—		5,984			—			—			—			5,984
	Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	640,805	64		2,392			—			—			—			2,456
	Minority interest capital contribution	—	—		—			—			—			1,600			1,600
	Distribution to partnership interests	—	—		—			—			—			(563		)	(563		)
	Treasury shares:
	Stock withheld (25,801 shares) for payroll tax withholdings related to equity-based compensation	25,801	3		—			—			(286		)	—			(283		)
	Balance at September 30, 2013 (Revised)	32,675,892	$	3,268	$	407,194		$	(337,516	)	$	(18,138	)	$	3,000		$	57,808
	Balance at December 31, 2013 (Restated)	37,713,302	$	3,771	$	462,262		$	(758,136	)	$	(18,773	)	$	2,875		$	(308,001	)
	Comprehensive income:
	Net income	—	—		—			17,687			—			170			17,857
	Total comprehensive income	—	—		—			17,687			—			170			17,857
	Income tax expense associated with the exercise of non-qualified stock options	—	—		(2,261		)	—			—			—			(2,261		)
	Equity-based compensation expense	—	—		6,643			—			—			—			6,643
	Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	559,528	56		1,881			—			—			—			1,937
	Minority interest capital contribution	—	—		—			—			—			1,160			1,160
	Acquisition of non-controlling interest	—	—		(1,748		)	—			—			—			(1,748		)
	Distribution to partnership interests	—	—		—			—			—			(393		)	(393		)
	Treasury shares:
	Stock withheld (32,662 shares) for payroll tax withholdings related to equity-based compensation	—	—		—			—			(392		)	—			(392		)
	Balance at September 30, 2014	38,272,830	$	3,827	$	466,777		$	(740,449	)	$	(19,165	)	$	3,812		$	(285,198	)

EquityBased_Compensation_Plans1

Equity-Based Compensation Plans (Tables)	9 Months Ended
	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Weighted-average fair values of the Company's stock options granted	'
	The weighted average fair values of the Company’s stock options granted during the first nine months of 2014 and 2013 calculated using the Black-Scholes option pricing model and other assumptions were as follows:
		Nine Months Ended
		September 30, 2014				September 30, 2013
	Weighted average fair value of options granted	$	5.08			$	10.74
	Risk-free interest rate	0.46% - 0.51%				0.29% - 0.54%
	Expected volatility	60% - 63%				76% - 79%
	Contractual life	7 years				7 years
	Expected life	3.4 - 5.4 years				3.4 - 5.4 years
	Expected dividend yield	—		%		—		%
Summary of stock option activity	'
	A summary of Gentiva stock option activity as of September 30, 2014 and changes during the nine months then ended is presented below:
		Number of			Weighted-				Weighted-		Aggregate
		Options			Average				Average		Intrinsic
					Exercise				Remaining		Value
					Price				Contractual
									Life (Years)
	Balance as of December 31, 2013	4,005,589			$	15.4
	Granted	737,500			10.9
	Exercised	(27,268	)		7.16
	Cancelled	(722,674	)		19.65
	Balance as of September 30, 2014	3,993,147			$	13.86			4.4		$	20,692,356
	Exercisable options	2,404,269			$	16.71			3.6		$	9,208,192
	Shares expected to vest as of September 30, 2014	1,534,806			$	9.51			5.5		$	11,163,322
Summary of restricted stock activity	'
	A summary of Gentiva restricted stock activity as of September 30, 2014 is presented below:
		Number of			Weighted-				Aggregate
		Restricted			Average				Intrinsic
		Shares			Exercise				Value
					Price
	Balance as of December 31, 2013	635,400			$	18.27
	Granted	366,000			10.79
	Exercised	(88,900	)		26.58
	Cancelled	(12,200	)		11.27
	Balance as of September 30, 2014	900,300			$	14.54			$	15,107,034
	Nonvested shares expected to vest as of September 30, 2014	846,994			$	14.74			$	14,212,557
Performance Cash Award [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Summary of performance share unit	'
	A summary of Gentiva's performance based cash award activity by grant year as of September 30, 2014 is presented below:
		2012				2013				2014
	Service period to vest:	3 years				3 years				3 years
	Performance range of target:	0% - 200%				0% - 240%				0% - 240%
	Performance measured on:	EPS				EPS				EPS
	Performance measurement period:	1/2 based on 2012 results				30% based on 2013 results				100% based on 2016 results
		1/2 based on 2014 results				70% based on 2015 results
	Performance target achieved:	2012 - 85%				2013 - 0%
	Performance cash:
	Balance at December 31, 2013 - Earned	$	1,804,656			$	—			$	—
	Cancellations	(28,688		)		—				—
	Balance at September 30, 2014 - Earned	$	1,775,968			$	—			$	—
	Balance at December 31, 2013 - Unearned	$	2,123,125			$	4,638,750			$	—
	Granted	—				—				5,795,250
	Performance target not achieved	—				(1,076,250		)		—
	Cancellations	(33,750		)		—				(80,000		)
	Balance at September 30, 2014 - Unearned	$	2,089,375			$	3,562,500			$	5,715,250

Business_Segment_Information_T

Business Segment Information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment net revenues by major payer source	'
	Segment net revenues by major payer source were as follows (in millions):
		Third Quarter
		2014													2013
		Home			Hospice			Community Care				Total			Home			Hospice		Total
		Health													Health
	Medicare	$	214.9		$	161.6		$	—			$	376.5		$	191.8		$	163.8	$	355.6
	Medicaid and Local Government	8.6			6.1			56.2				70.9			10.8			6.6		17.4
	Commercial Insurance and Other:
	Paid at episodic rates	21.5			—			—				21.5			15.1			—		15.1
	Other	23.4			4.7			1				29.1			17.2			5.2		22.4
	Total net revenues	$	268.4		$	172.4		$	57.2			$	498		$	234.9		$	175.6	$	410.5
		First Nine Months
		2014													2013
		Home			Hospice			Community Care				Total			Home			Hospice		Total
		Health													Health
	Medicare	$	642		$	486.3		$	—			$	1,128.30		$	577.7		$	498.8	$	1,076.50
	Medicaid and Local Government	25.7			18.6			168.5				212.8			33.1			21.3		54.4
	Commercial Insurance and Other:
	Paid at episodic rates	55			—			—				55			43.3			—		43.3
	Other	70.8			14.2			2.5				87.5			52			14.3		66.3
	Total net revenues	$	793.5		$	519.1		$	171			$	1,483.60		$	706.1		$	534.4	$	1,240.50
Segment information about the Company's operations	'
	Segment information about the Company’s operations is as follows (in thousands):
		Home Health				Hospice				Community Care				Total
	For the three months ended September 30, 2014
	Net revenue	$	268,423			$	172,349			$	57,234			$	498,006
	Operating contribution	$	36,725	-1		$	27,043	-1		$	8,081			$	71,849
	Corporate expenses													(25,709		)	-1
	Depreciation and amortization													(7,287		)
	Interest expense and other, net													(24,719		)
	Income before income taxes and equity in net loss of CareCentrix													$	14,134
	For the three months ended September 30, 2013 (Revised)
	Net revenue	$	234,864			$	175,628			$	—			$	410,492
	Operating contribution	$	31,922	-1		$	22,365			$	—			$	54,287
	Corporate expenses													(20,672		)	-1
	Depreciation and amortization													(4,679		)
	Interest expense and other, net													(22,342		)
	Income before income taxes													$	6,594
	For the nine months ended September 30, 2014
	Net revenue	$	793,467			$	519,073			$	171,011			$	1,483,551
	Operating contribution	$	107,355	-1		$	66,674	-1		$	25,867		-1	$	199,896
	Corporate expenses													(73,937		)	-1
	Depreciation and amortization													(21,207		)
	Interest expense and other, net													(73,906		)
	Income before income taxes and equity in net loss of CareCentrix													$	30,846
	Segment assets	$	397,678			$	340,412			$	168,686			$	906,776
	Corporate assets													318,450
	Total assets													$	1,225,226
	For the nine months ended September 30, 2013 (Revised)
	Net revenue	$	706,141			$	534,366			$	—			$	1,240,507
	Operating contribution	$	92,027	-1		$	76,223	-1		$	—			$	168,250
	Corporate expenses													(57,443		)	-1
	Goodwill and other long-lived asset impairment													(210,672		)	-2
	Depreciation and amortization													(14,541		)
	Interest expense and other, net													(66,783		)
	Loss before income taxes													$	(181,189	)
	Segment assets	$	249,313			$	636,705	-2		$	—			$	886,018
	Corporate assets													377,935			-2
	Total assets													$	1,263,953
	-1	For the third quarter and first nine months of 2014, the Company recorded charges relating to cost savings initiatives and acquisition and integration activities of $0.5 million and $10.5 million, respectively. For the third quarter and first nine months of 2013, the Company recorded charges relating to cost savings initiatives and acquisition and integration activities of $1.7 million and $2.6 million, respectively.
	The charges were reflected as follows for segment reporting purposes (in millions):
		Third Quarter						First Nine Months
		2014			2013			2014				2013
	Home Health	$	0.1		$	0.1		$	0.7			$	0.1
	Hospice	0.1			—			5.5				0.7
	Community Care	—			—			0.1				—
	Corporate expenses	0.3			1.6			4.2				1.8
	Total	$	0.5		$	1.7		$	10.5			$	2.6
	-2	At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. See Note 9.
	In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million.
	Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of the impairment.
Schedule of segment reporting cost allocation to segment	'
	The charges were reflected as follows for segment reporting purposes (in millions):
		Third Quarter						First Nine Months
		2014			2013			2014				2013
	Home Health	$	0.1		$	0.1		$	0.7			$	0.1
	Hospice	0.1			—			5.5				0.7
	Community Care	—			—			0.1				—
	Corporate expenses	0.3			1.6			4.2				1.8
	Total	$	0.5		$	1.7		$	10.5			$	2.6

Supplemental_Guarantor_and_Non1

Supplemental Guarantor and Non-Guarantor Financial Information (Tables)	9 Months Ended
	Sep. 30, 2014
Supplemental Guarantor and Non-Guarantor Financial Information [Abstract]	'
Condensed Consolidating Balance Sheet	'
	Condensed Consolidating Balance Sheet
	30-Sep-14
	(In thousands)
		Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.			Subsidiaries			Subsidiaries						Total
	ASSETS
	Current assets:
	Cash and cash equivalents	$	84,708		$	—		$	29,498		$	—		$	114,206
	Receivables, net	—			277,263			41,275			(32,820		)	285,718
	Deferred tax assets, net	—			21,840			2,430			—			24,270
	Prepaid expenses and other current assets	—			39,291			9,485			—			48,776
	Total current assets	84,708			338,394			82,688			(32,820		)	472,970
	Note receivable from CareCentrix	—			25,000			—			—			25,000
	Fixed assets, net	—			41,511			537			—			42,048
	Intangible assets, net	—			244,433			2,600			—			247,033
	Goodwill	—			367,550			6,474			—			374,024
	Investment in subsidiaries	766,995			23,709			—			(790,704		)	—
	Other assets	24,440			39,704			7			—			64,151
	Total assets	$	876,143		$	1,080,301		$	92,306		$	(823,524	)	$	1,225,226
	LIABILITIES AND EQUITY
	Current liabilities:
	Current portion of long-term debt	$	51,138		$	—		$	—		$	—		$	51,138
	Accounts payable	—			16,370			—			—			16,370
	Other current liabilities	1,959			241,522			64,785			(32,820		)	275,446
	Total current liabilities	53,097			257,892			64,785			(32,820		)	342,954
	Long-term debt	1,105,750			—			—			—			1,105,750
	Deferred tax liabilities, net	—			6,264			—			—			6,264
	Other liabilities	6,306			49,150			—			—			55,456
	Total Gentiva shareholders’ (deficit) equity	(289,010		)	766,995			23,709			(790,704		)	(289,010		)
	Noncontrolling interests	—			—			3,812			—			3,812
	Total (deficit) equity	(289,010		)	766,995			27,521			(790,704		)	(285,198		)
	Total liabilities and equity (deficit)	$	876,143		$	1,080,301		$	92,306		$	(823,524	)	$	1,225,226
	Condensed Consolidating Balance Sheet
	31-Dec-13
	(In thousands)
	As Restated	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.			Subsidiaries			Subsidiaries						Total
	ASSETS
	Current assets:
	Cash and cash equivalents	$	55,388		$	—		$	31,569		$	—		$	86,957
	Receivables, net	—			284,637			33,878			(28,610		)	289,905
	Deferred tax assets, net	—			25,845			2,308			—			28,153
	Prepaid expenses and other current assets	—			52,971			11,775			—			64,746
	Total current assets	55,388			363,453			79,530			(28,610		)	469,761
	Notes receivable from CareCentrix	—			28,471			—			—			28,471
	Fixed assets, net	—			48,855			520			—			49,375
	Intangible assets, net	—			251,127			2,600			—			253,727
	Goodwill	—			379,880			3,607			—			383,487
	Investment in subsidiaries	782,470			23,493			—			(805,963		)	—
	Other assets	28,266			40,375			6			—			68,647
	Total assets	$	866,124		$	1,135,654		$	86,263		$	(834,573	)	$	1,253,468
	LIABILITIES AND EQUITY
	Current liabilities:
	Current portion of long-term debt	$	45,325		$	—		$	—		$	—		$	45,325
	Accounts payable	—			15,377			282			—			15,659
	Other current liabilities	—			283,483			59,613			(28,610		)	314,486
	Total current liabilities	45,325			298,860			59,895			(28,610		)	375,470
	Long-term debt	1,124,432			—			—			—			1,124,432
	Deferred tax liabilities, net	—			8,483			—			—			8,483
	Other liabilities	7,243			45,841			—			—			53,084
	Total Gentiva shareholders’ (deficit) equity	(310,876		)	782,470			23,493			(805,963		)	(310,876		)
	Noncontrolling interests	—			—			2,875			—			2,875
	Total (deficit) equity	(310,876		)	782,470			26,368			(805,963		)	(308,001		)
Total liabilities and equity (deficit)	$	866,124		$	1,135,654		$	86,263		$	(834,573	)	$	1,253,468
Condensed Consolidating Statement of Comprehensive Income	'
	Condensed Consolidating Statement of Comprehensive Income
	For the Three Months Ended September 30, 2014
	(In thousands)
		Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.			Subsidiaries			Subsidiaries						Total
	Net revenues	$	—		$	485,106		$	16,645		$	(3,745	)	$	498,006
	Cost of services sold	—			262,795			11,609			(3,745		)	270,659
	Gross profit	—			222,311			5,036			—			227,347
	Selling, general and administrative expenses	—			(182,876		)	(5,618		)	—			(188,494		)
	Interest (expense) and other, net	(24,772		)	—			53			—			(24,719		)
	Equity in earnings of subsidiaries	23,000			(261		)	—			(22,739		)	—
	(Loss) income before income taxes and equity in net loss of CareCentrix	(1,772		)	39,174			(529		)	(22,739		)	14,134
	Income tax benefit (expense)	9,817			(15,684		)	266			—			(5,601		)
	Equity in net loss of CareCentrix	—			(490		)	—			—			(490		)
	Net income (loss)	8,045			23,000			(263		)	(22,739		)	8,043
	Noncontrolling interests	—			—			2			—			2
	Net income (loss) attributable to Gentiva shareholders	$	8,045		$	23,000		$	(261	)	$	(22,739	)	$	8,045
	Total comprehensive income (loss)	$	8,045		$	23,000		$	(263	)	$	(22,739	)	$	8,043
	Condensed Consolidating Statement of Comprehensive Income
	For the Three Months Ended September 30, 2013
	(In thousands)
	As Revised	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.			Subsidiaries			Subsidiaries						Total
	Net revenues	$	—		$	398,047		$	16,429		$	(3,984	)	$	410,492
	Cost of services sold	—			212,543			11,919			(3,984		)	220,478
	Gross profit	—			185,504			4,510			—			190,014
	Selling, general and administrative expenses	—			(156,119		)	(4,959		)	—			(161,078		)
	Interest (expense) and other, net	(22,355		)	—			13			—			(22,342		)
	Equity in earnings of subsidiaries	15,987			(459		)	—			(15,528		)	—
	(Loss) income before income taxes	(6,368		)	28,926			(436		)	(15,528		)	6,594
	Income tax benefit (expense)	9,931			(12,939		)	65			—			(2,943		)
	Net income (loss)	3,563			15,987			(371		)	(15,528		)	3,651
	Noncontrolling interests	—			—			(88		)	—			(88		)
	Net income (loss) attributable to Gentiva shareholders	$	3,563		$	15,987		$	(459	)	$	(15,528	)	$	3,563
	Total comprehensive income (loss)	$	3,563		$	15,987		$	(371	)	$	(15,528	)	$	3,651
	Condensed Consolidating Statement of Comprehensive Income
	For the Nine Months Ended September 30, 2014
	(In thousands)
		Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.			Subsidiaries			Subsidiaries						Total
	Net revenues	$	—		$	1,446,339		$	48,648		$	(11,436	)	$	1,483,551
	Cost of services sold	—			790,399			32,114			(11,436		)	811,077
	Gross profit	—			655,940			16,534			—			672,474
	Selling, general and administrative expenses	—			(551,875		)	(15,847		)	—			(567,722		)
	Interest (expense) and other, net	(74,063		)	—			157			—			(73,906		)
	Equity in earnings of subsidiaries	62,347			427			—			(62,774		)	—
	(Loss) income before income taxes and equity in net loss of CareCentrix	(11,716		)	104,492			844			(62,774		)	30,846
	Income tax benefit (expense)	29,403			(41,655		)	(247		)	—			(12,499		)
	Equity in net loss of CareCentrix	—			(490		)	—			—			(490		)
	Net income	17,687			62,347			597			(62,774		)	17,857
	Noncontrolling interests	—			—			(170		)	—			(170		)
	Net income attributable to Gentiva shareholders	$	17,687		$	62,347		$	427		$	(62,774	)	$	17,687
	Total comprehensive income	$	17,687		$	62,347		$	597		$	(62,774	)	$	17,857
	Condensed Consolidating Statement of Comprehensive Income
	For the Nine Months Ended September 30, 2013
	(In thousands)
	As Reported	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.			Subsidiaries			Subsidiaries						Total
	Net revenues	$	—		$	1,203,258		$	48,498		$	(11,249	)	$	1,240,507
	Cost of services sold	—			638,418			33,829			(11,249		)	660,998
	Gross profit	—			564,840			14,669			—			579,509
	Selling, general and administrative expenses	—			(468,270		)	(14,364		)	—			(482,634		)
	Goodwill and other long-lived asset impairment	—			(224,320		)	—			—			(224,320		)
Interest (expense) and other, net	(66,829		)	—			46			—			(66,783		)
Equity in earnings of subsidiaries	(156,813		)	(7		)	—			156,820			—
(Loss) income before income taxes	(223,642		)	(127,757		)	351			156,820			(194,228		)
Income tax benefit (expense)	26,532			(29,056		)	67			—			(2,457		)
Net (loss) income	(197,110		)	(156,813		)	418			156,820			(196,685		)
Noncontrolling interests	—			—			(425		)	—			(425		)
Net (loss) income attributable to Gentiva shareholders	$	(197,110	)	$	(156,813	)	$	(7	)	$	156,820		$	(197,110	)
Total comprehensive (loss) income	$	(182,706	)	$	(156,813	)	$	418		$	142,416		$	(196,685	)
Revision Adjustments	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries						Total
Selling, general and administrative expenses	$	—		$	(609	)	$	—		$	—		(609	)
Goodwill and other long-lived asset impairment	—			13,648			—			—			13,648
Equity in earnings of subsidiaries	12,669			—			—			(12,669		)	—
(Loss) income before income taxes	12,669			13,039			—			(12,669		)	13,039
Income tax benefit (expense)	—			(370		)	—			—			(370	)
Net (loss) income	12,669			12,669			—			(12,669		)	12,669
Net (loss) income attributable to Gentiva shareholders	12,669			12,669			—			(12,669		)	12,669
Total comprehensive (loss) income	12,669			12,669			—			(12,669		)	12,669
As Revised	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Services, Inc.			Subsidiaries			Subsidiaries						Total
Net revenues	$	—		$	1,203,258		$	48,498		$	(11,249	)	$	1,240,507
Cost of services sold	—			638,418			33,829			(11,249		)	660,998
Gross profit	—			564,840			14,669			—			579,509
Selling, general and administrative expenses	—			(468,879		)	(14,364		)	—			(483,243		)
Goodwill and other long-lived asset impairment	—			(210,672		)	—			—			(210,672		)
Interest (expense) and other, net	(66,829		)	—			46			—			(66,783		)
Equity in earnings of subsidiaries	(144,144		)	(7		)	—			144,151			—
(Loss) income before income taxes	(210,973		)	(114,718		)	351			144,151			(181,189		)
Income tax benefit (expense)	26,532			(29,426		)	67			—			(2,827		)
Net (loss) income	(184,441		)	(144,144		)	418			144,151			(184,016		)
Noncontrolling interests	—			—			(425		)	—			(425		)
Net (loss) income attributable to Gentiva shareholders	$	(184,441	)	$	(144,144	)	$	(7	)	$	144,151		$	(184,441	)
Total comprehensive (loss) income	$	(184,441	)	$	(144,144	)	$	418		$	144,151		$	(184,016	)
Condensed Consolidating Statement of Cash Flows	'
	Condensed Consolidating Statement of Cash Flows
	For the Nine Months Ended September 30, 2014
	(In thousands)
		Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.			Subsidiaries			Subsidiaries						Total
	OPERATING ACTIVITIES:
	Net cash (used in) provided by operating activities	$	(32,770	)	$	80,338		$	(503	)	$	(1,026	)	$	46,039
	INVESTING ACTIVITIES:
	Purchase of fixed assets	—			(9,119		)	(149		)	—			(9,268		)
	Proceeds from sale of assets	—			2,004			—			—			2,004
	Capital contribution	—			(1,740		)	—			1,740			—
	Proceeds from sale of businesses	—			2,900			—			(2,900		)	—
	Acquisition of businesses, net of cash acquired	—			—			(2,900		)	2,900			—
	Net cash used in investing activities	—			(5,955		)	(3,049		)	1,740			(7,264		)
	FINANCING ACTIVITIES:
	Proceeds from issuance of common stock	1,937			—			—			—			1,937
	Windfall tax benefits associated with equity-based compensation	56			—			—			—			56
	Repayment of long-term debt	(13,744		)	—			—			—			(13,744		)
	Debt issuance costs	(150		)	—			—			—			(150		)
	Minority interest capital contributions	—			—			1,160			—			1,160
	Majority interest capital contributions	—			—			1,740			(1,740		)	—
	Distribution to minority interests	—			—			(393		)	—			(393		)
	Distribution to majority interests	—			—			(1,026		)	1,026			—
	Other	(361		)	(31		)	—			—			(392		)
	Net payments related to intercompany financing	74,352			(74,352		)	—			—			—
	Net cash provided by (used in) financing activities	62,090			(74,383		)	1,481			(714		)	(11,526		)
	Net change in cash and cash equivalents	29,320			—			(2,071		)	—			27,249
	Cash and cash equivalents at beginning of period	55,388			—			31,569			—			86,957
	Cash and cash equivalents at end of period	$	84,708		$	—		$	29,498		$	—		$	114,206
	Condensed Consolidating Statement of Cash Flows
	For the Nine Months Ended September 30, 2013
	(In thousands)
	As Revised	Gentiva Health			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Services, Inc.			Subsidiaries			Subsidiaries						Total
	OPERATING ACTIVITIES:
	Net cash (used in) provided by operating activities	$	(39,122	)	$	41,545		$	3,038		$	13,108		$	18,569
	INVESTING ACTIVITIES:
	Purchase of fixed assets	—			(13,872		)	(342		)	—			(14,214		)
	Proceeds from sale of businesses	—			508			—			—			508
	Acquisition of businesses, net of cash acquired	—			(4,538		)	(2,500		)	2,400			(4,638		)
	Net cash (used in) provided by investing activities	—			(17,902		)	(2,842		)	2,400			(18,344		)
	FINANCING ACTIVITIES:
	Proceeds from issuance of common stock	2,459			—			—			—			2,459
	Windfall tax benefits associated with equity-based compensation	92			—			—			—			92
	Payment of contingent consideration accrued at acquisition date	—			(1,675		)	—			—			(1,675		)
	Intercompany dividend	2,300			—			(2,300		)	—			—
	Repayment of long-term debt	(25,000		)	—			—			—			(25,000		)
	Debt issuance costs	(449		)	—			—			—			(449		)
	Minority interest capital contribution	—			—			1,600			—			1,600
	Majority interest capital contribution	—			—			2,400			(2,400		)	—
	Distribution to minority interests	—			—			(563		)	—			(563		)
	Distribution to majority interests	—			—			(1,296		)	1,296			—
	Other	(416		)	(31		)	—			—			(447		)
	Net payments related to intercompany financing	21,937			(21,937		)	—			—			—
	Net cash provided by (used in) financing activities	923			(23,643		)	(159		)	(1,104		)	(23,983		)
	Net change in cash and cash equivalents	(38,199		)	—			37			14,404			(23,758		)
	Cash and cash equivalents at beginning of period	166,140			—			40,912			—			207,052
	Cash and cash equivalents at end of period	$	127,941		$	—		$	40,949		$	14,404		$	183,294

Background_and_Basis_of_Presen1

Background and Basis of Presentation (Details Textual)	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Noncontrolling Interest, ownership percentage by parent	50.00%

Restatement_and_Revision_of_Pr2

Restatement and Revision of Previously Reported Consolidated Financial Statements (Details) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Selling, General and Administrative Expense	($188,494)	($161,078)	($322,165)	($567,722)	($483,243)
Goodwill and other long-lived asset impairment	0	0	-210,672	0	-210,672	[1]
Income (Loss) before income taxes	14,134	6,594	-187,783	30,846	-181,189
Income Tax Expense (Benefit)	-5,601	-2,943	116	-12,499	-2,827
Net Income (Loss)	8,043	3,651	-187,667	17,857	-184,016
Net income (loss) attributable to Gentiva shareholders	8,045	3,563	-188,044	17,687	-184,441
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	8,043	3,651	-187,667	17,857	-184,016
Earnings Per Share, Basic	$0.22	$0.12	($6.09)	$0.49	($5.97)
Earnings Per Share, Diluted	$0.21	$0.11	($6.09)	$0.48	($5.97)
Scenario, Previously Reported [Member]	'	'	'	'	'
Selling, General and Administrative Expense	'	'	-321,814	'	-482,634
Goodwill and other long-lived asset impairment	'	'	-224,320	'	-224,320
Income (Loss) before income taxes	'	'	-201,080	'	-194,228
Income Tax Expense (Benefit)	'	'	587	'	-2,457
Net Income (Loss)	'	'	-200,493	'	-196,685
Net income (loss) attributable to Gentiva shareholders	'	'	-200,830	'	-197,110
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	'	'	-200,493	'	-196,685
Earnings Per Share, Basic	'	'	($6.51)	'	($6.38)
Earnings Per Share, Diluted	'	'	($6.51)	'	($6.38)
Revision Adjustment [Member]	'	'	'	'	'
Selling, General and Administrative Expense	'	'	-351	'	-609
Goodwill and other long-lived asset impairment	'	'	13,648	'	13,648
Income (Loss) before income taxes	'	'	13,297	'	13,039
Income Tax Expense (Benefit)	'	'	-471	'	-370
Net Income (Loss)	'	'	12,826	'	12,669
Net income (loss) attributable to Gentiva shareholders	'	'	12,826	'	12,669
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	'	'	$12,826	'	$12,669
Earnings Per Share, Basic	'	'	$0.42	'	$0.41
Earnings Per Share, Diluted	'	'	$0.42	'	$0.41
[1]	(2)At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. See Note 9.In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million.Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of the impairment.

Restatement_and_Revision_of_Pr3

Restatement and Revision of Previously Reported Consolidated Financial Statements (Details 1) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net Income (Loss)	$8,043	$3,651	($187,667)	$17,857	($184,016)
Depreciation and amortization	'	'	9,862	21,207	14,541
Goodwill and other long-lived asset impairment	0	0	210,672	0	210,672	[1]
Deferred income tax expense (benefit)	'	'	-7,512	7,715	-6,696
Scenario, Previously Reported [Member]	'	'	'	'	'
Net Income (Loss)	'	'	-200,493	'	-196,685
Depreciation and amortization	'	'	9,511	'	13,932
Goodwill and other long-lived asset impairment	'	'	224,320	'	224,320
Deferred income tax expense (benefit)	'	'	-7,983	'	-7,066
Revision Adjustment [Member]	'	'	'	'	'
Net Income (Loss)	'	'	12,826	'	12,669
Depreciation and amortization	'	'	351	'	609
Goodwill and other long-lived asset impairment	'	'	-13,648	'	-13,648
Deferred income tax expense (benefit)	'	'	$471	'	$370
[1]	(2)At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. See Note 9.In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million.Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of the impairment.

Accounting_Policies_Details

Accounting Policies (Details) (USD $)	3 Months Ended		9 Months Ended					9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013
						CareCentrix [Member]	CareCentrix [Member]	Hospice [Member]	Hospice [Member]	Non-profit hospice [Member]	Non-profit hospice [Member]
Schedule of Accounting Policies [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Operating funds	'	'	'	'	'	'	'	'	'	$4,200,000	$5,500,000
Cost method investments	'	'	'	'	'	900,000	900,000	'	'	'	'
Assets held in rabbi trust	36,100,000	'	36,100,000	'	34,700,000	'	'	'	'	'	'
Unamortized debt issuance costs	24,400,000	'	24,400,000	'	28,300,000	'	'	'	'	'	'
Fixed assets, net	42,048,000	'	42,048,000	'	49,375,000	'	'	'	'	'	'
Goodwill, impairment loss	'	'	'	'	'	'	'	'	207,200,000	'	'
Obligations under insurance programs	78,310,000	'	78,310,000	'	82,634,000	'	'	'	'	'	'
Workers compensation and professional and general liability expenses	5,000,000	6,600,000	15,000,000	19,200,000	'	'	'	'	'	'	'
Employee health and welfare expenses	21,400,000	21,000,000	67,800,000	64,000,000	'	'	'	'	'	'	'
Percentage of Medicaid daily nursing home rate	'	'	'	'	'	'	'	95.00%	'	'	'
Net nursing home expense	$2,900,000	$1,700,000	$7,300,000	$7,200,000	'	'	'	'	'	'	'

Accounting_Policies_Accounting

Accounting Policies Accounting Policies (Fixed Assets) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Land and Building [Member]	'
Property, Plant and Equipment [Line Items]	'
Asset impairment charges	$1.90
Software Development [Member]	'
Property, Plant and Equipment [Line Items]	'
Asset impairment charges	$1.60

Acquisitions_and_Dispositions_

Acquisitions and Dispositions (Details Textual) (USD $)

9 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Sep. 30, 2014

Oct. 18, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Aug. 23, 2013

Aug. 23, 2013

Aug. 23, 2013

Sep. 30, 2013

Feb. 28, 2014

Sep. 30, 2014

Oct. 18, 2013

Apr. 30, 2013

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

Harden Healthcare Holdings Inc. [Member]

NORTH CAROLINA

NORTH CAROLINA

NORTH CAROLINA

NORTH CAROLINA

NORTH CAROLINA

NORTH CAROLINA

UNITED STATES

INDIANA

Home Health [Member]

Community Care [Member]

Wake Forest Baptist Health Care at Home, LLC [Member]

Wake Forest Baptist Health Care at Home, LLC [Member]

Wake Forest Baptist Health Care at Home, LLC [Member]

Appalachian Regional Health Systems [Member]

Wake Forest Baptist Health Care at Home, LLC [Member]

Wake Forest Baptist Health Care at Home, LLC [Member]

Harden Healthcare Holdings Inc. [Member]

Hope Hospice Inc [Member]

Cash [Member]

Other Assets [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to Acquire Equity Method Investments

'

'

'

'

'

'

'

'

'

$2,900,000

'

'

'

Noncontrolling Interest, Ownership Percentage by Parent

50.00%

'

'

'

'

60.00%

'

'

'

'

60.00%

'

'

Effective date of acquisition

'

'

'

'

'

23-Aug-13

'

'

30-Sep-13

'

'

18-Oct-13

30-Apr-13

Name of acquired entity

'

'

'

'

'

'Wake Forest Baptist Health Care at Home, LLC

'

'

'Appalachian Regional Health Systems

'

'

'Harden Healthcare Holdings, Inc.

'Hope Hospice, Inc.

Payments to Acquire Interest in Subsidiaries and Affiliates

0

'

'

'

'

2,400,000

2,200,000

200,000

'

'

'

'

'

Purchase price

'

'

'

'

'

'

'

'

2,700,000

'

'

426,800,000

1,000,000

Cost of acquired entity, cash paid

'

365,000,000

'

'

'

'

'

'

2,100,000

'

'

'

'

Issuance of stock in connection with Harden acquisition, value

'

53,800,000

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration arrangements, range of outcomes, value, high

'

9,500,000

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, liability

'

8,100,000

'

'

'

'

'

'

'

'

'

'

'

Increase in deferred taxes

'

'

9,700,000

'

'

'

'

'

'

'

'

'

'

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles

'

'

300,000

'

'

'

'

'

'

'

'

'

'

Increase in other accrued liabilities

'

'

200,000

'

'

'

'

'

'

'

'

'

'

Increase in accounts receivable

'

'

'

1,500,000

-1,500,000

'

'

'

'

'

'

'

'

Escrow fund liability

'

'

'

'

'

'

'

'

600,000

'

'

'

'

Purchase price allocation, intangible assets not amortizable

'

'

'

'

'

'

'

'

100,000

'

'

'

500,000

Purchase price allocation, current assets, receivables

'

'

'

'

'

'

'

'

'

'

'

'

$300,000

Acquisitions_and_Dispositions_1

Acquisitions and Dispositions Acquisitions and Dispositions (Goodwill) (Details Textual) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Apr. 30, 2013
In Thousands, unless otherwise specified			NORTH CAROLINA	INDIANA
			Appalachian Regional Health Systems [Member]	Hope Hospice Inc [Member]
Goodwill [Line Items]	'	'	'	'
Goodwill	$374,024	$383,487	$2,600	$200

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Inputs, Level 3 [Member] | Accrued Liabilities [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$8,514	$8,110
Fair Value, Measurements, Recurring [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	59,229	58,377
Financial and Nonfinancial Liabilities, Fair Value Disclosure	44,652	42,792
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	23,091	23,695
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | Rabbi Trust [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	4,963	5,737
Fair Value, Measurements, Recurring [Member] | Equity Funds [Member] | Rabbi Trust [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	31,175	28,945
Fair Value, Measurements, Recurring [Member] | Accounts Payable [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Financial and Nonfinancial Liabilities, Fair Value Disclosure	36,138	34,682
Fair Value, Measurements, Recurring [Member] | Accrued Liabilities [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Financial and Nonfinancial Liabilities, Fair Value Disclosure	8,514	8,110
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	59,229	58,377
Financial and Nonfinancial Liabilities, Fair Value Disclosure	36,138	34,682
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	23,091	23,695
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | Rabbi Trust [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	4,963	5,737
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Equity Funds [Member] | Rabbi Trust [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	31,175	28,945
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Accounts Payable [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Financial and Nonfinancial Liabilities, Fair Value Disclosure	36,138	34,682
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Accrued Liabilities [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	0	0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member] | Rabbi Trust [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Equity Funds [Member] | Rabbi Trust [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Accounts Payable [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Accrued Liabilities [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	0	0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	8,514	8,110
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member] | Rabbi Trust [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Equity Funds [Member] | Rabbi Trust [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Assets, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Accounts Payable [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Accrued Liabilities [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$8,514	$8,110

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments Fair Value of Financial Instruments (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Sensitivity Analysis of Fair Value, Transferor's Interests in Transferred Financial Assets, Impact of 20 Percent Adverse Change in Discount Rate	$200,000
Fair Value, Inputs, Level 3 [Member] | Accrued Liabilities [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Beginning Balance	8,110,000
Payment of contingent liability	-125,000
Included in Earnings	279,000	[1]
Harden acquisition contingent liability adjustment	250,000
Ending Balance	$8,514,000
[1]	(1)Accretion of the present value of the contingent liability is recorded in interest expense and other in the Company's consolidated statements of comprehensive income. A 1 percent change in the discount rate would have an impact on the fair value of the contingent liability of approximately $0.2 million.

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments (Details 2) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Carrying Amount [Member]	'	'
Assets:	'	'
Note receivable from CareCentrix	$25,000	$25,000
Seller financing note receivable from CareCentrix	0	3,471
Liabilities:	'	'
Long-term obligation	1,163,256	1,177,000
Estimate Fair Value [Member]	'	'
Assets:	'	'
Note receivable from CareCentrix	26,055	26,403
Seller financing note receivable from CareCentrix	0	3,471
Liabilities:	'	'
Long-term obligation	$1,182,837	$1,183,863

Net_Revenues_and_Accounts_Rece2

Net Revenues and Accounts Receivable (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net revenues by major payer classification	'	'	'	'
Net revenues	$498,006	$410,492	$1,483,551	$1,240,507
Percentage variance	21.30%	'	19.60%	'
Home Health [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	268,400	234,900	793,500	706,100
Hospice [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	172,400	175,600	519,100	534,400
Medicare [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	376,500	355,600	1,128,300	1,076,500
Percentage variance	5.90%	'	4.80%	'
Medicare [Member] | Home Health [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	214,900	191,800	642,000	577,700
Percentage variance	12.00%	'	11.10%	'
Medicare [Member] | Hospice [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	161,600	163,800	486,300	498,800
Percentage variance	-1.30%	'	-2.50%	'
Medicaid and Local Government [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	70,900	17,400	212,800	54,400
Percentage variance	307.00%	'	291.40%	'
Medicaid and Local Government [Member] | Home Health [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	8,600	10,800	25,700	33,100
Medicaid and Local Government [Member] | Hospice [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	6,100	6,600	18,600	21,300
Commercial Insurance and Other [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	50,600	37,500	142,500	109,700
Percentage variance	35.00%	'	29.90%	'
Commercial Insurance and Other [Member] | Paid at Episodic Rates [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	21,500	15,100	55,000	43,300
Percentage variance	42.80%	'	27.00%	'
Commercial Insurance and Other [Member] | Commercial Insurance Other [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	29,100	22,400	87,500	66,300
Percentage variance	29.70%	'	31.80%	'
Commercial Insurance and Other [Member] | Home Health [Member] | Paid at Episodic Rates [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	21,500	15,100	55,000	43,300
Commercial Insurance and Other [Member] | Home Health [Member] | Commercial Insurance Other [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	23,400	17,200	70,800	52,000
Commercial Insurance and Other [Member] | Hospice [Member] | Paid at Episodic Rates [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	0	0	0	0
Commercial Insurance and Other [Member] | Hospice [Member] | Commercial Insurance Other [Member]	'	'	'	'
Net revenues by major payer classification	'	'	'	'
Net revenues	$4,700	$5,200	$14,200	$14,300

Net_Revenues_and_Accounts_Rece3

Net Revenues and Accounts Receivable (Details 1) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts receivable attributable to major payer sources of reimbursement	'	'
Gross Accounts Receivable	$296,021	$300,585
Less: Allowance for doubtful accounts	-10,303	-10,680
Net Accounts Receivable	285,718	289,905
Medicare [Member]	'	'
Accounts receivable attributable to major payer sources of reimbursement	'	'
Gross Accounts Receivable	200,902	214,366
Medicaid and Local Government [Member]	'	'
Accounts receivable attributable to major payer sources of reimbursement	'	'
Gross Accounts Receivable	51,113	48,183
Commercial Insurance and Other [Member]	'	'
Accounts receivable attributable to major payer sources of reimbursement	'	'
Gross Accounts Receivable	$44,006	$38,036

Net_Revenues_and_Accounts_Rece4

Net Revenues and Accounts Receivable (Details Textual) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Schedule of Health Care Revenue Adjustment [Line Items]	'	'	'	'	'
Medicare Hospice Cap (income) expense	$0.40	($2.90)	$1.50	($4.50)	'
Medicare Hospice Cap Liabilities	3.7	'	3.7	'	6.5
Commercials Insurance self pay accounts receivables related to patient	2.1	'	2.1	'	2.4
Medicare Cap Year 2014 [Member]	'	'	'	'	'
Schedule of Health Care Revenue Adjustment [Line Items]	'	'	'	'	'
Medicare Hospice Cap (income) expense	'	'	1.8	'	'
Hospice programs exceeding Medicare Payment Cap	7	'	7	'	'
Prior Year Medicare Cap Settlement [Member]	'	'	'	'	'
Schedule of Health Care Revenue Adjustment [Line Items]	'	'	'	'	'
Medicare Hospice Cap (income) expense	'	3.4	'	5.9	'
Hospice [Member] | Eligibility Review [Member]	'	'	'	'	'
Schedule of Health Care Revenue Adjustment [Line Items]	'	'	'	'	'
Patient service revenue adjustments	-0.4	3.5	1.9	5	'
Home Health [Member] | PRRB Appeal [Member]	'	'	'	'	'
Schedule of Health Care Revenue Adjustment [Line Items]	'	'	'	'	'
Patient service revenue adjustments	'	$4	'	$4	'

Investment_in_and_Notes_Receiv1

Investment in and Notes Receivable from CareCentrix (Details Textual) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

12 Months Ended

Aug. 24, 2012

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Aug. 24, 2012

Dec. 31, 2012

CareCentrix [Member]

CareCentrix [Member]

Escrow fund, reclass to note receivable [Member]

Escrow fund, indemnified claims [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Promissory note

'

$25,000,000

'

'

$25,000,000

'

'

'

'

'

'

'

Investment maturity date

19-Mar-17

'

'

'

'

'

'

'

'

'

'

'

Fixed interest rate on promissory note

'

'

'

'

10.00%

'

'

'

'

'

'

'

Investment income, nonoperating

'

625,000

625,000

'

1,875,000

1,875,000

'

'

'

'

'

'

Escrow fund receivable

'

'

'

'

'

'

'

10,600,000

'

'

'

'

Reduction in escrow fund receivable

'

'

'

'

'

'

'

'

'

'

9,900,000

700,000

Seller financing note receivable

9,900,000

3,400,000

'

'

3,400,000

'

'

'

'

'

'

'

Interest rate on promissory note, thereafter

18.00%

'

'

'

'

'

'

'

'

'

'

'

Increase (decrease) in notes receivable

'

'

'

6,500,000

'

'

'

'

'

'

'

'

Cost method investments

'

'

'

'

'

'

'

'

900,000

900,000

'

'

Proceeds from Collection of Notes Receivable

'

3,600,000

'

'

'

'

'

'

'

'

'

'

Equity in net loss of CareCentrix, net of tax

'

-490,000

0

'

-490,000

0

'

'

'

'

'

'

Allowance for credit losses

'

$0

'

'

$0

'

$0

'

'

'

'

'

Cost_Savings_Initiatives_and_A2

Cost Savings Initiatives and Acquisition and Integration Activities (Details) (USD $)	3 Months Ended						9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2014	Sep. 30, 2013
Costs incurred and cash expenditures	'	'	'	'	'	'	'	'
Beginning Balance	$12,382	$14,705	$16,425	$1,236	$1,411	$2,696	$16,425	$2,696
Restructuring charges	479	4,659	5,341	1,699	744	141	10,500	2,600
Cash Expenditure	-3,210	-6,711	-6,915	-523	-919	-1,426	'	'
Non-cash expenditures	38	-271	-146	'	'	'	'	'
Non-cash reclassification	'	'	'	0	'	'	'	'
Ending Balance	9,689	12,382	14,705	2,412	1,236	1,411	9,689	2,412
Cost Savings and Other Restructuring [Member]	'	'	'	'	'	'	'	'
Costs incurred and cash expenditures	'	'	'	'	'	'	'	'
Beginning Balance	4,071	5,932	6,722	81	628	1,685	6,722	1,685
Restructuring charges	195	1,409	2,713	77	138	47	4,300	300
Cash Expenditure	-1,302	-2,994	-3,443	-240	-685	-1,104	'	'
Non-cash expenditures	35	-276	-60	'	'	'	'	'
Non-cash reclassification	'	'	'	476	'	'	'	'
Ending Balance	2,999	4,071	5,932	394	81	628	2,999	394
Acquisition & Integration [Member]	'	'	'	'	'	'	'	'
Costs incurred and cash expenditures	'	'	'	'	'	'	'	'
Beginning Balance	8,311	8,773	9,703	1,155	783	1,011	9,703	1,011
Restructuring charges	284	3,250	2,628	1,622	606	94	6,200	2,300
Cash Expenditure	-1,908	-3,717	-3,472	-283	-234	-322	'	'
Non-cash expenditures	3	5	-86	'	'	'	'	'
Non-cash reclassification	'	'	'	-476	'	'	'	'
Ending Balance	$6,690	$8,311	$8,773	$2,018	$1,155	$783	$6,690	$2,018

Cost_Savings_Initiatives_and_A3

Cost Savings Initiatives and Acquisition and Integration Activities (Details Textual) (USD $)	3 Months Ended						9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Restructuring charges	$479	$4,659	$5,341	$1,699	$744	$141	$10,500	$2,600	'	'
Restructuring reserve	9,689	12,382	14,705	2,412	1,236	1,411	9,689	2,412	16,425	2,696
Cost Savings Initiative [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Restructuring charges	195	1,409	2,713	77	138	47	4,300	300	'	'
Number of Branches closed, consolidated or divested	'	'	'	'	'	'	94	'	'	'
Restructuring reserve	2,999	4,071	5,932	394	81	628	2,999	394	6,722	1,685
Acquisition Integration [Member]	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'
Restructuring charges	284	3,250	2,628	1,622	606	94	6,200	2,300	'	'
Restructuring reserve	$6,690	$8,311	$8,773	$2,018	$1,155	$783	$6,690	$2,018	$9,703	$1,011

Goodwill_and_Identifiable_Inta2

Goodwill and Identifiable Intangible Assets (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

In Thousands, unless otherwise specified

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Licenses and certificates of need [Member]

Licenses and certificates of need [Member]

Licenses and certificates of need [Member]

Licenses and certificates of need [Member]

Licenses and certificates of need [Member]

Licenses and certificates of need [Member]

Licenses and certificates of need [Member]

Licenses and certificates of need [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Covenants not to compete [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Home Health [Member]

Home Health [Member]

Hospice [Member]

Hospice [Member]

Community Care [Member]

Community Care [Member]

Covenants not to compete [Member]

Customer Relationships [Member]

Trade Names [Member]

Covenants not to compete [Member]

Customer Relationships [Member]

Trade Names [Member]

Amortized intangible assets:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Gross

'

'

'

'

'

'

'

'

$10,003

$8,735

$714

$714

$9,289

$8,021

$0

$0

$19,369

$19,369

$2,157

$2,157

$16,183

$16,183

$1,029

$1,029

$28,106

$28,106

$27,196

$27,196

$910

$910

$0

$0

$48,717

$48,717

$19,267

$19,267

$17,528

$17,528

$11,922

$11,922

'

'

'

'

'

'

Less: Accumulated Amortization

'

'

'

'

'

'

'

'

-9,496

-7,400

-714

-588

-8,782

-6,812

0

0

-17,873

-17,364

-1,709

-1,553

-15,837

-15,720

-327

-91

-22,252

-20,478

-21,703

-19,997

-549

-481

0

0

-18,297

-15,982

-12,795

-11,992

-4,368

-3,763

-1,134

-227

'

'

'

'

'

'

Finite Lived Intangible Assets, Accumulated Impairment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-27

-27

-27

-27

0

0

0

0

-19,543

-19,543

-6,421

-6,421

-13,122

-13,122

0

0

'

'

'

'

'

'

Finite-Lived Intangible Assets, Net

18,707

24,133

5,965

8,756

1,252

2,744

11,490

12,633

507

1,335

0

126

507

1,209

0

0

1,496

2,005

448

604

346

463

702

938

5,827

7,601

5,466

7,172

361

429

0

0

10,877

13,192

51

854

38

643

10,788

11,695

'

'

'

'

'

'

Finite-Lived Intangible Asset, useful life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'10 years

'10 years

'2 years

'5 years

'5 years

Indefinite-lived intangible assets:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Indefinite-Lived Intangible Assets

'

'

'

'

'

'

'

'

375,461

376,729

245,086

245,086

104,364

105,632

26,011

26,011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Indefinite Lived Intangible Assets, Accumulated Impairment

'

'

'

'

'

'

'

'

-147,135

-147,135

-144,672

-144,672

-2,463

-2,463

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Indefinite Lived Intangible Assets, Net

'

'

'

'

'

'

'

'

228,326

229,594

100,414

100,414

101,901

103,169

26,011

26,011

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total identifiable intangible assets

$247,033

$253,727

$106,379

$109,170

$103,153

$105,913

$37,501

$38,644

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill_and_Identifiable_Inta3

Goodwill and Identifiable Intangible Assets (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Goodwill [Roll Forward]	'	'	'
Goodwill, Gross	$1,437,977,000	'	$1,447,440,000
Goodwill, Impaired, Accumulated Impairment Loss	-1,063,953,000	'	-1,063,953,000
Goodwill, Purchase Accounting Adjustments	-9,463,000	'	'
Goodwill	374,024,000	'	383,487,000
Home Health [Member]	'	'	'
Goodwill [Roll Forward]	'	'	'
Goodwill, Gross	383,696,000	'	386,719,000
Goodwill, Impaired, Accumulated Impairment Loss	-263,370,000	'	-263,370,000
Goodwill, Purchase Accounting Adjustments	-3,023,000	'	'
Hospice [Member]	'	'	'
Goodwill [Roll Forward]	'	'	'
Goodwill, Gross	941,166,000	'	944,187,000
Goodwill, Impaired, Accumulated Impairment Loss	-800,583,000	'	-800,583,000
Goodwill, Purchase Accounting Adjustments	-3,021,000	'	'
Goodwill, Impairment Loss	'	-207,200,000	'
Community Care [Member]	'	'	'
Goodwill [Roll Forward]	'	'	'
Goodwill, Gross	113,115,000	'	116,534,000
Goodwill, Purchase Accounting Adjustments	($3,419,000)	'	'

Goodwill_and_Identifiable_Inta4

Goodwill and Identifiable Intangible Assets (Details Textual) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2013	Mar. 31, 2013
					Hospice [Member]	Hospice [Member]
Goodwill [Line Items]	'	'	'	'	'	'
Discount rate	'	'	'	'	9.50%	'
Goodwill impairment test, net book value of reporting unit	'	'	'	'	'	$555
Goodwill, impairment loss	'	'	'	'	207.2	'
Amortization expense	2.5	1.2	6.7	4	'	'
Estimated amortization expense for the remainder of 2014	1.6	'	1.6	'	'	'
Estimated amortization expense for 2015	4.1	'	4.1	'	'	'
Estimated amortization expense for 2016	3.1	'	3.1	'	'	'
Estimated amortization expense for 2017	2.4	'	2.4	'	'	'
Estimated amortization expense for 2018	1.6	'	1.6	'	'	'
Estimated amortization expense for 2019	$1.30	'	$1.30	'	'	'

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Computations of the basic and diluted per share amounts	'	'	'	'	'
Net income (loss) attributable to Gentiva shareholders	$8,045	$3,563	($188,044)	$17,687	($184,441)
Basic weighted average common shares outstanding	36,369	31,037	'	36,285	30,921
Shares issuable upon the assumed exercise of stock options and under stock plans for employees and directors using the treasury stock method	1,177	495	'	767	0
Diluted weighted average common shares outstanding	37,546	31,532	'	37,052	30,921
Basic earnings per common share	'	'	'	'	'
Net income (loss) attributable to Gentiva shareholders	$0.22	$0.12	($6.09)	$0.49	($5.97)
Diluted earnings per common share:	'	'	'	'	'
Net income (loss) attributable to Gentiva shareholders	$0.21	$0.11	($6.09)	$0.48	($5.97)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Anti-dilutive shares	1,492	3,054	'	2,674	3,259
Employee Stock Option [Member]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Anti-dilutive shares	1,492	3,054	'	2,674	2,947
Performance Shares [Member]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Anti-dilutive shares	0	0	'	0	80
Restricted Stock [Member]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Anti-dilutive shares	0	0	'	0	232

Earnings_Per_Share_Details_Tex

Earnings Per Share (Details Textual)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	1,492	3,054	2,674	3,259

LongTerm_Debt_Details

Long-Term Debt (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Long-term debt	'	'
Total debt	$1,156,888	$1,169,757
Less: current portion of long-term debt	-51,138	-45,325
Total long-term debt	1,105,750	1,124,432
Senior Subordinated Notes [Member]	'	'
Long-term debt	'	'
Senior notes, noncurrent	325,000	325,000
Revolving Credit Facility [Member]	'	'
Long-term debt	'	'
Line of Credit Facility, Amount Outstanding	27,000	27,000
Term Loan B, dated October 18, 2013 [Member] | Loans Payable [Member]	'	'
Long-term debt	'	'
Total debt	659,196	663,492
Term Loan C, Dated October 18, 2013 [Member] | Loans Payable [Member]	'	'
Long-term debt	'	'
Total debt	$145,692	$154,265

LongTerm_Debt_LongTerm_Debt_Pa

Long-Term Debt Long-Term Debt (Parenthetical) (Details) (Loans Payable [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Term Loan B, dated October 18, 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Unamortized Discount	$5,780	$6,508
Term Loan C, Dated October 18, 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Unamortized Discount	$589	$735

LongTerm_Debt_Details_1

Long-Term Debt (Details 1)	Sep. 30, 2014
Eurodollar Rate [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	1.00%
Revolver, Dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.50%
Revolver, Dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.25%
Revolver, Dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	3.50%
Revolver, Dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	3.25%
Term Loan B, dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	5.25%
Term Loan B, dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	5.25%
Term Loan B, dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.25%
Term Loan B, dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.25%
Term Loan C, Dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.50%
Term Loan C, Dated October 18, 2013 [Member] | Eurodollar Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	4.50%
Term Loan C, Dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range greater than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	3.50%
Term Loan C, Dated October 18, 2013 [Member] | Base Rate [Member] | Leverage Ratio Range less than 4.0:1 [Member]	'
Debt Instrument [Line Items]	'
Effective interest rate	3.50%

LongTerm_Debt_Details_2

Long-Term Debt (Details 2) (Scenario, Forecast [Member])	9 Months Ended	12 Months Ended		15 Months Ended
	Dec. 31, 2017	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2019	Mar. 31, 2015
Scenario, Forecast [Member]	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'
Maximum leverage ratio permitted for future period	6	6.25	6.5	5.75	6.75

LongTerm_Debt_Details_3

Long-Term Debt (Details 3)	9 Months Ended
	Sep. 30, 2014
Senior Notes at redemption prices set forth below plus accrued and unpaid interest and Additional Interest	'
2014	105.75%
2015	102.88%
2016 and thereafter	100.00%

LongTerm_Debt_Details_Textual

Long-Term Debt (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Long-Term Debt (Textual) [Abstract]	'	'
Outstanding letter of credit	$56,200,000	$52,000,000
Weighted average cash interest rate on outstanding borrowings	7.80%	8.20%
Excess cash flow with two step downs based on company leverage ratio	75.00%	'
Consolidated leverage ratio	5.8	'
Pledge of capital stock to lenders percentage	100.00%	'
Revolving Credit Facility [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Line of credit facility, maximum borrowing capacity	100,000,000	'
Unused and available borrowing capacity under the Credit Agreement	16,800,000	'
Federal Funds [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Effective interest rate	0.50%	'
Eurodollar Rate [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Effective interest rate	1.00%	'
Eurodollar Rate [Member] | Minimum [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Effective interest rate	1.25%	'
Base Rate [Member] | Minimum [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Effective interest rate	2.25%	'
Loans Payable [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Maturity, repayments of principal for 12 months ending September 30, 2015	51,100,000	'
Maturity, repayments of principal for 12 months ending September 30, 2016	29,000,000	'
Maturity, repayments of principal for 12 months ending September 30, 2017	35,800,000	'
Maturity, repayments of principal for 12 months ending September 30, 2018	60,900,000	'
Maturity, repayments of principal for 12 months ending September 30, 2019	30,000,000	'
Maturity, repayments of principal thereafter	631,500,000	'
Senior Subordinated Notes [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Senior notes, noncurrent	325,000,000	325,000,000
Effective interest rate	11.50%	'
Maturity, repayments of principal for 12 months ending September 30, 2018	325,000,000	'
Debt instrument redemption price terms	'Gentiva may redeem the Senior Notes, in whole or in part, at any time prior to the first interest payment of 2014, at a price equal to 100 percent of the principal amount of the Senior Notes redeemed plus an applicable make-whole premium based on the present value of the remaining payments discounted at the treasury rate plus 50 basis points plus accrued and unpaid interest, if any, to the date of redemption.	'
Term Loan B, dated October 18, 2013 [Member] | Loans Payable [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Debt instrument, face amount	670,000,000	'
Effective interest rate	6.50%	'
Annual principal payment	6,700,000	'
Term Loan C, Dated October 18, 2013 [Member] | Loans Payable [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Debt instrument, face amount	155,000,000	'
Effective interest rate	5.75%	'
Annual principal payment	11,600,000	'
Revolver, Dated October 18, 2013 [Member] | Letter of Credit [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Line of credit facility, maximum borrowing capacity	80,000,000	'
Revolver, Dated October 18, 2013 [Member] | Revolving Credit Facility [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Line of credit facility, maximum borrowing capacity	100,000,000	'
Effective interest rate	4.77%	'
Line of Credit Facility, Expiration Date	18-Oct-18	'
Line of Credit Facility, unused commitment fee percentage	0.50%	'
Revolver, Dated October 18, 2013 [Member] | Same-Day Borrowing [Member]	'	'
Long-Term Debt (Textual) [Abstract]	'	'
Line of credit facility, maximum borrowing capacity	$15,000,000	'

Equity_Details

Equity (Details) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Comprehensive (loss) income:	'	'	'	'	'
Beginning Balance	'	'	$232,960	($308,001)	$232,960
Comprehensive Income	'	'	'	'	'
Net income (loss)	8,043	3,651	-187,667	17,857	-184,016
Total comprehensive income (loss)	8,043	3,651	-187,667	17,857	-184,016
Income tax benefits associated with the exercise of non-qualified stock options	'	'	'	-2,261	-330
Equity-based compensation expense	'	'	'	6,643	5,984
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	'	'	'	1,937	2,456
Minority interest capital contribution	'	'	'	1,160	1,600
Acquisition of non-controlling interest	'	'	'	-1,748	'
Distribution to partnership interests	'	'	'	-393	-563
Treasury shares:	'	'	'	'	'
Treasury Stock, Value, Acquired, Cost Method	'	'	'	-392	-283
Ending Balance	-285,198	57,808	'	-285,198	57,808
Common Stock [Member]	'	'	'	'	'
Comprehensive (loss) income:	'	'	'	'	'
Shares, Beginning Balance	'	'	32,009,286	37,713,302	32,009,286
Beginning Balance	'	'	3,201	3,771	3,201
Comprehensive Income	'	'	'	'	'
Net income (loss)	'	'	'	0	0
Total comprehensive income (loss)	'	'	'	0	0
Income tax benefits associated with the exercise of non-qualified stock options	'	'	'	0	0
Equity-based compensation expense	'	'	'	0	0
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors, Shares	'	'	'	559,528	640,805
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	'	'	'	56	64
Minority interest capital contribution	'	'	'	0	0
Acquisition of non-controlling interest	'	'	'	0	'
Distribution to partnership interests	'	'	'	0	0
Treasury shares:	'	'	'	'	'
Treasury Stock, Shares, Acquired	'	'	'	0	25,801
Treasury Stock, Value, Acquired, Cost Method	'	'	'	0	3
Shares, Ending Balance	38,272,830	32,675,892	'	38,272,830	32,675,892
Ending Balance	3,827	3,268	'	3,827	3,268
Additional Paid-in Capital [Member]	'	'	'	'	'
Comprehensive (loss) income:	'	'	'	'	'
Beginning Balance	'	'	399,148	462,262	399,148
Comprehensive Income	'	'	'	'	'
Net income (loss)	'	'	'	0	0
Total comprehensive income (loss)	'	'	'	0	0
Income tax benefits associated with the exercise of non-qualified stock options	'	'	'	-2,261	-330
Equity-based compensation expense	'	'	'	6,643	5,984
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	'	'	'	1,881	2,392
Minority interest capital contribution	'	'	'	0	0
Acquisition of non-controlling interest	'	'	'	-1,748	'
Distribution to partnership interests	'	'	'	0	0
Treasury shares:	'	'	'	'	'
Treasury Stock, Value, Acquired, Cost Method	'	'	'	0	0
Ending Balance	466,777	407,194	'	466,777	407,194
Retained Earnings / Accumulated (deficit) [Member]	'	'	'	'	'
Comprehensive (loss) income:	'	'	'	'	'
Beginning Balance	'	'	-153,075	-758,136	-153,075
Comprehensive Income	'	'	'	'	'
Net income (loss)	'	'	'	17,687	-184,441
Total comprehensive income (loss)	'	'	'	17,687	-184,441
Income tax benefits associated with the exercise of non-qualified stock options	'	'	'	0	0
Equity-based compensation expense	'	'	'	0	0
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	'	'	'	0	0
Minority interest capital contribution	'	'	'	0	0
Acquisition of non-controlling interest	'	'	'	0	'
Distribution to partnership interests	'	'	'	0	0
Treasury shares:	'	'	'	'	'
Treasury Stock, Value, Acquired, Cost Method	'	'	'	0	0
Ending Balance	-740,449	-337,516	'	-740,449	-337,516
Accumulated Other Comprehensive Income (Loss) [Member]	'	'	'	'	'
Comprehensive Income	'	'	'	'	'
Acquisition of non-controlling interest	'	'	'	0	'
Treasury Stock [Member]	'	'	'	'	'
Comprehensive (loss) income:	'	'	'	'	'
Beginning Balance	'	'	-17,852	-18,773	-17,852
Comprehensive Income	'	'	'	'	'
Net income (loss)	'	'	'	0	0
Total comprehensive income (loss)	'	'	'	0	0
Income tax benefits associated with the exercise of non-qualified stock options	'	'	'	0	0
Equity-based compensation expense	'	'	'	0	0
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	'	'	'	0	0
Minority interest capital contribution	'	'	'	0	0
Acquisition of non-controlling interest	'	'	'	0	'
Distribution to partnership interests	'	'	'	0	0
Treasury shares:	'	'	'	'	'
Treasury Stock, Value, Acquired, Cost Method	'	'	'	-392	-286
Ending Balance	-19,165	-18,138	'	-19,165	-18,138
Noncontrolling Interests [Member]	'	'	'	'	'
Comprehensive (loss) income:	'	'	'	'	'
Beginning Balance	'	'	1,538	2,875	1,538
Comprehensive Income	'	'	'	'	'
Net income (loss)	'	'	'	170	425
Total comprehensive income (loss)	'	'	'	170	425
Income tax benefits associated with the exercise of non-qualified stock options	'	'	'	0	0
Equity-based compensation expense	'	'	'	0	0
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	'	'	'	0	0
Minority interest capital contribution	'	'	'	1,160	1,600
Distribution to partnership interests	'	'	'	-393	-563
Treasury shares:	'	'	'	'	'
Treasury Stock, Value, Acquired, Cost Method	'	'	'	0	0
Ending Balance	$3,812	$3,000	'	$3,812	$3,000

Equity_Equity_Parenthetical_De

Equity Equity (Parenthetical) (Details)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'	'
Stock withheld for payroll tax withholdings related to equity-based compensation, shares	32,662	25,801

Equity_Details_Textual

Equity (Details Textual) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Mar. 13, 2012
						2012 Repurchase Program [Member]	2012 Repurchase Program [Member]
Equity (Textual) [Abstract]	'	'	'	'	'	'	'
Repurchase Limitations	'	'	'	'	'	'	5,000,000
Remaining authorization to repurchase common stock under	'	'	'	'	'	$1,500,000	'
Equity (Additional Textual) [Abstract]	'	'	'	'	'	'	'
Comprehensive income (loss)	8,043,000	3,651,000	-187,667,000	17,857,000	-184,016,000	'	'
Senior note governing repurchases of the Company's common stock limitations per year	7,500,000	'	'	7,500,000	'	'	'
Limitations per year for leverage ratio less than or equal to 3.5:1.0	$25,000,000	'	'	$25,000,000	'	'	'
Consolidated leverage ratio	'	'	'	'less than or equal to 3.5:1	'	'	'

EquityBased_Compensation_Plans2

Equity-Based Compensation Plans (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Weighted-average fair values of the Company's stock options granted	'	'
Weighted average fair value of options granted	$5.08	$10.74
Contractual life	'7 years	'7 years
Expected dividend yield	0.00%	0.00%
Minimum [Member]	'	'
Weighted-average fair values of the Company's stock options granted	'	'
Risk-free interest rate	0.46%	0.29%
Expected volatility	60.00%	76.00%
Expected life	'3 years 4 months 24 days	'3 years 4 months 24 days
Maximum [Member]	'	'
Weighted-average fair values of the Company's stock options granted	'	'
Risk-free interest rate	0.51%	0.54%
Expected volatility	63.00%	79.00%
Expected life	'5 years 4 months 24 days	'5 years 4 months 24 days

EquityBased_Compensation_Plans3

Equity-Based Compensation Plans (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2014
Summary of stock option activity	'
Number of options, Beginning balance	4,005,589
Weighted Average Exercise Price, Beginning balance	$15.40
Number of Options, Granted	737,500
Weighted Average Exercise Price, Granted	$10.90
Number of Options, Exercised	-27,268
Weighted Average Exercise Price, Exercised	$7.16
Number of Options, Cancelled	-722,674
Weighted Average Exercise Price, Cancelled	$19.65
Number of options, Ending balance	3,993,147
Weighted Average Exercise Price, Ending balance	$13.86
Weighted Average Remaining Contractual Life-Years	'4 years 4 months 22 days
Aggregate intrinsic value, Ending balance	$20,692,356
Number of Options, Exercisable options	2,404,269
Weighted Average Exercise Price, Exercisable options	$16.71
Weighted Average Remaining Contractual Term, Exercisable options	'3 years 7 months 12 days
Aggregate Intrinsic Value, Exercisable options	9,208,192
Number of Options, Expected to vest	1,534,806
Weighted Average Exercise Price, Expected to vest options	$9.51
Weighted Average Remaining Contractual Term, Expected to vest options	'5 years 6 months 12 days
Aggregate Intrinsic Value, Expected to vest	$11,163,322

EquityBased_Compensation_Plans4

Equity-Based Compensation Plans (Details 2) (USD $)	9 Months Ended	12 Months Ended			9 Months Ended	12 Months Ended			9 Months Ended
	Sep. 30, 2014	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
	Performance Cash Award 2012 [Member]	Performance Cash Award 2012 [Member]	Performance Cash Award 2012 [Member]	Performance Cash Award 2012 [Member]	Performance Cash Award 2013 [Member]	Performance Cash Award 2013 [Member]	Performance Cash Award 2013 [Member]	Performance Cash Award 2013 [Member]	Performance Cash Award 2014 [Member]	Performance Cash Award 2014 [Member]	Performance Cash Award 2014 [Member]
			Minimum [Member]	Maximum [Member]			Minimum [Member]	Maximum [Member]		Minimum [Member]	Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Requisite Service Period	'	'3 years	'	'	'	'3 years	'	'	'3 years	'	'
Share Based Compensation Arrangement by Share Based Payment Award Equity Instrument Other Than Option Stock Issuance Percentage Multiplier	'	'	0.00%	200.00%	'	'	0.00%	240.00%	'	0.00%	240.00%
Percent allocated to performance year one	50.00%	'	'	'	30.00%	'	'	'	0.00%	'	'
Percent allocated to performance year two	0.00%	'	'	'	0.00%	'	'	'	0.00%	'	'
Percent allocated to performance year three	50.00%	'	'	'	70.00%	'	'	'	100.00%	'	'
Performance percent target achieved year one	'	85.00%	'	'	'	0.00%	'	'	'	'	'
Performance Cash Earned:	'	'	'	'	'	'	'	'	'	'	'
Beginning Balance Long-term incentives, Settled in Cash, Earned	$1,804,656	'	'	'	$0	'	'	'	$0	'	'
Long Term Incentives, Settled in Cash Earned - Cancelled	-28,688	'	'	'	0	'	'	'	0	'	'
Ending Balance Long-term incentives, Settled in Cash, Earned	1,775,968	'	'	'	0	0	'	'	0	'	'
Performance cash Unearned:	'	'	'	'	'	'	'	'	'	'	'
Beginning Balance Long-term incentives, Settled in Cash, Unearned	2,123,125	'	'	'	4,638,750	'	'	'	0	'	'
Long Term Incentive, Settled in Cash Granted	0	'	'	'	0	'	'	'	5,795,250	'	'
Long Term Incentives, Settled in Cash Performance target not achieved	0	'	'	'	-1,076,250	'	'	'	0	'	'
Long-Term Incentive Award, Settled in Cash Unearned Cancelled	-33,750	'	'	'	0	'	'	'	-80,000	'	'
Ending Balance Long-term incentives, Settled in Cash, Unearned	$2,089,375	'	'	'	$3,562,500	$4,638,750	'	'	$5,715,250	'	'

EquityBased_Compensation_Plans5

Equity-Based Compensation Plans Equity-Based Compensation Plans (Details 3) (USD $)	9 Months Ended
	Sep. 30, 2014
Summary of restricted Stock activity	'
Nonvested shares, Expected to vest	1,534,806
Weighted Average Exercise Price, Nonvested shares Expected to vest	$9.51
Aggregate Intrinsic Value, Nonvested shares Expected to vest	$11,163,322
Restricted Stock [Member]	'
Summary of restricted Stock activity	'
Number of Shares, Beginning Balance	635,400
Weighted Average Exercise Price, Beginning Balance	$18.27
Number of Restricted Shares, Granted	366,000
Weighted Average Exercise Price, Granted	$10.79
Number of Restricted Shares, Exercised	-88,900
Weighted Average Exercise Price, Exercised	$26.58
Number of Restricted Shares, Cancelled	-12,200
Weighted Average Exercise Price, Cancelled	$11.27
Number of Share Units, Ending Balance	900,300
Weighted Average Exercise Price, Ending Balance	$14.54
Aggregate Intrinsic Value, Ending Balance	15,107,034
Nonvested shares, Expected to vest	846,994
Weighted Average Exercise Price, Nonvested shares Expected to vest	$14.74
Aggregate Intrinsic Value, Nonvested shares Expected to vest	$14,212,557

EquityBased_Compensation_Plans6

Equity-Based Compensation Plans (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Equity-based compensation expense	'	'	$6,643,000	$5,984,000
Number of Options, Granted	'	'	737,500	'
Weighted average fair value of options granted	'	'	$5.08	$10.74
Expected dividend yield	'	'	0.00%	0.00%
Contractual Life	'	'	'3 years 7 months 12 days	'
Stock option grants in 2011 through 2014 [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Stock option vesting rights	'	'	'three-year period	'
Stock option grants 2010 [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Stock option vesting rights	'	'	'four-year period	'
Employee Stock Option Market vesting feature [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Number of Options, Granted	'	'	375,000	'
Expected volatility	'	'	63.00%	'
Risk-free interest rate	'	'	1.32%	'
Expected dividend yield	'	'	0.00%	'
Contractual Life	'	'	'7 years	'
Employee Stock Option [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Intrinsic value of options	'	'	200,000	400,000
Unrecognized compensation expense	4,200,000	4,300,000	4,200,000	4,300,000
Compensation expense recognized over a weighted-average period	'	'	'1 year 5 months 8 days	'1 year 6 months
Fair Value of Vested Options	'	'	2,400,000	'
Performance Shares [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Requisite Service Period	'	'	'3 years	'
Performance Cash Award [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Compensation expense recognized over a weighted-average period	'	'	'1 year 10 months 21 days	'
Share-based Compensation Arrangement by Award Type, Performance Cash Award, Expense	1,000,000	800,000	2,900,000	1,700,000
Unrecognized compensation cost total	5,300,000	'	5,300,000	'
Restricted Stock Units R S U [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Number of shares of common stock available for issuance	650,000	'	650,000	'
Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance	160,294	'	160,294	'
Stock & Deferred Compensation Plan for Non-Employee, Granted	'	'	46,543	48,894
Weighted-average fair value	'	'	$13.54	$11.04
Share units outstanding under the plan	379,319	'	379,319	'
Restricted Stock [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Compensation expense recognized over a weighted-average period	'	'	'1 year 10 months 3 days	'2 years 2 months
Unrecognized compensation cost total	6,200,000	5,800,000	6,200,000	5,800,000
Intrinsic Value of restricted stock awards	15,107,034	'	15,107,034	'
Employee Stock [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Offering Period of Employee Stock Purchase Plan	'	'	'3 months	'
ESPP under which the offering purchase price of shares	'	'	85.00%	'
Company issued common stock under its ESPP	'	'	15.00%	'
Stock issued under ESPP	'	'	170,076	217,230
Minimum [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Expected volatility	'	'	60.00%	76.00%
Risk-free interest rate	'	'	0.46%	0.29%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'	'	'3 years 4 months 24 days	'3 years 4 months 24 days
Minimum [Member] | Employee Stock Option Market vesting feature [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Weighted average fair value of options granted	'	'	$5.15	'
Minimum [Member] | Restricted Stock [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Requisite Service Period	'	'	'3 years	'
Maximum [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Expected volatility	'	'	63.00%	79.00%
Risk-free interest rate	'	'	0.51%	0.54%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'	'	'5 years 4 months 24 days	'5 years 4 months 24 days
Maximum [Member] | Employee Stock Option Market vesting feature [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Weighted average fair value of options granted	'	'	$5.88	'
Maximum [Member] | Restricted Stock [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Stock option vesting Period	'	'	'5 years	'
Selling, General and Administrative Expenses [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Equity-based compensation expense	$2,300,000	$2,000,000	$6,600,000	$6,000,000
Market Vesting Feature Stock Price Threshold 1 [Member] | Employee Stock Option Market vesting feature [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Share-based compensation arrangement by award type, market condition target	'	'	$14	'
Market Vesting Feature Stock Price Threshold 2 [Member] | Employee Stock Option Market vesting feature [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Share-based compensation arrangement by award type, market condition target	'	'	$16	'
Market Vesting Feature Stock Price Threshold 3 [Member] | Employee Stock Option Market vesting feature [Member]	'	'	'	'
Equity-Based Compensation Plans (Textual) [Abstract]	'	'	'	'
Share-based compensation arrangement by award type, market condition target	'	'	$18	'

Legal_Matters_Legal_Matters_De

Legal Matters Legal Matters (Details Textual) (USD $)	0 Months Ended			9 Months Ended	12 Months Ended	36 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended
In Millions, unless otherwise specified	Jul. 30, 2014	Jun. 17, 2014	10-May-10	Sep. 30, 2014	Oct. 25, 2011	Dec. 31, 2006	Sep. 30, 2013	Sep. 30, 2013	Jun. 19, 2014	Jun. 09, 2014
	Plaintiffs	Plaintiffs	Plaintiffs		Plaintiffs		PRRB Appeal [Member]	PRRB Appeal [Member]	Patient Medical Records [Member]	Patient Medical Records [Member]
							Home Health [Member]	Home Health [Member]
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'
Number of plaintiffs	217	194	5	'	'	'	'	'	'	'
Number of opt in plaintiffs	'	'	999	'	'	'	'	'	'	'
Settlement of damages claims	'	'	'	$5	'	'	'	'	'	'
Shareholder class actions filed against company	'	'	'	'	5	'	'	'	'	'
Legal Matters Aggregate Adjustment To Allowable Costs	'	'	'	'	'	15.9	'	'	'	'
Legal Matters [Line Items]	'	'	'	'	'	'	'	'	'	'
Patient service revenue adjustments	'	'	'	'	'	'	$4	$4	'	'
Request for information	'	'	'	'	'	'	'	'	'14	'17

Income_Taxes_Income_Taxes_Deta

Income Taxes Income Taxes (Details Textual) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'	'	'	'	'	'
Income tax expense	($5,601,000)	($2,943,000)	$116,000	($12,499,000)	($2,827,000)	'
Income Taxes Receivable	$11,400,000	'	'	$11,400,000	'	$21,200,000

Income_Taxes_Rate_Reconciliati

Income Taxes (Rate Reconciliation) (Details Textual)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'
Effective federal tax rate	35.00%	35.00%
Impairment of goodwill and other long-lived assets	'	-36.00%
State income taxes, net of federal benefit	3.50%	'
Other items	2.00%	-0.60%
Company's effective rate	40.50%	-1.60%

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment net revenues by major payer source	'	'	'	'
Total net revenues	$498,006	$410,492	$1,483,551	$1,240,507
Medicare [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	376,500	355,600	1,128,300	1,076,500
Medicaid and Local Government [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	70,900	17,400	212,800	54,400
Commercial Insurance and Other [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	50,600	37,500	142,500	109,700
Commercial Insurance and Other [Member] | Paid at Episodic Rates [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	21,500	15,100	55,000	43,300
Commercial Insurance and Other [Member] | Other [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	29,100	22,400	87,500	66,300
Home Health [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	268,400	234,900	793,500	706,100
Home Health [Member] | Medicare [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	214,900	191,800	642,000	577,700
Home Health [Member] | Medicaid and Local Government [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	8,600	10,800	25,700	33,100
Home Health [Member] | Commercial Insurance and Other [Member] | Paid at Episodic Rates [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	21,500	15,100	55,000	43,300
Home Health [Member] | Commercial Insurance and Other [Member] | Other [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	23,400	17,200	70,800	52,000
Hospice [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	172,400	175,600	519,100	534,400
Hospice [Member] | Medicare [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	161,600	163,800	486,300	498,800
Hospice [Member] | Medicaid and Local Government [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	6,100	6,600	18,600	21,300
Hospice [Member] | Commercial Insurance and Other [Member] | Paid at Episodic Rates [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	0	0	0	0
Hospice [Member] | Commercial Insurance and Other [Member] | Other [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	4,700	5,200	14,200	14,300
Community Care [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	57,200	'	171,000	'
Community Care [Member] | Medicare [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	0	'	0	'
Community Care [Member] | Medicaid and Local Government [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	56,200	'	168,500	'
Community Care [Member] | Commercial Insurance and Other [Member] | Paid at Episodic Rates [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	0	'	0	'
Community Care [Member] | Commercial Insurance and Other [Member] | Other [Member]	'	'	'	'
Segment net revenues by major payer source	'	'	'	'
Total net revenues	$1,000	'	$2,500	'

Business_Segment_Information_D1

Business Segment Information (Details 1) (USD $)	3 Months Ended				6 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013		Jun. 30, 2013	Sep. 30, 2014		Sep. 30, 2013		Dec. 31, 2013
Segment information about the Company's operations	'		'		'	'		'		'
Total net revenues	$498,006		$410,492		'	$1,483,551		$1,240,507		'
Operating contribution	71,849		54,287		'	199,896		168,250		'
Goodwill and other long-lived asset impairment	0		0		-210,672	0		-210,672	[1]	'
Depreciation and amortization	-7,287		-4,679		'	-21,207		-14,541		'
Interest expense and other, net	-24,719		-22,342		'	-73,906		-66,783		'
Income (loss) before income taxes	14,134		6,594		-187,783	30,846		-181,189		'
Assets	1,225,226		1,263,953		'	1,225,226		1,263,953		1,253,468
Home Health [Member]	'		'		'	'		'		'
Segment information about the Company's operations	'		'		'	'		'		'
Total net revenues	268,423		234,864		'	793,467		706,141		'
Operating contribution	36,725	[2]	31,922	[2]	'	107,355	[2]	92,027	[2]	'
Assets	397,678		249,313		'	397,678		249,313		'
Hospice [Member]	'		'		'	'		'		'
Segment information about the Company's operations	'		'		'	'		'		'
Total net revenues	172,349		175,628		'	519,073		534,366		'
Operating contribution	27,043	[2]	22,365		'	66,674	[2]	76,223	[2]	'
Assets	340,412		636,705	[1]	'	340,412		636,705	[1]	'
Community Care [Member]	'		'		'	'		'		'
Segment information about the Company's operations	'		'		'	'		'		'
Total net revenues	57,234		0		'	171,011		0		'
Operating contribution	8,081		0		'	25,867	[2]	0		'
Assets	168,686		0		'	168,686		0		'
Home Health, Hospice and Community Care [Member]	'		'		'	'		'		'
Segment information about the Company's operations	'		'		'	'		'		'
Assets	906,776		886,018		'	906,776		886,018		'
Corporate [Member]	'		'		'	'		'		'
Segment information about the Company's operations	'		'		'	'		'		'
Corporate expenses	-25,709	[2]	-20,672	[2]	'	-73,937	[2]	-57,443	[2]	'
Assets	$318,450		$377,935	[1]	'	$318,450		$377,935	[1]	'
[1]	(2)At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. See Note 9.In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million.Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of the impairment.
[2]	(1)For the third quarter and first nine months of 2014, the Company recorded charges relating to cost savings initiatives and acquisition and integration activities of $0.5 million and $10.5 million, respectively. For the third quarter and first nine months of 2013, the Company recorded charges relating to cost savings initiatives and acquisition and integration activities of $1.7 million and $2.6 million, respectively.The charges were reflected as follows for segment reporting purposes (in millions): Third QuarterB First Nine MonthsB 2014B 2013B 2014B 2013Home Health$0.1B $0.1B $0.7B $0.1Hospice0.1B bB 5.5B 0.7Community CarebB bB 0.1B bCorporate expenses0.3B 1.6B 4.2B 1.8Total$0.5B $1.7B $10.5B $2.6

Business_Segment_Information_D2

Business Segment Information (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Charges reflecting for segment reporting purposes	'	'	'	'
Restructuring and Acquisition and Integration Provisions	$0.50	$1.70	$10.50	$2.60
Home Health [Member]	'	'	'	'
Charges reflecting for segment reporting purposes	'	'	'	'
Restructuring and Acquisition and Integration Provisions	0.1	0.1	0.7	0.1
Hospice [Member]	'	'	'	'
Charges reflecting for segment reporting purposes	'	'	'	'
Restructuring and Acquisition and Integration Provisions	0.1	0	5.5	0.7
Community Care [Member]	'	'	'	'
Charges reflecting for segment reporting purposes	'	'	'	'
Restructuring and Acquisition and Integration Provisions	0	0	0.1	0
Corporate expenses [Member]	'	'	'	'
Charges reflecting for segment reporting purposes	'	'	'	'
Restructuring and Acquisition and Integration Provisions	$0.30	$1.60	$4.20	$1.80

Business_Segment_Information_D3

Business Segment Information (Details Textual) (USD $)	3 Months Ended						9 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Restructuring charges	$479,000	$4,659,000	$5,341,000	$1,699,000	$744,000	$141,000	$10,500,000	$2,600,000
Home Health [Member]	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Number of states in certified providers serving	38	'	'	'	'	'	38	'
Hospice [Member]	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Number of states in certified providers serving	30	'	'	'	'	'	30	'
Goodwill, impairment loss	'	'	'	'	'	'	'	207,200,000
Community Care [Member]	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Number of states in certified providers serving	4	'	'	'	'	'	4	'
Corporate expenses [Member]	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Asset impairment charges	'	'	'	'	'	'	'	3,500,000
Land and Building [Member]	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Asset impairment charges	'	'	'	'	'	'	'	1,900,000
Software Development [Member]	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'
Asset impairment charges	'	'	'	'	'	'	'	$1,600,000

Supplemental_Guarantor_and_Non2

Supplemental Guarantor and Non-Guarantor Financial Information (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'	'	'
Cash and cash equivalents	$114,206	$86,957	$183,294	$207,052
Receivables, net	285,718	289,905	'	'
Deferred tax assets, net	24,270	28,153	'	'
Prepaid expenses and other current assets	48,776	64,746	'	'
Total current assets	472,970	469,761	'	'
Note receivable from CareCentrix	25,000	28,471	'	'
Fixed assets, net	42,048	49,375	'	'
Intangible assets, net	247,033	253,727	'	'
Goodwill	374,024	383,487	'	'
Investment in subsidiaries	0	0	'	'
Other assets	64,151	68,647	'	'
Total assets	1,225,226	1,253,468	1,263,953	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	51,138	45,325	'	'
Accounts payable	16,370	15,659	'	'
Other current liabilities	275,446	314,486	'	'
Total current liabilities	342,954	375,470	'	'
Long-term debt	1,105,750	1,124,432	'	'
Deferred tax liabilities, net	6,264	8,483	'	'
Other liabilities	55,456	53,084	'	'
Total Gentiva shareholders' deficit	-289,010	-310,876	'	'
Noncontrolling interests	3,812	2,875	'	'
Total deficit	-285,198	-308,001	57,808	232,960
Total liabilities and shareholders' deficit	1,225,226	1,253,468	'	'
Gentiva Health Services, Inc. [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	84,708	55,388	127,941	166,140
Receivables, net	0	0	'	'
Deferred tax assets, net	0	0	'	'
Prepaid expenses and other current assets	0	0	'	'
Total current assets	84,708	55,388	'	'
Note receivable from CareCentrix	0	0	'	'
Fixed assets, net	0	0	'	'
Intangible assets, net	0	0	'	'
Goodwill	0	0	'	'
Investment in subsidiaries	766,995	782,470	'	'
Other assets	24,440	28,266	'	'
Total assets	876,143	866,124	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	51,138	45,325	'	'
Accounts payable	0	0	'	'
Other current liabilities	1,959	0	'	'
Total current liabilities	53,097	45,325	'	'
Long-term debt	1,105,750	1,124,432	'	'
Deferred tax liabilities, net	0	0	'	'
Other liabilities	6,306	7,243	'	'
Total Gentiva shareholders' deficit	-289,010	-310,876	'	'
Noncontrolling interests	0	0	'	'
Total deficit	-289,010	-310,876	'	'
Total liabilities and shareholders' deficit	876,143	866,124	'	'
Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	0	0	0	0
Receivables, net	277,263	284,637	'	'
Deferred tax assets, net	21,840	25,845	'	'
Prepaid expenses and other current assets	39,291	52,971	'	'
Total current assets	338,394	363,453	'	'
Note receivable from CareCentrix	25,000	28,471	'	'
Fixed assets, net	41,511	48,855	'	'
Intangible assets, net	244,433	251,127	'	'
Goodwill	367,550	379,880	'	'
Investment in subsidiaries	23,709	23,493	'	'
Other assets	39,704	40,375	'	'
Total assets	1,080,301	1,135,654	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	16,370	15,377	'	'
Other current liabilities	241,522	283,483	'	'
Total current liabilities	257,892	298,860	'	'
Long-term debt	0	0	'	'
Deferred tax liabilities, net	6,264	8,483	'	'
Other liabilities	49,150	45,841	'	'
Total Gentiva shareholders' deficit	766,995	782,470	'	'
Noncontrolling interests	0	0	'	'
Total deficit	766,995	782,470	'	'
Total liabilities and shareholders' deficit	1,080,301	1,135,654	'	'
Non-Guarantor Subsidiaries [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	29,498	31,569	40,949	40,912
Receivables, net	41,275	33,878	'	'
Deferred tax assets, net	2,430	2,308	'	'
Prepaid expenses and other current assets	9,485	11,775	'	'
Total current assets	82,688	79,530	'	'
Note receivable from CareCentrix	0	0	'	'
Fixed assets, net	537	520	'	'
Intangible assets, net	2,600	2,600	'	'
Goodwill	6,474	3,607	'	'
Investment in subsidiaries	0	0	'	'
Other assets	7	6	'	'
Total assets	92,306	86,263	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	0	282	'	'
Other current liabilities	64,785	59,613	'	'
Total current liabilities	64,785	59,895	'	'
Long-term debt	0	0	'	'
Deferred tax liabilities, net	0	0	'	'
Other liabilities	0	0	'	'
Total Gentiva shareholders' deficit	23,709	23,493	'	'
Noncontrolling interests	3,812	2,875	'	'
Total deficit	27,521	26,368	'	'
Total liabilities and shareholders' deficit	92,306	86,263	'	'
Eliminations [Member]	'	'	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	0	0	14,404	0
Receivables, net	-32,820	-28,610	'	'
Deferred tax assets, net	0	0	'	'
Prepaid expenses and other current assets	0	0	'	'
Total current assets	-32,820	-28,610	'	'
Note receivable from CareCentrix	0	0	'	'
Fixed assets, net	0	0	'	'
Intangible assets, net	0	0	'	'
Goodwill	0	0	'	'
Investment in subsidiaries	-790,704	-805,963	'	'
Other assets	0	0	'	'
Total assets	-823,524	-834,573	'	'
Current liabilities:	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	0	0	'	'
Other current liabilities	-32,820	-28,610	'	'
Total current liabilities	-32,820	-28,610	'	'
Long-term debt	0	0	'	'
Deferred tax liabilities, net	0	0	'	'
Other liabilities	0	0	'	'
Total Gentiva shareholders' deficit	-790,704	-805,963	'	'
Noncontrolling interests	0	0	'	'
Total deficit	-790,704	-805,963	'	'
Total liabilities and shareholders' deficit	($823,524)	($834,573)	'	'

Supplemental_Guarantor_and_Non3

Supplemental Guarantor and Non-Guarantor Financial Information (Details 1) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Total net revenues	$498,006	$410,492	'	$1,483,551	$1,240,507
Cost of services sold	270,659	220,478	'	811,077	660,998
Gross profit	227,347	190,014	'	672,474	579,509
Selling, general and administrative expenses	-188,494	-161,078	-322,165	-567,722	-483,243
Goodwill and other long-lived asset impairment	0	0	-210,672	0	-210,672	[1]
Interest expense and other, net	-24,719	-22,342	'	-73,906	-66,783
Equity in earnings (loss) of subsidiaries	0	0	'	0	0
Income (loss) before income taxes and equity in net loss of CareCentrix	14,134	6,594	-187,783	30,846	-181,189
Income tax expense	-5,601	-2,943	116	-12,499	-2,827
Equity in net loss of CareCentrix, net of tax	-490	0	'	-490	0
Net income (loss)	8,043	3,651	-187,667	17,857	-184,016
Less: Net income attributable to noncontrolling interests	2	-88	'	-170	-425
Net income (loss) attributable to Gentiva shareholders	8,045	3,563	-188,044	17,687	-184,441
Comprehensive income (loss)	8,043	3,651	-187,667	17,857	-184,016
Gentiva Health Services, Inc. [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Total net revenues	0	0	'	0	0
Cost of services sold	0	0	'	0	0
Gross profit	0	0	'	0	0
Selling, general and administrative expenses	0	0	'	0	0
Goodwill and other long-lived asset impairment	'	'	'	'	0
Interest expense and other, net	-24,772	-22,355	'	-74,063	-66,829
Equity in earnings (loss) of subsidiaries	23,000	15,987	'	62,347	-144,144
Income (loss) before income taxes and equity in net loss of CareCentrix	-1,772	-6,368	'	-11,716	-210,973
Income tax expense	9,817	9,931	'	29,403	26,532
Equity in net loss of CareCentrix, net of tax	0	'	'	0	'
Net income (loss)	8,045	3,563	'	17,687	-184,441
Less: Net income attributable to noncontrolling interests	0	0	'	0	0
Net income (loss) attributable to Gentiva shareholders	8,045	3,563	'	17,687	-184,441
Comprehensive income (loss)	8,045	3,563	'	17,687	-184,441
Guarantor Subsidiaries [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Total net revenues	485,106	398,047	'	1,446,339	1,203,258
Cost of services sold	262,795	212,543	'	790,399	638,418
Gross profit	222,311	185,504	'	655,940	564,840
Selling, general and administrative expenses	-182,876	-156,119	'	-551,875	-468,879
Goodwill and other long-lived asset impairment	'	'	'	'	-210,672
Interest expense and other, net	0	0	'	0	0
Equity in earnings (loss) of subsidiaries	-261	-459	'	427	-7
Income (loss) before income taxes and equity in net loss of CareCentrix	39,174	28,926	'	104,492	-114,718
Income tax expense	-15,684	-12,939	'	-41,655	-29,426
Equity in net loss of CareCentrix, net of tax	-490	'	'	-490	'
Net income (loss)	23,000	15,987	'	62,347	-144,144
Less: Net income attributable to noncontrolling interests	0	0	'	0	0
Net income (loss) attributable to Gentiva shareholders	23,000	15,987	'	62,347	-144,144
Comprehensive income (loss)	23,000	15,987	'	62,347	-144,144
Non-Guarantor Subsidiaries [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Total net revenues	16,645	16,429	'	48,648	48,498
Cost of services sold	11,609	11,919	'	32,114	33,829
Gross profit	5,036	4,510	'	16,534	14,669
Selling, general and administrative expenses	-5,618	-4,959	'	-15,847	-14,364
Goodwill and other long-lived asset impairment	'	'	'	'	0
Interest expense and other, net	53	13	'	157	46
Equity in earnings (loss) of subsidiaries	0	0	'	0	0
Income (loss) before income taxes and equity in net loss of CareCentrix	-529	-436	'	844	351
Income tax expense	266	65	'	-247	67
Equity in net loss of CareCentrix, net of tax	0	'	'	0	'
Net income (loss)	-263	-371	'	597	418
Less: Net income attributable to noncontrolling interests	2	-88	'	-170	-425
Net income (loss) attributable to Gentiva shareholders	-261	-459	'	427	-7
Comprehensive income (loss)	-263	-371	'	597	418
Eliminations [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Total net revenues	-3,745	-3,984	'	-11,436	-11,249
Cost of services sold	-3,745	-3,984	'	-11,436	-11,249
Gross profit	0	0	'	0	0
Selling, general and administrative expenses	0	0	'	0	0
Goodwill and other long-lived asset impairment	'	'	'	'	0
Interest expense and other, net	0	0	'	0	0
Equity in earnings (loss) of subsidiaries	-22,739	-15,528	'	-62,774	144,151
Income (loss) before income taxes and equity in net loss of CareCentrix	-22,739	-15,528	'	-62,774	144,151
Income tax expense	0	0	'	0	0
Equity in net loss of CareCentrix, net of tax	0	'	'	0	'
Net income (loss)	-22,739	-15,528	'	-62,774	144,151
Less: Net income attributable to noncontrolling interests	0	0	'	0	0
Net income (loss) attributable to Gentiva shareholders	-22,739	-15,528	'	-62,774	144,151
Comprehensive income (loss)	-22,739	-15,528	'	-62,774	144,151
Scenario, Previously Reported [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Total net revenues	'	'	'	'	1,240,507
Cost of services sold	'	'	'	'	660,998
Gross profit	'	'	'	'	579,509
Selling, general and administrative expenses	'	'	-321,814	'	-482,634
Goodwill and other long-lived asset impairment	'	'	-224,320	'	-224,320
Interest expense and other, net	'	'	'	'	-66,783
Equity in earnings (loss) of subsidiaries	'	'	'	'	0
Income (loss) before income taxes and equity in net loss of CareCentrix	'	'	-201,080	'	-194,228
Income tax expense	'	'	587	'	-2,457
Net income (loss)	'	'	-200,493	'	-196,685
Less: Net income attributable to noncontrolling interests	'	'	'	'	-425
Net income (loss) attributable to Gentiva shareholders	'	'	-200,830	'	-197,110
Comprehensive income (loss)	'	'	-200,493	'	-196,685
Scenario, Previously Reported [Member] | Gentiva Health Services, Inc. [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Total net revenues	'	'	'	'	0
Cost of services sold	'	'	'	'	0
Gross profit	'	'	'	'	0
Selling, general and administrative expenses	'	'	'	'	0
Goodwill and other long-lived asset impairment	'	'	'	'	0
Interest expense and other, net	'	'	'	'	-66,829
Equity in earnings (loss) of subsidiaries	'	'	'	'	-156,813
Income (loss) before income taxes and equity in net loss of CareCentrix	'	'	'	'	-223,642
Income tax expense	'	'	'	'	26,532
Net income (loss)	'	'	'	'	-197,110
Less: Net income attributable to noncontrolling interests	'	'	'	'	0
Net income (loss) attributable to Gentiva shareholders	'	'	'	'	-197,110
Comprehensive income (loss)	'	'	'	'	-182,706
Scenario, Previously Reported [Member] | Guarantor Subsidiaries [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Total net revenues	'	'	'	'	1,203,258
Cost of services sold	'	'	'	'	638,418
Gross profit	'	'	'	'	564,840
Selling, general and administrative expenses	'	'	'	'	-468,270
Goodwill and other long-lived asset impairment	'	'	'	'	-224,320
Interest expense and other, net	'	'	'	'	0
Equity in earnings (loss) of subsidiaries	'	'	'	'	-7
Income (loss) before income taxes and equity in net loss of CareCentrix	'	'	'	'	-127,757
Income tax expense	'	'	'	'	-29,056
Net income (loss)	'	'	'	'	-156,813
Less: Net income attributable to noncontrolling interests	'	'	'	'	0
Net income (loss) attributable to Gentiva shareholders	'	'	'	'	-156,813
Comprehensive income (loss)	'	'	'	'	-156,813
Scenario, Previously Reported [Member] | Non-Guarantor Subsidiaries [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Total net revenues	'	'	'	'	48,498
Cost of services sold	'	'	'	'	33,829
Gross profit	'	'	'	'	14,669
Selling, general and administrative expenses	'	'	'	'	-14,364
Goodwill and other long-lived asset impairment	'	'	'	'	0
Interest expense and other, net	'	'	'	'	46
Equity in earnings (loss) of subsidiaries	'	'	'	'	0
Income (loss) before income taxes and equity in net loss of CareCentrix	'	'	'	'	351
Income tax expense	'	'	'	'	67
Net income (loss)	'	'	'	'	418
Less: Net income attributable to noncontrolling interests	'	'	'	'	-425
Net income (loss) attributable to Gentiva shareholders	'	'	'	'	-7
Comprehensive income (loss)	'	'	'	'	418
Scenario, Previously Reported [Member] | Eliminations [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Total net revenues	'	'	'	'	-11,249
Cost of services sold	'	'	'	'	-11,249
Gross profit	'	'	'	'	0
Selling, general and administrative expenses	'	'	'	'	0
Goodwill and other long-lived asset impairment	'	'	'	'	0
Interest expense and other, net	'	'	'	'	0
Equity in earnings (loss) of subsidiaries	'	'	'	'	156,820
Income (loss) before income taxes and equity in net loss of CareCentrix	'	'	'	'	156,820
Income tax expense	'	'	'	'	0
Net income (loss)	'	'	'	'	156,820
Less: Net income attributable to noncontrolling interests	'	'	'	'	0
Net income (loss) attributable to Gentiva shareholders	'	'	'	'	156,820
Comprehensive income (loss)	'	'	'	'	142,416
Revision Adjustment [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Selling, general and administrative expenses	'	'	-351	'	-609
Goodwill and other long-lived asset impairment	'	'	13,648	'	13,648
Equity in earnings (loss) of subsidiaries	'	'	'	'	0
Income (loss) before income taxes and equity in net loss of CareCentrix	'	'	13,297	'	13,039
Income tax expense	'	'	-471	'	-370
Net income (loss)	'	'	12,826	'	12,669
Net income (loss) attributable to Gentiva shareholders	'	'	12,826	'	12,669
Comprehensive income (loss)	'	'	12,826	'	12,669
Revision Adjustment [Member] | Gentiva Health Services, Inc. [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Selling, general and administrative expenses	'	'	'	'	0
Goodwill and other long-lived asset impairment	'	'	'	'	0
Equity in earnings (loss) of subsidiaries	'	'	'	'	12,669
Income (loss) before income taxes and equity in net loss of CareCentrix	'	'	'	'	12,669
Income tax expense	'	'	'	'	0
Net income (loss)	'	'	'	'	12,669
Net income (loss) attributable to Gentiva shareholders	'	'	'	'	12,669
Comprehensive income (loss)	'	'	'	'	12,669
Revision Adjustment [Member] | Guarantor Subsidiaries [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Selling, general and administrative expenses	'	'	'	'	-609
Goodwill and other long-lived asset impairment	'	'	'	'	13,648
Equity in earnings (loss) of subsidiaries	'	'	'	'	0
Income (loss) before income taxes and equity in net loss of CareCentrix	'	'	'	'	13,039
Income tax expense	'	'	'	'	-370
Net income (loss)	'	'	'	'	12,669
Net income (loss) attributable to Gentiva shareholders	'	'	'	'	12,669
Comprehensive income (loss)	'	'	'	'	12,669
Revision Adjustment [Member] | Non-Guarantor Subsidiaries [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Selling, general and administrative expenses	'	'	'	'	0
Goodwill and other long-lived asset impairment	'	'	'	'	0
Equity in earnings (loss) of subsidiaries	'	'	'	'	0
Income (loss) before income taxes and equity in net loss of CareCentrix	'	'	'	'	0
Income tax expense	'	'	'	'	0
Net income (loss)	'	'	'	'	0
Net income (loss) attributable to Gentiva shareholders	'	'	'	'	0
Comprehensive income (loss)	'	'	'	'	0
Revision Adjustment [Member] | Eliminations [Member]	'	'	'	'	'
Condensed Consolidating Statement of Comprehensive Income	'	'	'	'	'
Selling, general and administrative expenses	'	'	'	'	0
Goodwill and other long-lived asset impairment	'	'	'	'	0
Equity in earnings (loss) of subsidiaries	'	'	'	'	-12,669
Income (loss) before income taxes and equity in net loss of CareCentrix	'	'	'	'	-12,669
Income tax expense	'	'	'	'	0
Net income (loss)	'	'	'	'	-12,669
Net income (loss) attributable to Gentiva shareholders	'	'	'	'	-12,669
Comprehensive income (loss)	'	'	'	'	($12,669)
[1]	(2)At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $207.2 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. See Note 9.In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million.Hospice and corporate assets were reduced by $207.2 million and $3.5 million, respectively, as a result of the impairment.

Supplemental_Guarantor_and_Non4

Supplemental Guarantor and Non-Guarantor Financial Information (Details 2) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
OPERATING ACTIVITIES:	'	'
Net cash (used in) provided by operating activities	$46,039	$18,569
INVESTING ACTIVITIES:	'	'
Purchase of fixed assets	-9,268	-14,214
Proceeds from Sale of Property, Plant, and Equipment	-2,004	0
Capital contribution	0	'
Proceeds from sale of businesses	0	508
Acquisition of businesses, net of cash acquired	0	-4,638
Net cash used in investing activities	-7,264	-18,344
FINANCING ACTIVITIES:	'	'
Proceeds from issuance of common stock	1,937	2,459
Windfall tax benefits associated with equity-based compensation	56	92
Payment of contingent consideration accrued at acquisition date	0	-1,675
Intercompany dividend	'	0
Repayment of long-term debt	-13,744	-25,000
Debt issuance costs	-150	-449
Minority interest capital contribution	1,160	1,600
Majority interest capital contributions	0	0
Distribution to minority interests	-393	-563
Distribution to majority interests	0	0
Other	-392	-447
Net payments related to intercompany financing	0	0
Net cash used in financing activities	-11,526	-23,983
Net change in cash and cash equivalents	27,249	-23,758
Cash and cash equivalents at beginning of period	86,957	207,052
Cash and cash equivalents at end of period	114,206	183,294
Gentiva Health Services, Inc. [Member]	'	'
OPERATING ACTIVITIES:	'	'
Net cash (used in) provided by operating activities	-32,770	-39,122
INVESTING ACTIVITIES:	'	'
Purchase of fixed assets	0	0
Proceeds from Sale of Property, Plant, and Equipment	0	'
Capital contribution	0	'
Proceeds from sale of businesses	0	0
Acquisition of businesses, net of cash acquired	0	0
Net cash used in investing activities	0	0
FINANCING ACTIVITIES:	'	'
Proceeds from issuance of common stock	1,937	2,459
Windfall tax benefits associated with equity-based compensation	56	92
Payment of contingent consideration accrued at acquisition date	'	0
Intercompany dividend	'	2,300
Repayment of long-term debt	-13,744	-25,000
Debt issuance costs	-150	-449
Minority interest capital contribution	0	0
Majority interest capital contributions	0	0
Distribution to minority interests	0	0
Distribution to majority interests	0	0
Other	-361	-416
Net payments related to intercompany financing	74,352	21,937
Net cash used in financing activities	62,090	923
Net change in cash and cash equivalents	29,320	-38,199
Cash and cash equivalents at beginning of period	55,388	166,140
Cash and cash equivalents at end of period	84,708	127,941
Guarantor Subsidiaries [Member]	'	'
OPERATING ACTIVITIES:	'	'
Net cash (used in) provided by operating activities	80,338	41,545
INVESTING ACTIVITIES:	'	'
Purchase of fixed assets	-9,119	-13,872
Proceeds from Sale of Property, Plant, and Equipment	-2,004	'
Capital contribution	-1,740	'
Proceeds from sale of businesses	2,900	508
Acquisition of businesses, net of cash acquired	0	-4,538
Net cash used in investing activities	-5,955	-17,902
FINANCING ACTIVITIES:	'	'
Proceeds from issuance of common stock	0	0
Windfall tax benefits associated with equity-based compensation	0	0
Payment of contingent consideration accrued at acquisition date	'	-1,675
Intercompany dividend	'	0
Repayment of long-term debt	0	0
Debt issuance costs	0	0
Minority interest capital contribution	0	0
Majority interest capital contributions	0	0
Distribution to minority interests	0	0
Distribution to majority interests	0	0
Other	-31	-31
Net payments related to intercompany financing	-74,352	-21,937
Net cash used in financing activities	-74,383	-23,643
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Non-Guarantor Subsidiaries [Member]	'	'
OPERATING ACTIVITIES:	'	'
Net cash (used in) provided by operating activities	-503	3,038
INVESTING ACTIVITIES:	'	'
Purchase of fixed assets	-149	-342
Proceeds from Sale of Property, Plant, and Equipment	0	'
Capital contribution	0	'
Proceeds from sale of businesses	0	0
Acquisition of businesses, net of cash acquired	-2,900	-2,500
Net cash used in investing activities	-3,049	-2,842
FINANCING ACTIVITIES:	'	'
Proceeds from issuance of common stock	0	0
Windfall tax benefits associated with equity-based compensation	0	0
Payment of contingent consideration accrued at acquisition date	'	0
Intercompany dividend	'	-2,300
Repayment of long-term debt	0	0
Debt issuance costs	0	0
Minority interest capital contribution	1,160	1,600
Majority interest capital contributions	1,740	2,400
Distribution to minority interests	-393	-563
Distribution to majority interests	-1,026	-1,296
Other	0	0
Net payments related to intercompany financing	0	0
Net cash used in financing activities	1,481	-159
Net change in cash and cash equivalents	-2,071	37
Cash and cash equivalents at beginning of period	31,569	40,912
Cash and cash equivalents at end of period	29,498	40,949
Eliminations [Member]	'	'
OPERATING ACTIVITIES:	'	'
Net cash (used in) provided by operating activities	-1,026	13,108
INVESTING ACTIVITIES:	'	'
Purchase of fixed assets	0	0
Proceeds from Sale of Property, Plant, and Equipment	0	'
Capital contribution	1,740	'
Proceeds from sale of businesses	-2,900	0
Acquisition of businesses, net of cash acquired	2,900	2,400
Net cash used in investing activities	1,740	2,400
FINANCING ACTIVITIES:	'	'
Proceeds from issuance of common stock	0	0
Windfall tax benefits associated with equity-based compensation	0	0
Payment of contingent consideration accrued at acquisition date	'	0
Intercompany dividend	'	0
Repayment of long-term debt	0	0
Debt issuance costs	0	0
Minority interest capital contribution	0	0
Majority interest capital contributions	-1,740	-2,400
Distribution to minority interests	0	0
Distribution to majority interests	1,026	1,296
Other	0	0
Net payments related to intercompany financing	0	0
Net cash used in financing activities	-714	-1,104
Net change in cash and cash equivalents	0	14,404
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	$0	$14,404

Subsequent_Event_Details

Subsequent Event (Details) (Subsequent Event [Member], USD $)	0 Months Ended
In Millions, except Per Share data, unless otherwise specified	Oct. 09, 2014	Oct. 09, 2014
Common Stock [Member]	'	'
Subsequent Event [Line Items]	'	'
Merger, Price per Share Received	'	$14.50
Business Combination, Conversion Ratio	0.257	'
Gentiva Health Services, Inc. (Gentiva) [Member] | Common Stock [Member]	'	'
Subsequent Event [Line Items]	'	'
Business Acquisition, Share Price	$5	$5
Kindred Healthcare, Inc. (Kindred) [Member]	'	'
Subsequent Event [Line Items]	'	'
Purchase price	$1,800	'
Kindred Healthcare, Inc. (Kindred) [Member] | Common Stock [Member]	'	'
Subsequent Event [Line Items]	'	'
Business Acquisition, Share Price	$19.50	$19.50